data_2khb_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2khb _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 . . . . . 0 N--CA 1.453 -0.315 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.556 ' HB ' HG21 ' A' ' 10' ' ' VAL . 18.8 p -71.72 122.43 20.61 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 120.909 0.385 . . . . 0.0 110.452 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.521 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 17.0 t -93.05 37.05 1.03 Allowed 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.981 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.556 HG21 ' HB ' ' A' ' 8' ' ' THR . 46.1 t -60.4 -41.14 86.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.777 -179.241 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.86 24.92 24.1 Favored Glycine 0 N--CA 1.451 -0.3 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.948 179.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.85 47.92 88.06 Favored Glycine 0 C--N 1.333 0.363 0 C-N-CA 121.223 -0.513 . . . . 0.0 113.326 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 t -150.97 154.1 36.46 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.872 0.368 . . . . 0.0 111.082 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 76.8 m -134.48 138.07 44.43 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.87 179.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -79.91 -53.99 6.23 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.889 -178.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.573 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 6.7 m -73.1 115.06 36.77 Favored Pre-proline 0 C--O 1.243 0.732 0 CA-C-O 121.368 0.604 . . . . 0.0 112.297 -178.321 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -63.69 121.86 9.75 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.529 2.153 . . . . 0.0 110.635 179.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.14 -16.11 13.16 Favored Glycine 0 N--CA 1.439 -1.112 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 -178.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.573 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 76.5 m -89.14 132.43 34.83 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 m -88.77 144.97 25.89 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.272 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.9 t -78.48 126.35 30.64 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.077 0.465 . . . . 0.0 110.811 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.0 m -132.66 67.93 1.52 Allowed 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 4.7 t90 -29.15 127.88 0.24 Allowed Pre-proline 0 N--CA 1.465 0.279 0 CA-C-N 114.06 -1.427 . . . . 0.0 112.841 -177.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -97.04 32.8 10.51 Favored 'Cis proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.582 -1.424 . . . . 0.0 114.053 0.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 10.8 m -140.68 139.39 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.521 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.3 m -83.36 137.82 33.79 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.649 178.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.1 t . . . . . 0 C--N 1.322 -0.591 0 CA-C-O 121.092 0.472 . . . . 0.0 110.227 178.817 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.452 ' OE2' ' HB3' ' A' ' 15' ' ' ASN . 20.7 mt-10 . . . . . 0 C--O 1.233 0.185 0 CA-C-O 120.798 0.332 . . . . 0.0 111.01 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.434 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 3.0 p -88.29 127.51 35.47 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 121.105 0.478 . . . . 0.0 110.825 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.561 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 15.0 t -91.28 40.52 1.03 Allowed 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.136 0.493 . . . . 0.0 109.84 179.465 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.6 p -61.81 -36.28 72.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.08 -179.129 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.56 24.23 31.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.829 -0.7 . . . . 0.0 112.72 179.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.5 41.59 97.23 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.257 -0.497 . . . . 0.0 113.181 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.8 t -151.48 152.58 33.2 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 121.011 0.434 . . . . 0.0 111.309 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 71.1 m -132.07 140.1 48.75 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.076 179.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.452 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 9.7 t30 -91.95 -47.91 7.04 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.609 -178.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 85.2 m -70.57 116.45 45.64 Favored Pre-proline 0 C--O 1.242 0.709 0 CA-C-O 121.322 0.582 . . . . 0.0 111.801 -179.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -61.56 126.29 18.78 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.681 2.254 . . . . 0.0 111.019 179.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 110.62 -18.25 27.38 Favored Glycine 0 N--CA 1.44 -1.043 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -178.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.0 m -87.4 124.85 33.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.174 0.512 . . . . 0.0 110.273 179.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 m -89.35 145.52 25.3 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.854 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 53.7 t -77.03 126.81 31.58 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 121.173 0.511 . . . . 0.0 111.306 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -137.37 68.69 1.41 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 4.7 t90 -31.04 129.07 0.27 Allowed Pre-proline 0 N--CA 1.463 0.216 0 CA-C-N 114.111 -1.404 . . . . 0.0 112.832 -177.164 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -97.08 33.24 10.01 Favored 'Cis proline' 0 N--CA 1.456 -0.678 0 C-N-CA 123.591 -1.421 . . . . 0.0 114.026 0.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.434 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 14.8 m -140.11 141.95 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 N-CA-C 113.222 0.823 . . . . 0.0 113.222 -179.121 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.561 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 84.1 m -84.01 135.47 34.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.03 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.2 t . . . . . 0 C--N 1.322 -0.616 0 CA-C-O 121.126 0.488 . . . . 0.0 110.226 179.044 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 . . . . . 0 N--CA 1.451 -0.419 0 CA-C-O 121.089 0.471 . . . . 0.0 110.133 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 p -77.34 125.48 29.4 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-O 121.313 0.577 . . . . 0.0 110.908 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.484 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 26.0 t -92.71 37.75 1.01 Allowed 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.784 -0.643 . . . . 0.0 109.616 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.1 p -62.02 -35.46 68.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.008 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.78 21.64 43.67 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.723 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.56 45.61 95.98 Favored Glycine 0 CA--C 1.519 0.34 0 C-N-CA 121.249 -0.501 . . . . 0.0 113.297 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.9 t -150.82 152.52 33.88 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.881 0.372 . . . . 0.0 111.108 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 90.1 m -130.48 140.44 50.53 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.799 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.5 t30 -89.5 -48.91 7.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.918 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.424 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 1.8 m -76.1 112.54 21.21 Favored Pre-proline 0 C--O 1.244 0.801 0 CA-C-O 121.426 0.631 . . . . 0.0 112.572 -178.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 19.3 Cg_endo -60.2 133.04 47.37 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.682 2.255 . . . . 0.0 111.481 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.51 -27.19 17.56 Favored Glycine 0 N--CA 1.438 -1.218 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 12.3 m -90.7 128.64 36.72 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.061 0.458 . . . . 0.0 110.232 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.5 t -90.83 160.98 15.46 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.929 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 46.1 t -80.67 131.45 35.47 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.55 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.2 m -138.38 68.77 1.39 Allowed 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 178.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 2.0 t90 -29.56 129.16 0.24 Allowed Pre-proline 0 N--CA 1.466 0.33 0 CA-C-N 114.062 -1.426 . . . . 0.0 113.015 -177.047 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.402 ' O ' HG12 ' A' ' 25' ' ' VAL . 94.3 Cg_endo -96.66 33.26 10.02 Favored 'Cis proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.484 -1.465 . . . . 0.0 114.151 0.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.402 HG12 ' O ' ' A' ' 24' ' ' PRO . 10.6 m -144.01 143.96 23.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -179.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.484 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.1 m -82.76 143.81 30.61 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.2 t . . . . . 0 C--N 1.326 -0.454 0 CA-C-O 121.371 0.605 . . . . 0.0 111.311 -179.864 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 . . . . . 0 N--CA 1.452 -0.326 0 CA-C-O 120.81 0.338 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.478 ' HB ' HG23 ' A' ' 10' ' ' VAL . 10.8 p -82.25 124.87 30.33 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.151 179.105 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 23.9 t -87.62 53.03 2.65 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.246 0.546 . . . . 0.0 110.725 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.478 HG23 ' HB ' ' A' ' 8' ' ' THR . 4.1 t -78.99 48.84 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-O 121.46 0.648 . . . . 0.0 110.781 -179.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.06 26.89 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.888 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 55.06 43.95 83.31 Favored Glycine 0 C--N 1.336 0.529 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.099 179.358 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.2 t -151.55 153.74 35.13 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.11 0.481 . . . . 0.0 111.545 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.4 m -142.33 134.34 27.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.186 -0.915 . . . . 0.0 108.578 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 62.0 m-80 -84.07 -45.18 13.32 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.591 0.234 . . . . 0.0 111.561 -178.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 4.1 m -69.94 113.66 19.26 Favored Pre-proline 0 C--O 1.244 0.811 0 CA-C-O 121.44 0.638 . . . . 0.0 112.002 -178.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -60.12 131.0 36.75 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.695 2.264 . . . . 0.0 111.345 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.48 -26.2 15.41 Favored Glycine 0 N--CA 1.439 -1.129 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -178.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.7 m -89.31 126.17 35.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.504 0.669 . . . . 0.0 111.112 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.3 m -94.07 147.55 23.03 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.597 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.1 t -72.38 114.87 10.97 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.074 0.464 . . . . 0.0 111.278 -179.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 36.8 m -123.43 64.47 1.01 Allowed 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 178.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.44 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 8.8 t90 -27.6 129.39 0.2 Allowed Pre-proline 0 N--CA 1.463 0.203 0 CA-C-N 113.798 -1.547 . . . . 0.0 113.104 -177.063 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.44 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 96.6 Cg_endo -94.71 27.89 18.05 Favored 'Cis proline' 0 N--CA 1.457 -0.668 0 C-N-CA 123.226 -1.573 . . . . 0.0 114.143 0.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.3 m -137.37 140.1 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -179.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 72.8 m -82.7 129.95 35.04 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.672 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.324 -0.535 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.962 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.58 ' HG2' ' HB3' ' A' ' 15' ' ' ASN . 2.8 mp0 . . . . . 0 N--CA 1.453 -0.3 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.3 p -73.31 124.24 25.33 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 120.844 0.354 . . . . 0.0 110.351 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.57 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 21.2 t -89.44 38.35 0.9 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.255 0.55 . . . . 0.0 110.019 179.669 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.01 -36.23 72.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.964 -179.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.04 25.59 26.96 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.746 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.14 45.29 95.53 Favored Glycine 0 C--N 1.331 0.277 0 C-N-CA 121.165 -0.54 . . . . 0.0 113.131 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.7 t -151.04 154.43 37.02 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.927 0.394 . . . . 0.0 111.065 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 98.8 m -130.98 139.58 50.03 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.813 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.58 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 30.4 t30 -85.26 -50.27 7.5 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.764 -179.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 5.6 m -80.59 109.1 11.64 Favored Pre-proline 0 C--O 1.251 1.174 0 CA-C-O 121.821 0.82 . . . . 0.0 112.584 -178.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.505 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 24.5 Cg_exo -61.4 127.08 20.85 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.686 2.257 . . . . 0.0 111.103 179.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.02 -29.73 5.47 Favored Glycine 0 N--CA 1.434 -1.458 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -178.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 19.0 m -88.99 143.1 27.09 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.256 -0.577 . . . . 0.0 110.529 179.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 m -97.08 149.33 22.08 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.559 -179.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.3 t -74.93 128.21 35.04 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.153 0.502 . . . . 0.0 111.15 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.0 m -133.84 67.79 1.51 Allowed 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 4.8 t90 -29.58 128.49 0.24 Allowed Pre-proline 0 N--CA 1.464 0.256 0 CA-C-N 114.118 -1.401 . . . . 0.0 112.811 -177.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -96.78 34.13 9.15 Favored 'Cis proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.615 -1.41 . . . . 0.0 114.201 0.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 10.8 m -143.11 139.97 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.57 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 70.9 m -83.05 132.21 35.13 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.038 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.9 t . . . . . 0 C--N 1.325 -0.485 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.646 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.435 ' OE2' ' HB3' ' A' ' 15' ' ' ASN . 23.1 mt-10 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.749 0.309 . . . . 0.0 110.706 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 2.8 p -88.33 127.14 35.48 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-O 121.099 0.476 . . . . 0.0 110.989 179.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.527 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 18.1 t -91.79 40.43 1.04 Allowed 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.159 0.504 . . . . 0.0 109.881 179.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -62.12 -36.22 73.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.086 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.6 24.1 30.96 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.798 179.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.23 42.04 97.05 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.25 -0.5 . . . . 0.0 113.072 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.0 t -151.82 156.18 39.68 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.842 0.353 . . . . 0.0 111.023 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.9 m -135.8 136.88 41.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.302 179.386 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.435 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 9.8 t30 -87.48 -48.95 7.53 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.996 -178.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 88.4 m -70.98 118.38 65.0 Favored Pre-proline 0 C--O 1.241 0.647 0 CA-C-O 121.473 0.654 . . . . 0.0 111.946 -179.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -59.19 131.35 40.7 Favored 'Trans proline' 0 N--CA 1.458 -0.576 0 C-N-CA 122.717 2.278 . . . . 0.0 110.987 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 102.33 -13.64 56.96 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.369 -0.919 . . . . 0.0 111.505 -178.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.3 m -87.82 123.23 32.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.415 0.626 . . . . 0.0 110.561 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.25 141.49 28.49 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.675 179.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 45.8 t -73.65 120.9 19.89 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 121.104 0.478 . . . . 0.0 111.241 -179.487 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.1 t -129.03 64.85 1.46 Allowed 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 5.1 t90 -29.38 128.63 0.24 Allowed Pre-proline 0 N--CA 1.465 0.325 0 CA-C-N 114.26 -1.336 . . . . 0.0 112.978 -176.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -96.64 33.53 9.75 Favored 'Cis proline' 0 CA--C 1.536 0.621 0 C-N-CA 123.542 -1.441 . . . . 0.0 114.149 0.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 15.3 m -140.93 141.77 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 112.96 0.726 . . . . 0.0 112.96 -179.328 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.527 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 77.3 m -82.35 136.34 35.01 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.771 178.344 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.4 t . . . . . 0 C--N 1.323 -0.559 0 CA-C-O 120.852 0.358 . . . . 0.0 110.587 179.731 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.416 ' HG3' ' H ' ' A' ' 15' ' ' ASN . 23.9 pm0 . . . . . 0 N--CA 1.448 -0.57 0 CA-C-O 121.191 0.52 . . . . 0.0 110.293 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.752 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.4 p -75.46 126.43 31.0 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.496 0.665 . . . . 0.0 111.429 -179.674 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.479 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 34.7 t -93.58 37.23 1.06 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.603 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.752 HG23 ' HB ' ' A' ' 8' ' ' THR . 48.0 t -60.91 -41.06 87.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.693 -179.16 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.37 23.22 22.93 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.753 179.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.94 45.16 95.54 Favored Glycine 0 CA--C 1.52 0.357 0 C-N-CA 121.394 -0.431 . . . . 0.0 113.288 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.9 t -150.85 151.98 33.04 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.046 0.45 . . . . 0.0 111.149 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 95.2 m -118.12 144.53 45.59 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.354 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.416 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 31.0 t30 -94.29 -48.53 6.13 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.366 -179.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.405 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 1.6 m -81.03 114.71 50.87 Favored Pre-proline 0 C--O 1.242 0.684 0 CA-C-O 121.334 0.588 . . . . 0.0 112.158 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 14.9 Cg_endo -56.95 137.92 83.89 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.686 2.257 . . . . 0.0 111.998 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 96.76 -23.28 36.1 Favored Glycine 0 N--CA 1.439 -1.147 0 C-N-CA 120.572 -0.823 . . . . 0.0 111.642 -178.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 7.3 m -90.64 131.89 36.08 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 120.404 -0.518 . . . . 0.0 110.913 179.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.9 t -89.87 158.28 17.52 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.823 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.2 t -79.29 129.17 34.2 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.216 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 29.6 m -134.79 67.24 1.51 Allowed 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 178.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 1.3 t90 -28.32 128.95 0.22 Allowed Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 114.11 -1.405 . . . . 0.0 113.091 -177.077 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -95.64 31.69 12.1 Favored 'Cis proline' 0 N--CA 1.457 -0.642 0 C-N-CA 123.475 -1.469 . . . . 0.0 114.371 0.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.2 m -144.26 141.3 24.46 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 98.0 m -82.99 142.8 31.09 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.112 178.3 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.5 t . . . . . 0 C--N 1.326 -0.421 0 CA-C-O 121.092 0.472 . . . . 0.0 110.925 -179.706 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.234 0.278 0 CA-C-O 121.262 0.553 . . . . 0.0 111.009 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.412 ' HB ' HG21 ' A' ' 10' ' ' VAL . 7.9 p -69.12 126.66 30.48 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.202 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 35.9 t -86.66 47.21 1.45 Allowed 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.542 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.412 HG21 ' HB ' ' A' ' 8' ' ' THR . 17.8 t -76.15 69.63 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.505 0.669 . . . . 0.0 110.005 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 163.81 -20.58 0.15 Allowed Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.582 -0.736 . . . . 0.0 111.845 -179.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.87 42.89 4.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.873 -0.68 . . . . 0.0 111.593 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.9 t -152.11 154.42 35.87 Favored 'General case' 0 N--CA 1.446 -0.642 0 CA-C-O 120.67 0.271 . . . . 0.0 110.383 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 96.9 m -131.32 137.07 48.62 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.202 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 35.4 t30 -66.65 -56.54 10.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.082 -178.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 4.8 m -80.74 116.27 61.07 Favored Pre-proline 0 C--O 1.245 0.867 0 CA-C-O 121.622 0.725 . . . . 0.0 112.062 -178.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_exo -60.45 125.91 18.63 Favored 'Trans proline' 0 N--CA 1.46 -0.449 0 C-N-CA 122.543 2.162 . . . . 0.0 110.834 179.329 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.51 -22.31 8.87 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -178.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.2 m -88.6 133.86 34.05 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.932 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.1 m -88.87 146.28 25.05 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.451 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 t -80.07 103.4 9.93 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.472 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 61.3 m -103.82 60.88 0.74 Allowed 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.464 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 11.5 t90 -28.51 130.21 0.21 Allowed Pre-proline 0 N--CA 1.465 0.298 0 CA-C-N 113.492 -1.686 . . . . 0.0 112.703 -177.536 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.4 Cg_endo -93.96 33.07 10.04 Favored 'Cis proline' 0 N--CA 1.456 -0.7 0 C-N-CA 123.16 -1.6 . . . . 0.0 114.492 1.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.5 m -138.9 138.59 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 N-CA-C 112.724 0.638 . . . . 0.0 112.724 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 67.6 m -81.96 135.84 35.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.326 178.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.7 m . . . . . 0 C--N 1.322 -0.601 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -179.764 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 . . . . . 0 N--CA 1.447 -0.582 0 CA-C-O 121.182 0.515 . . . . 0.0 110.28 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 p -78.86 125.77 29.81 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.65 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 22.4 t -87.67 42.21 1.03 Allowed 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.423 0.63 . . . . 0.0 109.869 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.25 -34.84 71.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.865 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.93 22.56 40.37 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.552 179.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.99 45.9 94.5 Favored Glycine 0 C--N 1.332 0.328 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.12 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.3 t -151.36 155.56 38.92 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 120.933 0.397 . . . . 0.0 111.093 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 92.0 m -131.89 139.95 48.92 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.851 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -90.02 -47.29 7.94 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.629 -179.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 m -74.26 112.04 15.31 Favored Pre-proline 0 C--O 1.243 0.728 0 CA-C-O 121.328 0.585 . . . . 0.0 112.33 -178.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -60.76 131.56 38.19 Favored 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 122.625 2.217 . . . . 0.0 111.398 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.25 -28.72 11.25 Favored Glycine 0 N--CA 1.44 -1.083 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -178.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 6.5 m -91.52 128.44 37.35 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.165 0.507 . . . . 0.0 110.566 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 t -91.63 163.74 14.0 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.726 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.5 t -80.22 127.84 32.82 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.278 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 45.1 m -136.89 68.52 1.42 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 178.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.426 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.0 t90 -29.32 130.16 0.23 Allowed Pre-proline 0 N--CA 1.463 0.225 0 CA-C-N 114.133 -1.394 . . . . 0.0 113.064 -177.138 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.9 Cg_endo -95.76 31.28 12.66 Favored 'Cis proline' 0 N--CA 1.458 -0.604 0 C-N-CA 123.252 -1.562 . . . . 0.0 114.247 0.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.412 HG12 ' O ' ' A' ' 24' ' ' PRO . 11.4 m -144.46 146.49 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -179.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 71.5 m -82.57 138.52 34.22 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.77 178.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.4 t . . . . . 0 C--N 1.325 -0.467 0 CA-C-O 120.724 0.297 . . . . 0.0 110.843 -179.664 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 89.3 mt-10 . . . . . 0 C--O 1.235 0.293 0 CA-C-O 121.234 0.54 . . . . 0.0 111.333 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.51 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 5.9 p -95.69 127.58 41.84 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.711 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.427 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 16.1 t -89.48 39.05 0.93 Allowed 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.169 0.509 . . . . 0.0 109.908 179.618 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.42 HG13 ' N ' ' A' ' 11' ' ' GLY . 8.3 p -63.01 -35.17 70.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.938 -179.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.42 ' N ' HG13 ' A' ' 10' ' ' VAL . . . -96.82 23.27 36.22 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.434 179.187 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.99 41.14 99.31 Favored Glycine 0 C--N 1.333 0.366 0 C-N-CA 121.284 -0.484 . . . . 0.0 113.167 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.0 t -151.38 153.17 34.21 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 121.025 0.44 . . . . 0.0 111.467 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 76.9 m -138.26 137.11 37.17 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -92.9 -47.17 7.16 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.559 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.402 ' HA ' ' HD3' ' A' ' 17' ' ' PRO . 86.8 m -65.53 115.46 22.32 Favored Pre-proline 0 C--O 1.24 0.589 0 CA-C-O 121.437 0.637 . . . . 0.0 111.805 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 25.5 Cg_exo -61.83 127.13 20.61 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.674 2.25 . . . . 0.0 111.097 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.74 -18.43 31.97 Favored Glycine 0 N--CA 1.441 -1.014 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.5 m -87.75 124.27 33.42 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.255 0.55 . . . . 0.0 110.361 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.6 m -91.88 146.16 23.98 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.795 179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.9 t -74.22 129.63 38.18 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.28 0.562 . . . . 0.0 111.805 -179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 51.0 m -141.09 68.57 1.34 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 178.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 5.8 t90 -31.21 128.73 0.28 Allowed Pre-proline 0 N--CA 1.463 0.202 0 CA-C-N 114.306 -1.315 . . . . 0.0 112.892 -177.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -97.82 34.18 8.94 Favored 'Cis proline' 0 CA--C 1.538 0.69 0 C-N-CA 123.527 -1.447 . . . . 0.0 113.906 0.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 17.0 m -141.0 145.95 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 -179.225 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.427 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 79.9 m -83.66 128.56 34.62 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 178.042 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.8 t . . . . . 0 C--N 1.324 -0.532 0 N-CA-C 110.129 -0.322 . . . . 0.0 110.129 179.873 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.766 ' HG3' ' HA ' ' A' ' 14' ' ' CYS . 1.1 pm0 . . . . . 0 C--O 1.237 0.421 0 CA-C-O 121.56 0.695 . . . . 0.0 111.2 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.843 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.7 p -85.66 129.71 34.75 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.98 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.449 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 41.0 t -80.77 20.83 0.72 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.284 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.843 HG23 ' HB ' ' A' ' 8' ' ' THR . 53.4 t -58.68 -39.74 77.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 121.059 0.457 . . . . 0.0 110.583 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.12 23.78 33.37 Favored Glycine 0 N--CA 1.446 -0.665 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.055 179.025 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.13 53.48 44.32 Favored Glycine 0 C--N 1.334 0.449 0 C-N-CA 121.369 -0.443 . . . . 0.0 112.95 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 t -151.86 151.32 31.14 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.004 0.43 . . . . 0.0 111.739 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.766 ' HA ' ' HG3' ' A' ' 7' ' ' GLU . 84.4 m -142.34 134.66 27.74 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.189 179.165 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.481 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 71.5 m-80 -95.17 -46.24 6.86 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.933 0.397 . . . . 0.0 111.123 -179.239 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.551 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 7.7 m -64.41 121.2 71.15 Favored Pre-proline 0 C--O 1.238 0.469 0 CA-C-O 121.43 0.633 . . . . 0.0 111.77 -178.808 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -59.07 132.86 49.64 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.81 2.34 . . . . 0.0 112.191 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.68 -10.78 73.84 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.175 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.551 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 71.2 m -88.1 123.15 32.48 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.384 0.611 . . . . 0.0 110.163 179.61 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.6 m -88.97 143.3 26.95 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.184 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -72.85 119.05 16.55 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 30.2 m -135.15 70.67 1.43 Allowed 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.183 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.413 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 8.9 t90 -27.41 128.54 0.2 Allowed Pre-proline 0 N--CA 1.466 0.362 0 CA-C-N 114.036 -1.438 . . . . 0.0 112.916 -178.203 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.413 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 92.3 Cg_endo -96.37 29.53 15.24 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 C-N-CA 123.396 -1.501 . . . . 0.0 114.105 0.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.449 ' HA ' ' H ' ' A' ' 9' ' ' CYS . 9.3 m -145.89 148.06 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 -179.211 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HG2' ' A' ' 7' ' ' GLU . 72.7 m -83.58 141.25 31.71 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.836 178.041 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.2 t . . . . . 0 C--N 1.324 -0.511 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 -179.893 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.433 ' HG2' ' H ' ' A' ' 15' ' ' ASN . 6.6 tp10 . . . . . 0 C--O 1.235 0.336 0 CA-C-O 121.184 0.516 . . . . 0.0 110.229 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 12.6 p -109.92 127.94 55.05 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.041 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.485 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 20.5 t -90.7 38.46 0.95 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.278 0.561 . . . . 0.0 109.873 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.45 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.7 p -62.9 -36.8 77.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.239 -179.155 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.45 ' N ' HG13 ' A' ' 10' ' ' VAL . . . -98.47 28.05 16.68 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.662 179.371 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.07 40.97 97.8 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 121.271 -0.49 . . . . 0.0 112.933 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -151.75 160.06 43.72 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.578 0.228 . . . . 0.0 110.528 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.7 m -143.81 120.57 11.21 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.147 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.433 ' H ' ' HG2' ' A' ' 7' ' ' GLU . 48.8 m-80 -79.32 -35.61 40.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.672 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.491 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 0.2 OUTLIER -67.91 114.27 19.45 Favored Pre-proline 0 C--O 1.242 0.709 0 CA-C-O 121.252 0.549 . . . . 0.0 111.639 -179.112 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -59.37 135.8 67.64 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.765 2.31 . . . . 0.0 112.322 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.65 -6.39 73.87 Favored Glycine 0 N--CA 1.444 -0.821 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.698 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.491 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 84.2 m -89.76 132.5 35.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 117.461 0.63 . . . . 0.0 111.335 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 m -88.93 148.4 23.83 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.297 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.6 t -79.31 127.54 32.2 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.012 0.434 . . . . 0.0 111.285 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.6 m -137.93 67.84 1.41 Allowed 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.703 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 9.3 t90 -31.39 128.83 0.29 Allowed Pre-proline 0 N--CA 1.465 0.294 0 CA-C-N 114.356 -1.293 . . . . 0.0 112.793 -177.211 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -97.18 31.9 11.64 Favored 'Cis proline' 0 N--CA 1.456 -0.709 0 C-N-CA 123.554 -1.436 . . . . 0.0 113.772 0.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.487 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 16.1 m -136.64 141.79 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -178.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.485 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 80.7 m -85.0 135.02 34.2 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.608 178.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.2 t . . . . . 0 C--N 1.323 -0.569 0 CA-C-O 121.557 0.694 . . . . 0.0 110.959 178.971 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 . . . . . 0 CA--C 1.518 -0.287 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.499 ' HB ' HG22 ' A' ' 10' ' ' VAL . 2.2 p -74.89 123.55 25.27 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-O 121.443 0.64 . . . . 0.0 110.52 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.503 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 21.8 t -93.77 35.14 1.15 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.91 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.499 HG22 ' HB ' ' A' ' 8' ' ' THR . 44.5 t -62.31 -40.76 89.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.286 -179.635 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.05 24.68 23.61 Favored Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.629 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.91 47.55 90.07 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 121.34 -0.457 . . . . 0.0 113.287 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.8 t -150.89 155.9 40.11 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.854 0.359 . . . . 0.0 110.954 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 94.8 m -133.26 -44.02 0.85 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.756 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 73.76 -46.51 0.63 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.778 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.6 m -63.04 110.68 3.75 Favored Pre-proline 0 C--O 1.243 0.749 0 CA-C-O 121.511 0.672 . . . . 0.0 111.863 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.62 131.77 37.24 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.573 2.182 . . . . 0.0 111.989 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.62 -22.85 37.07 Favored Glycine 0 N--CA 1.437 -1.272 0 C-N-CA 120.398 -0.906 . . . . 0.0 111.583 -179.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 15.3 m -98.43 134.7 41.05 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.342 0.591 . . . . 0.0 111.623 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.3 m -99.05 149.47 22.98 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.802 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 23.3 t -76.44 125.04 28.49 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.079 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 32.0 t -126.17 64.44 1.23 Allowed 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 178.365 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 5.1 t90 -26.74 128.48 0.19 Allowed Pre-proline 0 N--CA 1.467 0.417 0 CA-C-N 114.066 -1.425 . . . . 0.0 113.236 -177.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -95.34 30.03 14.64 Favored 'Cis proline' 0 CA--C 1.536 0.584 0 C-N-CA 123.451 -1.479 . . . . 0.0 113.964 0.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.7 m -139.15 137.17 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 121.558 0.694 . . . . 0.0 112.633 -179.498 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 79.2 m -81.99 140.05 34.19 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.475 178.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.3 t . . . . . 0 C--N 1.323 -0.563 0 CA-C-O 120.802 0.334 . . . . 0.0 110.636 -179.662 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.616 ' HG2' HD22 ' A' ' 15' ' ' ASN . 1.1 mp0 . . . . . 0 CA--C 1.515 -0.384 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.4 p -70.25 121.79 18.28 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-O 121.528 0.68 . . . . 0.0 110.498 179.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 18.9 t -87.96 40.98 0.97 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.903 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.1 m -62.36 -33.93 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.333 -179.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.84 22.45 39.55 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.177 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.47 45.69 94.12 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.837 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -151.87 155.74 38.73 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.012 0.434 . . . . 0.0 111.426 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 55.9 m -133.61 146.6 51.08 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 179.349 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.616 HD22 ' HG2' ' A' ' 7' ' ' GLU . 21.4 p30 -102.71 -35.07 8.81 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.303 -0.559 . . . . 0.0 112.247 -179.005 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 13.0 m -80.74 112.84 35.21 Favored Pre-proline 0 C--O 1.244 0.795 0 CA-C-O 121.542 0.687 . . . . 0.0 111.488 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 39.2 Cg_exo -59.52 129.06 29.42 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.677 2.251 . . . . 0.0 111.803 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.2 -23.21 19.19 Favored Glycine 0 N--CA 1.438 -1.194 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.2 m -95.16 127.08 40.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.306 0.574 . . . . 0.0 111.515 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.62 147.19 23.47 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.195 -179.52 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.2 t -71.3 123.94 23.42 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.201 0.524 . . . . 0.0 111.176 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 37.9 m -128.44 66.54 1.39 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 178.361 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.424 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 3.9 t90 -27.79 129.07 0.21 Allowed Pre-proline 0 N--CA 1.467 0.396 0 CA-C-N 113.904 -1.498 . . . . 0.0 113.051 -177.104 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 90.0 Cg_endo -95.3 31.34 12.61 Favored 'Cis proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.347 -1.522 . . . . 0.0 114.338 0.637 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.6 m -141.49 137.59 32.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 83.0 m -82.26 134.55 35.29 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.595 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.2 t . . . . . 0 C--N 1.324 -0.529 0 CA-C-O 121.296 0.57 . . . . 0.0 110.879 179.492 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.462 ' H ' ' CD ' ' A' ' 7' ' ' GLU . 1.1 pm0 . . . . . 0 N--CA 1.452 -0.363 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.405 ' HB ' HG22 ' A' ' 10' ' ' VAL . 1.4 p -72.0 125.41 27.18 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-O 121.684 0.754 . . . . 0.0 111.625 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.566 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.8 t -104.25 42.22 1.22 Allowed 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.164 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.405 HG22 ' HB ' ' A' ' 8' ' ' THR . 45.9 t -59.11 -40.94 82.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.967 -178.649 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.11 16.79 54.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.523 179.252 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.72 41.2 97.39 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 121.504 -0.379 . . . . 0.0 113.106 179.487 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.8 t -152.84 140.64 20.05 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-O 121.42 0.629 . . . . 0.0 112.26 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 91.1 m -152.49 148.9 27.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.613 -1.176 . . . . 0.0 109.087 178.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.543 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 4.5 m120 -115.71 11.64 15.76 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.864 -0.334 . . . . 0.0 111.281 -179.549 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -81.12 107.58 8.08 Favored Pre-proline 0 C--O 1.24 0.601 0 CA-C-O 121.248 0.547 . . . . 0.0 110.995 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.543 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 29.4 Cg_exo -60.91 131.81 39.11 Favored 'Trans proline' 0 CA--C 1.515 -0.431 0 C-N-CA 122.64 2.227 . . . . 0.0 112.684 -179.225 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.11 -18.16 56.75 Favored Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.221 -179.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 36.3 m -105.36 130.75 53.4 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.6 0.714 . . . . 0.0 111.668 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.6 m -97.98 148.47 23.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.141 -178.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.598 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 37.6 t -72.0 128.73 36.63 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.954 179.666 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.5 m -132.26 67.41 1.53 Allowed 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.408 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 3.7 t90 -26.61 128.67 0.19 Allowed Pre-proline 0 N--CA 1.467 0.385 0 CA-C-N 114.054 -1.43 . . . . 0.0 113.095 -177.203 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.408 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 85.4 Cg_endo -94.76 29.23 15.98 Favored 'Cis proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.464 -1.473 . . . . 0.0 114.261 0.595 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 6.7 m -143.04 137.16 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 CA-C-O 121.484 0.659 . . . . 0.0 112.653 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.598 ' SG ' ' HA ' ' A' ' 21' ' ' CYS . 61.2 m -83.56 140.83 32.01 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.876 178.441 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.9 t . . . . . 0 N--CA 1.448 -0.526 0 CA-C-O 120.878 0.37 . . . . 0.0 110.311 179.84 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 . . . . . 0 C--O 1.237 0.416 0 CA-C-O 121.176 0.512 . . . . 0.0 111.007 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.657 HG21 HG13 ' A' ' 25' ' ' VAL . 3.2 p -89.8 126.84 35.83 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.563 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 17.3 t -83.99 45.21 1.07 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.05 0.452 . . . . 0.0 110.424 179.757 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 48.5 t -63.54 -39.89 87.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 120.993 0.425 . . . . 0.0 110.74 -179.143 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.73 22.38 25.07 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.738 -0.664 . . . . 0.0 112.948 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.98 39.81 94.67 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.335 -0.459 . . . . 0.0 113.269 179.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.7 t -152.25 158.31 42.64 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-O 120.773 0.32 . . . . 0.0 110.944 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -139.91 131.33 26.9 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -83.0 -46.42 12.89 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -178.35 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 4.5 m -70.38 113.61 19.49 Favored Pre-proline 0 C--O 1.246 0.915 0 CA-C-O 121.572 0.701 . . . . 0.0 112.343 -178.412 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -61.22 127.56 22.46 Favored 'Trans proline' 0 N--CA 1.459 -0.555 0 C-N-CA 122.673 2.249 . . . . 0.0 111.291 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 116.52 -26.3 8.63 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -178.157 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.7 m -89.69 130.12 36.02 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 121.338 0.59 . . . . 0.0 110.947 179.178 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 m -96.6 146.95 24.37 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.063 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.7 t -72.26 127.49 32.74 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.203 0.525 . . . . 0.0 111.465 -179.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 28.3 t -136.94 64.66 1.53 Allowed 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 178.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 4.1 t90 -29.21 128.61 0.23 Allowed Pre-proline 0 N--CA 1.466 0.353 0 CA-C-N 114.381 -1.281 . . . . 0.0 113.04 -177.144 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -97.31 34.26 8.96 Favored 'Cis proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.671 -1.387 . . . . 0.0 114.011 0.67 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.657 HG13 HG21 ' A' ' 8' ' ' THR . 17.6 m -140.82 146.96 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 O-C-N 121.898 -0.501 . . . . 0.0 112.33 -179.331 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 72.6 m -81.93 123.73 29.12 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 178.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.8 t . . . . . 0 C--N 1.323 -0.551 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.775 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 . . . . . 0 N--CA 1.452 -0.373 0 CA-C-O 121.259 0.552 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 2.0 p -98.07 126.68 43.61 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.564 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 35.1 t -87.81 44.63 1.2 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.755 179.13 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.44 HG11 ' N ' ' A' ' 11' ' ' GLY . 7.2 p -62.38 -38.35 81.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.517 -178.734 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.44 ' N ' HG11 ' A' ' 10' ' ' VAL . . . -94.42 26.49 17.46 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.856 179.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.15 38.16 92.73 Favored Glycine 0 C--N 1.333 0.391 0 C-N-CA 121.31 -0.471 . . . . 0.0 112.949 179.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.9 t -152.51 163.11 40.22 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.6 m -145.02 120.12 10.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.027 179.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 33.5 t30 -78.94 -36.44 41.72 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.616 179.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 5.9 m -63.04 109.63 2.66 Favored Pre-proline 0 C--O 1.242 0.667 0 CA-C-O 121.414 0.626 . . . . 0.0 111.646 -179.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_exo -61.61 130.23 30.82 Favored 'Trans proline' 0 CA--C 1.515 -0.463 0 C-N-CA 122.844 2.362 . . . . 0.0 112.535 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.9 -20.02 52.27 Favored Glycine 0 N--CA 1.44 -1.062 0 CA-C-N 115.327 -0.852 . . . . 0.0 111.617 -179.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 72.0 m -89.81 123.93 34.22 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.321 0.581 . . . . 0.0 110.981 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.4 p -88.99 143.46 26.84 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.359 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.4 t -69.92 128.23 35.64 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.26 0.552 . . . . 0.0 112.005 -179.044 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 35.0 t -136.98 66.42 1.47 Allowed 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 6.8 t90 -29.46 128.62 0.24 Allowed Pre-proline 0 N--CA 1.464 0.269 0 CA-C-N 114.284 -1.325 . . . . 0.0 113.008 -176.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -97.0 32.47 10.96 Favored 'Cis proline' 0 N--CA 1.458 -0.599 0 C-N-CA 123.49 -1.463 . . . . 0.0 114.031 0.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 15.9 m -139.42 142.87 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 113.032 0.752 . . . . 0.0 113.032 -179.205 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 58.5 m -83.09 131.25 35.16 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.627 178.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 t . . . . . 0 C--N 1.324 -0.51 0 CA-C-O 121.129 0.49 . . . . 0.0 111.062 -179.781 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.604 ' OE1' ' HB3' ' A' ' 14' ' ' CYS . 64.6 mt-10 . . . . . 0 N--CA 1.451 -0.399 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 17.3 p -75.34 123.75 25.9 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.131 0.491 . . . . 0.0 110.958 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.2 t -103.74 39.81 1.54 Allowed 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.434 179.7 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.439 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.1 p -59.16 -36.96 65.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.343 -178.766 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.439 ' N ' HG13 ' A' ' 10' ' ' VAL . . . -101.33 27.89 18.49 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.317 179.304 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.47 35.67 89.43 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 121.365 -0.445 . . . . 0.0 112.993 179.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.8 t -153.06 156.4 38.66 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 120.646 0.26 . . . . 0.0 110.838 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.604 ' HB3' ' OE1' ' A' ' 7' ' ' GLU . 61.0 m -150.05 -153.09 0.47 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.787 179.237 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.407 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 72.4 m-80 -133.12 -52.94 0.9 Allowed 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -178.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 51.3 m -66.34 108.47 2.33 Favored Pre-proline 0 C--O 1.249 1.047 0 N-CA-C 113.523 0.934 . . . . 0.0 113.523 -177.375 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.407 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 37.4 Cg_endo -65.6 125.48 14.44 Favored 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 122.461 2.107 . . . . 0.0 110.485 178.353 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.55 -27.38 6.03 Favored Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -177.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 14.2 m -89.86 129.41 36.23 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 120.15 -0.62 . . . . 0.0 110.067 178.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.7 m -88.14 144.86 26.23 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.533 -179.17 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.2 t -72.98 122.68 22.11 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.12 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.0 m -127.73 67.28 1.33 Allowed 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 178.583 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.3 t90 -26.5 127.95 0.19 Allowed Pre-proline 0 N--CA 1.467 0.395 0 CA-C-N 113.921 -1.491 . . . . 0.0 113.058 -177.18 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 80.5 Cg_endo -95.56 31.55 12.3 Favored 'Cis proline' 0 N--CA 1.456 -0.707 0 C-N-CA 123.482 -1.466 . . . . 0.0 114.38 0.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.424 HG11 ' O ' ' A' ' 24' ' ' PRO . 6.0 m -145.03 138.06 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 N-CA-C 112.873 0.694 . . . . 0.0 112.873 -179.526 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.482 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 94.6 m -82.19 140.29 33.81 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.571 178.254 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.321 -0.646 0 CA-C-O 121.041 0.448 . . . . 0.0 110.196 179.387 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 . . . . . 0 N--CA 1.452 -0.368 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.7 p -77.98 123.9 27.36 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-O 121.414 0.625 . . . . 0.0 110.855 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 28.2 t -90.52 39.97 1.0 Allowed 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.052 179.775 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.3 t -61.99 -40.31 86.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.653 -179.245 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.47 22.83 30.81 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.881 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.19 47.6 88.4 Favored Glycine 0 CA--C 1.52 0.362 0 C-N-CA 121.289 -0.482 . . . . 0.0 113.206 179.306 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.4 t -151.18 155.98 39.99 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 122.565 -0.373 . . . . 0.0 111.095 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 82.9 m -140.1 127.73 21.67 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.656 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -81.44 -41.18 22.22 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -179.202 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.413 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 15.5 m -75.82 109.46 8.15 Favored Pre-proline 0 C--O 1.246 0.885 0 CA-C-O 121.545 0.688 . . . . 0.0 112.223 -178.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 27.6 Cg_endo -61.96 131.19 33.83 Favored 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 122.564 2.176 . . . . 0.0 111.386 179.524 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 110.61 -29.32 9.13 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 -178.305 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 7.4 m -89.59 133.37 34.65 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.526 179.221 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.3 m -95.23 148.79 22.02 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.959 -178.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.3 t -70.07 126.6 30.15 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.875 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.7 m -134.22 67.96 1.5 Allowed 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.41 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 1.5 t90 -28.35 128.16 0.22 Allowed Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 113.976 -1.465 . . . . 0.0 112.989 -176.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.8 Cg_endo -96.71 32.52 10.92 Favored 'Cis proline' 0 CA--C 1.537 0.64 0 C-N-CA 123.595 -1.419 . . . . 0.0 114.151 0.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.2 m -143.71 141.78 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -179.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.436 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 65.8 m -82.68 132.54 35.18 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.234 178.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.2 t . . . . . 0 C--O 1.239 0.508 0 CA-C-O 121.014 0.435 . . . . 0.0 111.557 -179.869 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.644 ' HG3' ' HB3' ' A' ' 15' ' ' ASN . 47.3 mm-40 . . . . . 0 C--O 1.239 0.539 0 CA-C-O 122.028 0.918 . . . . 0.0 112.61 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.575 ' HB ' HG22 ' A' ' 10' ' ' VAL . 5.9 p -110.22 127.85 55.18 Favored 'General case' 0 N--CA 1.439 -1.019 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.825 178.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 12.7 t -83.65 41.35 0.78 Allowed 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.919 0.39 . . . . 0.0 110.841 -179.403 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.575 HG22 ' HB ' ' A' ' 8' ' ' THR . 47.6 t -64.73 -42.01 93.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.174 0.511 . . . . 0.0 110.314 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.24 28.62 12.3 Favored Glycine 0 N--CA 1.45 -0.397 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.638 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.08 42.55 98.52 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 121.27 -0.49 . . . . 0.0 113.237 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.8 t -151.61 160.17 43.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.648 0.261 . . . . 0.0 110.756 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.7 m -146.03 124.75 12.57 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.191 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.644 ' HB3' ' HG3' ' A' ' 7' ' ' GLU . 28.2 t-20 -81.04 -46.73 14.58 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.657 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.458 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 0.2 OUTLIER -58.33 111.77 4.01 Favored Pre-proline 0 C--O 1.238 0.481 0 CA-C-O 121.221 0.534 . . . . 0.0 112.146 -178.857 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -62.24 130.59 31.0 Favored 'Trans proline' 0 N--CA 1.46 -0.448 0 C-N-CA 122.631 2.221 . . . . 0.0 111.63 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.38 -14.72 63.14 Favored Glycine 0 N--CA 1.442 -0.945 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.763 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.458 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 95.9 m -88.98 126.82 35.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.243 0.544 . . . . 0.0 110.816 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.87 148.76 23.69 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.412 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 t -75.48 128.6 35.67 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.127 0.489 . . . . 0.0 112.187 -178.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 57.6 m -139.99 69.13 1.35 Allowed 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 178.193 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 11.4 t90 -31.62 129.04 0.3 Allowed Pre-proline 0 N--CA 1.465 0.292 0 CA-C-N 114.227 -1.351 . . . . 0.0 112.886 -177.173 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -98.06 33.16 9.83 Favored 'Cis proline' 0 N--CA 1.457 -0.633 0 C-N-CA 123.71 -1.371 . . . . 0.0 113.75 0.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.404 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 24.6 m -139.43 145.85 26.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -178.837 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 61.3 m -84.63 138.26 32.8 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.7 t . . . . . 0 C--N 1.324 -0.533 0 CA-C-O 121.057 0.456 . . . . 0.0 110.449 179.417 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 111.972 -0.451 . . . . 0.0 111.972 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 47.0 tp -75.8 123.05 88.16 Favored Pre-proline 0 C--N 1.326 -0.43 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -68.72 131.58 23.08 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.627 2.218 . . . . 0.0 111.868 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 46.6 t -70.11 -44.75 77.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.445 0.64 . . . . 0.0 110.29 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 1.6 m -95.55 156.18 16.43 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.644 179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -162.34 17.87 0.16 Allowed Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.314 -0.946 . . . . 0.0 112.657 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -79.47 136.99 37.07 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.556 ' HB ' HG21 ' A' ' 10' ' ' VAL . 18.8 p -71.72 122.43 20.61 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 120.909 0.385 . . . . 0.0 110.452 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.521 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 17.0 t -93.05 37.05 1.03 Allowed 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.981 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.556 HG21 ' HB ' ' A' ' 8' ' ' THR . 46.1 t -60.4 -41.14 86.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.777 -179.241 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.86 24.92 24.1 Favored Glycine 0 N--CA 1.451 -0.3 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.948 179.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.85 47.92 88.06 Favored Glycine 0 C--N 1.333 0.363 0 C-N-CA 121.223 -0.513 . . . . 0.0 113.326 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 t -150.97 154.1 36.46 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.872 0.368 . . . . 0.0 111.082 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 76.8 m -134.48 138.07 44.43 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.87 179.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -79.91 -53.99 6.23 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.889 -178.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.573 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 6.7 m -73.1 115.06 36.77 Favored Pre-proline 0 C--O 1.243 0.732 0 CA-C-O 121.368 0.604 . . . . 0.0 112.297 -178.321 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -63.69 121.86 9.75 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.529 2.153 . . . . 0.0 110.635 179.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.14 -16.11 13.16 Favored Glycine 0 N--CA 1.439 -1.112 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 -178.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.573 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 76.5 m -89.14 132.43 34.83 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 m -88.77 144.97 25.89 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.272 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.9 t -78.48 126.35 30.64 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.077 0.465 . . . . 0.0 110.811 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.0 m -132.66 67.93 1.52 Allowed 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 4.7 t90 -29.15 127.88 0.24 Allowed Pre-proline 0 N--CA 1.465 0.279 0 CA-C-N 114.06 -1.427 . . . . 0.0 112.841 -177.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -97.04 32.8 10.51 Favored 'Cis proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.582 -1.424 . . . . 0.0 114.053 0.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 10.8 m -140.68 139.39 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.521 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.3 m -83.36 137.82 33.79 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.649 178.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.1 t -150.77 149.15 29.39 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.092 0.472 . . . . 0.0 110.227 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 39.8 ttt85 -100.17 125.16 46.26 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.096 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 5.9 m120 . . . . . 0 C--N 1.319 -0.739 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.474 -179.575 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.4 0 N-CA-C 111.87 -0.492 . . . . 0.0 111.87 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.497 HD12 ' HD2' ' A' ' 3' ' ' PRO . 46.9 tp -72.17 123.13 89.07 Favored Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.622 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.497 ' HD2' HD12 ' A' ' 2' ' ' LEU . 70.7 Cg_endo -74.73 48.49 1.93 Allowed 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.973 2.449 . . . . 0.0 112.367 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.36 -35.68 63.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.449 0.642 . . . . 0.0 110.653 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.7 m -137.42 -55.89 0.69 Allowed 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.102 -0.953 . . . . 0.0 110.035 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.76 -38.7 2.81 Favored Glycine 0 C--N 1.322 -0.234 0 CA-C-N 115.682 -0.69 . . . . 0.0 113.538 179.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.452 ' OE2' ' HB3' ' A' ' 15' ' ' ASN . 20.7 mt-10 -53.44 134.37 40.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.798 0.332 . . . . 0.0 111.01 -179.394 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.434 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 3.0 p -88.29 127.51 35.47 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 121.105 0.478 . . . . 0.0 110.825 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.561 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 15.0 t -91.28 40.52 1.03 Allowed 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.136 0.493 . . . . 0.0 109.84 179.465 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.6 p -61.81 -36.28 72.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.08 -179.129 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.56 24.23 31.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.829 -0.7 . . . . 0.0 112.72 179.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.5 41.59 97.23 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.257 -0.497 . . . . 0.0 113.181 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.8 t -151.48 152.58 33.2 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 121.011 0.434 . . . . 0.0 111.309 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 71.1 m -132.07 140.1 48.75 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.076 179.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.452 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 9.7 t30 -91.95 -47.91 7.04 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.609 -178.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 85.2 m -70.57 116.45 45.64 Favored Pre-proline 0 C--O 1.242 0.709 0 CA-C-O 121.322 0.582 . . . . 0.0 111.801 -179.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -61.56 126.29 18.78 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.681 2.254 . . . . 0.0 111.019 179.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 110.62 -18.25 27.38 Favored Glycine 0 N--CA 1.44 -1.043 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -178.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.0 m -87.4 124.85 33.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.174 0.512 . . . . 0.0 110.273 179.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 m -89.35 145.52 25.3 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.854 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 53.7 t -77.03 126.81 31.58 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 121.173 0.511 . . . . 0.0 111.306 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -137.37 68.69 1.41 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 4.7 t90 -31.04 129.07 0.27 Allowed Pre-proline 0 N--CA 1.463 0.216 0 CA-C-N 114.111 -1.404 . . . . 0.0 112.832 -177.164 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -97.08 33.24 10.01 Favored 'Cis proline' 0 N--CA 1.456 -0.678 0 C-N-CA 123.591 -1.421 . . . . 0.0 114.026 0.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.434 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 14.8 m -140.11 141.95 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 N-CA-C 113.222 0.823 . . . . 0.0 113.222 -179.121 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.561 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 84.1 m -84.01 135.47 34.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.03 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.2 t -150.72 146.69 26.6 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.126 0.488 . . . . 0.0 110.226 179.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.41 ' HG2' HH11 ' A' ' 28' ' ' ARG . 43.0 ttp85 -80.41 108.64 14.2 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.469 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 . . . . . 0 C--N 1.319 -0.738 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.852 -179.418 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.599 0 N-CA-C 111.971 -0.452 . . . . 0.0 111.971 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 14.6 mt -148.15 135.47 10.57 Favored Pre-proline 0 C--N 1.325 -0.47 0 CA-C-O 120.953 0.406 . . . . 0.0 110.838 179.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.15 52.63 3.16 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 123.441 2.76 . . . . 0.0 112.768 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 48.3 t -71.39 -45.49 68.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.432 0.634 . . . . 0.0 110.466 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.46 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 6.5 m -89.08 160.39 17.08 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.329 179.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -175.28 25.71 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.898 -0.668 . . . . 0.0 111.983 179.483 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -85.53 144.99 27.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.089 0.471 . . . . 0.0 110.133 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 p -77.34 125.48 29.4 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-O 121.313 0.577 . . . . 0.0 110.908 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.484 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 26.0 t -92.71 37.75 1.01 Allowed 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.784 -0.643 . . . . 0.0 109.616 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.1 p -62.02 -35.46 68.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.008 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.78 21.64 43.67 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.723 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.56 45.61 95.98 Favored Glycine 0 CA--C 1.519 0.34 0 C-N-CA 121.249 -0.501 . . . . 0.0 113.297 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.9 t -150.82 152.52 33.88 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.881 0.372 . . . . 0.0 111.108 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 90.1 m -130.48 140.44 50.53 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.799 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.5 t30 -89.5 -48.91 7.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.918 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.46 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 1.8 m -76.1 112.54 21.21 Favored Pre-proline 0 C--O 1.244 0.801 0 CA-C-O 121.426 0.631 . . . . 0.0 112.572 -178.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 19.3 Cg_endo -60.2 133.04 47.37 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.682 2.255 . . . . 0.0 111.481 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.51 -27.19 17.56 Favored Glycine 0 N--CA 1.438 -1.218 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 12.3 m -90.7 128.64 36.72 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.061 0.458 . . . . 0.0 110.232 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.5 t -90.83 160.98 15.46 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.929 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 46.1 t -80.67 131.45 35.47 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.55 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.2 m -138.38 68.77 1.39 Allowed 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 178.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 2.0 t90 -29.56 129.16 0.24 Allowed Pre-proline 0 N--CA 1.466 0.33 0 CA-C-N 114.062 -1.426 . . . . 0.0 113.015 -177.047 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.402 ' O ' HG12 ' A' ' 25' ' ' VAL . 94.3 Cg_endo -96.66 33.26 10.02 Favored 'Cis proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.484 -1.465 . . . . 0.0 114.151 0.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.402 HG12 ' O ' ' A' ' 24' ' ' PRO . 10.6 m -144.01 143.96 23.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -179.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.484 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.1 m -82.76 143.81 30.61 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.2 t -150.01 158.48 44.21 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.371 0.605 . . . . 0.0 111.311 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.427 ' HA ' ' HD2' ' A' ' 28' ' ' ARG . 29.8 tpt85 -81.22 52.44 1.81 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.003 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 . . . . . 0 C--N 1.323 -0.564 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.53 179.514 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.404 0 N-CA-C 112.125 -0.39 . . . . 0.0 112.125 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.6 tp -66.81 117.84 49.06 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 115.629 -0.285 . . . . 0.0 111.072 -179.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -76.92 58.98 6.28 Favored 'Trans proline' 0 N--CA 1.462 -0.349 0 C-N-CA 123.369 2.713 . . . . 0.0 111.718 179.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.563 HG13 ' N ' ' A' ' 5' ' ' CYS . 13.7 p -55.57 -39.85 56.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.397 -179.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.563 ' N ' HG13 ' A' ' 4' ' ' VAL . 62.7 m -65.61 -52.87 48.76 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.683 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.61 10.17 63.27 Favored Glycine 0 C--N 1.322 -0.24 0 CA-C-N 115.078 -0.965 . . . . 0.0 113.234 179.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -73.63 138.97 45.16 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.81 0.338 . . . . 0.0 110.583 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.478 ' HB ' HG23 ' A' ' 10' ' ' VAL . 10.8 p -82.25 124.87 30.33 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.151 179.105 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 23.9 t -87.62 53.03 2.65 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.246 0.546 . . . . 0.0 110.725 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.478 HG23 ' HB ' ' A' ' 8' ' ' THR . 4.1 t -78.99 48.84 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-O 121.46 0.648 . . . . 0.0 110.781 -179.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.06 26.89 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.888 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 55.06 43.95 83.31 Favored Glycine 0 C--N 1.336 0.529 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.099 179.358 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.2 t -151.55 153.74 35.13 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.11 0.481 . . . . 0.0 111.545 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.4 m -142.33 134.34 27.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.186 -0.915 . . . . 0.0 108.578 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 62.0 m-80 -84.07 -45.18 13.32 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.591 0.234 . . . . 0.0 111.561 -178.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.5 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 4.1 m -69.94 113.66 19.26 Favored Pre-proline 0 C--O 1.244 0.811 0 CA-C-O 121.44 0.638 . . . . 0.0 112.002 -178.649 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -60.12 131.0 36.75 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.695 2.264 . . . . 0.0 111.345 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.48 -26.2 15.41 Favored Glycine 0 N--CA 1.439 -1.129 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -178.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.7 m -89.31 126.17 35.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.504 0.669 . . . . 0.0 111.112 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.3 m -94.07 147.55 23.03 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.597 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.1 t -72.38 114.87 10.97 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.074 0.464 . . . . 0.0 111.278 -179.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 36.8 m -123.43 64.47 1.01 Allowed 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 178.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.44 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 8.8 t90 -27.6 129.39 0.2 Allowed Pre-proline 0 N--CA 1.463 0.203 0 CA-C-N 113.798 -1.547 . . . . 0.0 113.104 -177.063 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.44 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 96.6 Cg_endo -94.71 27.89 18.05 Favored 'Cis proline' 0 N--CA 1.457 -0.668 0 C-N-CA 123.226 -1.573 . . . . 0.0 114.143 0.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.3 m -137.37 140.1 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -179.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 72.8 m -82.7 129.95 35.04 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.672 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t -150.71 161.45 42.6 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 52.0 ttp85 -75.21 104.3 5.72 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 3.8 m120 . . . . . 0 C--N 1.321 -0.64 0 CA-C-O 121.032 0.444 . . . . 0.0 111.216 -179.366 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.444 0 N-CA-C 111.899 -0.481 . . . . 0.0 111.899 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.476 ' N ' HD13 ' A' ' 2' ' ' LEU . 7.3 mp -67.0 128.41 93.86 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.798 0.299 . . . . 0.0 110.468 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -73.81 48.42 1.65 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.146 2.564 . . . . 0.0 112.828 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 23.8 t -101.68 -20.98 5.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.418 0.628 . . . . 0.0 109.813 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.583 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 1.6 m -62.87 154.24 30.72 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.167 -0.924 . . . . 0.0 111.657 -179.288 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -160.14 28.46 0.35 Allowed Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.535 179.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.58 ' HG2' ' HB3' ' A' ' 15' ' ' ASN . 2.8 mp0 -85.32 137.33 33.03 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.3 p -73.31 124.24 25.33 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 120.844 0.354 . . . . 0.0 110.351 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.57 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 21.2 t -89.44 38.35 0.9 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.255 0.55 . . . . 0.0 110.019 179.669 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.01 -36.23 72.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.964 -179.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.04 25.59 26.96 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.746 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.14 45.29 95.53 Favored Glycine 0 C--N 1.331 0.277 0 C-N-CA 121.165 -0.54 . . . . 0.0 113.131 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.7 t -151.04 154.43 37.02 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.927 0.394 . . . . 0.0 111.065 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 98.8 m -130.98 139.58 50.03 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.813 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.58 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 30.4 t30 -85.26 -50.27 7.5 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.764 -179.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.583 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 5.6 m -80.59 109.1 11.64 Favored Pre-proline 0 C--O 1.251 1.174 0 CA-C-O 121.821 0.82 . . . . 0.0 112.584 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.505 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 24.5 Cg_exo -61.4 127.08 20.85 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.686 2.257 . . . . 0.0 111.103 179.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.523 ' O ' ' HG3' ' A' ' 28' ' ' ARG . . . 122.02 -29.73 5.47 Favored Glycine 0 N--CA 1.434 -1.458 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -178.039 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.609 ' HA ' ' HB2' ' A' ' 28' ' ' ARG . 19.0 m -88.99 143.1 27.09 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.256 -0.577 . . . . 0.0 110.529 179.061 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 m -97.08 149.33 22.08 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.559 -179.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.3 t -74.93 128.21 35.04 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.153 0.502 . . . . 0.0 111.15 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.0 m -133.84 67.79 1.51 Allowed 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 4.8 t90 -29.58 128.49 0.24 Allowed Pre-proline 0 N--CA 1.464 0.256 0 CA-C-N 114.118 -1.401 . . . . 0.0 112.811 -177.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -96.78 34.13 9.15 Favored 'Cis proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.615 -1.41 . . . . 0.0 114.201 0.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 10.8 m -143.11 139.97 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.57 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 70.9 m -83.05 132.21 35.13 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.038 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.9 t -152.01 168.41 25.32 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.609 ' HB2' ' HA ' ' A' ' 19' ' ' CYS . 0.3 OUTLIER -173.72 -160.53 0.11 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.046 0.45 . . . . 0.0 111.172 179.77 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 . . . . . 0 C--N 1.322 -0.595 0 CA-C-N 114.878 -1.056 . . . . 0.0 109.236 179.951 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.019 -0.432 . . . . 0.0 112.019 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.1 tp 63.41 94.07 0.05 OUTLIER Pre-proline 0 N--CA 1.464 0.236 0 C-N-CA 123.205 0.602 . . . . 0.0 111.404 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -71.31 120.45 6.99 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 122.333 2.022 . . . . 0.0 111.68 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 32.4 t -66.12 -40.93 88.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.324 0.583 . . . . 0.0 110.998 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.442 ' HB2' ' O ' ' A' ' 26' ' ' CYS . 81.4 m -89.31 -49.96 6.4 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.769 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.77 -38.25 3.19 Favored Glycine 0 C--N 1.319 -0.414 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.749 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.435 ' OE2' ' HB3' ' A' ' 15' ' ' ASN . 23.1 mt-10 -58.11 135.18 56.98 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.749 0.309 . . . . 0.0 110.706 -179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 2.8 p -88.33 127.14 35.48 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-O 121.099 0.476 . . . . 0.0 110.989 179.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.527 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 18.1 t -91.79 40.43 1.04 Allowed 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.159 0.504 . . . . 0.0 109.881 179.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -62.12 -36.22 73.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.086 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.6 24.1 30.96 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.798 179.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.23 42.04 97.05 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.25 -0.5 . . . . 0.0 113.072 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.0 t -151.82 156.18 39.68 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.842 0.353 . . . . 0.0 111.023 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.9 m -135.8 136.88 41.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.302 179.386 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.435 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 9.8 t30 -87.48 -48.95 7.53 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.996 -178.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 88.4 m -70.98 118.38 65.0 Favored Pre-proline 0 C--O 1.241 0.647 0 CA-C-O 121.473 0.654 . . . . 0.0 111.946 -179.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -59.19 131.35 40.7 Favored 'Trans proline' 0 N--CA 1.458 -0.576 0 C-N-CA 122.717 2.278 . . . . 0.0 110.987 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 102.33 -13.64 56.96 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.369 -0.919 . . . . 0.0 111.505 -178.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.3 m -87.82 123.23 32.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.415 0.626 . . . . 0.0 110.561 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.25 141.49 28.49 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.675 179.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 45.8 t -73.65 120.9 19.89 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 121.104 0.478 . . . . 0.0 111.241 -179.487 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.1 t -129.03 64.85 1.46 Allowed 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 5.1 t90 -29.38 128.63 0.24 Allowed Pre-proline 0 N--CA 1.465 0.325 0 CA-C-N 114.26 -1.336 . . . . 0.0 112.978 -176.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -96.64 33.53 9.75 Favored 'Cis proline' 0 CA--C 1.536 0.621 0 C-N-CA 123.542 -1.441 . . . . 0.0 114.149 0.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 15.3 m -140.93 141.77 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 112.96 0.726 . . . . 0.0 112.96 -179.328 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.527 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 77.3 m -82.35 136.34 35.01 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.771 178.344 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.4 t -150.84 167.02 28.75 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.852 0.358 . . . . 0.0 110.587 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 21.9 mmt85 -82.06 74.69 9.03 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.346 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 . . . . . 0 C--N 1.324 -0.524 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.476 -179.643 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 36.2 tp -160.74 127.77 2.6 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -67.29 135.72 37.81 Favored 'Trans proline' 0 N--CA 1.462 -0.341 0 C-N-CA 122.586 2.191 . . . . 0.0 111.835 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.7 p -65.92 -44.13 92.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.425 0.631 . . . . 0.0 110.635 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.56 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 4.6 m -94.75 157.02 16.13 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.844 178.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -172.98 24.82 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.099 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.416 ' HG3' ' H ' ' A' ' 15' ' ' ASN . 23.9 pm0 -83.15 144.86 29.55 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.191 0.52 . . . . 0.0 110.293 179.761 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.752 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.4 p -75.46 126.43 31.0 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.496 0.665 . . . . 0.0 111.429 -179.674 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.479 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 34.7 t -93.58 37.23 1.06 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.603 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.752 HG23 ' HB ' ' A' ' 8' ' ' THR . 48.0 t -60.91 -41.06 87.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.693 -179.16 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.37 23.22 22.93 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.753 179.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.94 45.16 95.54 Favored Glycine 0 CA--C 1.52 0.357 0 C-N-CA 121.394 -0.431 . . . . 0.0 113.288 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.9 t -150.85 151.98 33.04 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.046 0.45 . . . . 0.0 111.149 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 95.2 m -118.12 144.53 45.59 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.354 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.416 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 31.0 t30 -94.29 -48.53 6.13 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.366 -179.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.56 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 1.6 m -81.03 114.71 50.87 Favored Pre-proline 0 C--O 1.242 0.684 0 CA-C-O 121.334 0.588 . . . . 0.0 112.158 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 14.9 Cg_endo -56.95 137.92 83.89 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.686 2.257 . . . . 0.0 111.998 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 96.76 -23.28 36.1 Favored Glycine 0 N--CA 1.439 -1.147 0 C-N-CA 120.572 -0.823 . . . . 0.0 111.642 -178.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 7.3 m -90.64 131.89 36.08 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 120.404 -0.518 . . . . 0.0 110.913 179.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.9 t -89.87 158.28 17.52 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.823 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.2 t -79.29 129.17 34.2 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.216 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 29.6 m -134.79 67.24 1.51 Allowed 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 178.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 1.3 t90 -28.32 128.95 0.22 Allowed Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 114.11 -1.405 . . . . 0.0 113.091 -177.077 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -95.64 31.69 12.1 Favored 'Cis proline' 0 N--CA 1.457 -0.642 0 C-N-CA 123.475 -1.469 . . . . 0.0 114.371 0.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.2 m -144.26 141.3 24.46 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 98.0 m -82.99 142.8 31.09 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.112 178.3 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.5 t -150.12 171.4 16.95 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.092 0.472 . . . . 0.0 110.925 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 19.9 tpp85 -95.53 117.22 30.02 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.881 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 35.5 t30 . . . . . 0 C--N 1.321 -0.635 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.711 -179.993 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.61 0 N-CA-C 112.136 -0.386 . . . . 0.0 112.136 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.556 ' HG ' ' HD3' ' A' ' 3' ' ' PRO . 3.6 pp -68.42 -34.3 5.59 Favored Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 114.443 1.275 . . . . 0.0 114.443 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.599 ' O ' ' HD3' ' A' ' 28' ' ' ARG . 59.2 Cg_endo -75.35 61.4 5.93 Favored 'Trans proline' 0 C--N 1.354 0.846 0 C-N-CA 122.101 1.868 . . . . 0.0 112.78 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 41.5 t -68.07 -47.47 78.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.208 0.528 . . . . 0.0 109.755 179.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.788 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 96.2 m 62.2 -168.82 0.19 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 114.561 -1.199 . . . . 0.0 112.527 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 146.16 -10.23 1.55 Allowed Glycine 0 N--CA 1.449 -0.492 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.541 -179.154 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.429 ' OE2' ' HB3' ' A' ' 5' ' ' CYS . 0.8 OUTLIER -62.92 145.25 55.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.262 0.553 . . . . 0.0 111.009 179.933 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.412 ' HB ' HG21 ' A' ' 10' ' ' VAL . 7.9 p -69.12 126.66 30.48 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.202 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 35.9 t -86.66 47.21 1.45 Allowed 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.542 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.412 HG21 ' HB ' ' A' ' 8' ' ' THR . 17.8 t -76.15 69.63 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.505 0.669 . . . . 0.0 110.005 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 163.81 -20.58 0.15 Allowed Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.582 -0.736 . . . . 0.0 111.845 -179.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.87 42.89 4.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.873 -0.68 . . . . 0.0 111.593 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.9 t -152.11 154.42 35.87 Favored 'General case' 0 N--CA 1.446 -0.642 0 CA-C-O 120.67 0.271 . . . . 0.0 110.383 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 96.9 m -131.32 137.07 48.62 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.202 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 35.4 t30 -66.65 -56.54 10.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.082 -178.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.788 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 4.8 m -80.74 116.27 61.07 Favored Pre-proline 0 C--O 1.245 0.867 0 CA-C-O 121.622 0.725 . . . . 0.0 112.062 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_exo -60.45 125.91 18.63 Favored 'Trans proline' 0 N--CA 1.46 -0.449 0 C-N-CA 122.543 2.162 . . . . 0.0 110.834 179.329 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.51 -22.31 8.87 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -178.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.2 m -88.6 133.86 34.05 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.932 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.1 m -88.87 146.28 25.05 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.451 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 t -80.07 103.4 9.93 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.472 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 61.3 m -103.82 60.88 0.74 Allowed 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.464 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 11.5 t90 -28.51 130.21 0.21 Allowed Pre-proline 0 N--CA 1.465 0.298 0 CA-C-N 113.492 -1.686 . . . . 0.0 112.703 -177.536 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.4 Cg_endo -93.96 33.07 10.04 Favored 'Cis proline' 0 N--CA 1.456 -0.7 0 C-N-CA 123.16 -1.6 . . . . 0.0 114.492 1.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.5 m -138.9 138.59 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 N-CA-C 112.724 0.638 . . . . 0.0 112.724 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 67.6 m -81.96 135.84 35.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.326 178.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.529 ' HB ' ' OD1' ' A' ' 29' ' ' ASN . 10.7 m -150.74 149.82 30.26 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.599 ' HD3' ' O ' ' A' ' 3' ' ' PRO . 32.9 ptt180 -80.85 45.27 0.8 Allowed 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.206 0.526 . . . . 0.0 110.92 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.529 ' OD1' ' HB ' ' A' ' 27' ' ' THR . 15.3 p-10 . . . . . 0 C--N 1.322 -0.622 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.577 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.101 -0.4 . . . . 0.0 112.101 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -68.34 146.04 97.69 Favored Pre-proline 0 C--N 1.325 -0.5 0 CA-C-O 120.862 0.363 . . . . 0.0 111.075 179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.77 53.71 3.76 Favored 'Trans proline' 0 CA--C 1.529 0.237 0 C-N-CA 123.285 2.657 . . . . 0.0 112.726 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 47.2 t -68.08 -47.37 78.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.268 0.556 . . . . 0.0 110.342 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.3 m -85.26 155.25 21.46 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.195 179.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -177.89 26.38 0.06 OUTLIER Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.968 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -88.38 144.51 26.34 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-O 121.182 0.515 . . . . 0.0 110.28 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 p -78.86 125.77 29.81 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.65 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 22.4 t -87.67 42.21 1.03 Allowed 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.423 0.63 . . . . 0.0 109.869 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.25 -34.84 71.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.865 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.93 22.56 40.37 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.552 179.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.99 45.9 94.5 Favored Glycine 0 C--N 1.332 0.328 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.12 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.3 t -151.36 155.56 38.92 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 120.933 0.397 . . . . 0.0 111.093 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 92.0 m -131.89 139.95 48.92 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.851 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -90.02 -47.29 7.94 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.629 -179.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 m -74.26 112.04 15.31 Favored Pre-proline 0 C--O 1.243 0.728 0 CA-C-O 121.328 0.585 . . . . 0.0 112.33 -178.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -60.76 131.56 38.19 Favored 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 122.625 2.217 . . . . 0.0 111.398 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.25 -28.72 11.25 Favored Glycine 0 N--CA 1.44 -1.083 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -178.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 6.5 m -91.52 128.44 37.35 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.165 0.507 . . . . 0.0 110.566 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.716 HG22 ' HB2' ' A' ' 29' ' ' ASN . 13.5 t -91.63 163.74 14.0 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.726 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.5 t -80.22 127.84 32.82 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.278 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 45.1 m -136.89 68.52 1.42 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 178.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.426 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.0 t90 -29.32 130.16 0.23 Allowed Pre-proline 0 N--CA 1.463 0.225 0 CA-C-N 114.133 -1.394 . . . . 0.0 113.064 -177.138 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.9 Cg_endo -95.76 31.28 12.66 Favored 'Cis proline' 0 N--CA 1.458 -0.604 0 C-N-CA 123.252 -1.562 . . . . 0.0 114.247 0.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.412 HG12 ' O ' ' A' ' 24' ' ' PRO . 11.4 m -144.46 146.49 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -179.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 71.5 m -82.57 138.52 34.22 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.77 178.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.4 t -151.06 -171.45 3.94 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.724 0.297 . . . . 0.0 110.843 -179.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.9 ptp85 -89.76 136.68 32.89 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.716 ' HB2' HG22 ' A' ' 20' ' ' THR . 1.1 t-20 . . . . . 0 C--N 1.317 -0.806 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.553 -179.488 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.423 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.364 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.44 HD12 ' N ' ' A' ' 2' ' ' LEU . 9.8 mp 71.12 141.48 0.08 OUTLIER Pre-proline 0 N--CA 1.468 0.425 0 C-N-CA 123.228 0.611 . . . . 0.0 111.473 -179.725 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 18.2 Cg_exo -66.03 121.57 8.93 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 122.33 2.02 . . . . 0.0 111.477 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.1 m -64.44 -31.62 54.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.808 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 67.5 m -136.64 -52.95 0.71 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.954 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.4 -41.79 3.04 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.393 -0.821 . . . . 0.0 112.883 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 89.3 mt-10 -55.72 138.1 48.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.234 0.54 . . . . 0.0 111.333 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.51 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 5.9 p -95.69 127.58 41.84 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.711 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.427 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 16.1 t -89.48 39.05 0.93 Allowed 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.169 0.509 . . . . 0.0 109.908 179.618 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.42 HG13 ' N ' ' A' ' 11' ' ' GLY . 8.3 p -63.01 -35.17 70.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.938 -179.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.42 ' N ' HG13 ' A' ' 10' ' ' VAL . . . -96.82 23.27 36.22 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.434 179.187 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.99 41.14 99.31 Favored Glycine 0 C--N 1.333 0.366 0 C-N-CA 121.284 -0.484 . . . . 0.0 113.167 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.0 t -151.38 153.17 34.21 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 121.025 0.44 . . . . 0.0 111.467 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 76.9 m -138.26 137.11 37.17 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -92.9 -47.17 7.16 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.559 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.402 ' HA ' ' HD3' ' A' ' 17' ' ' PRO . 86.8 m -65.53 115.46 22.32 Favored Pre-proline 0 C--O 1.24 0.589 0 CA-C-O 121.437 0.637 . . . . 0.0 111.805 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 25.5 Cg_exo -61.83 127.13 20.61 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.674 2.25 . . . . 0.0 111.097 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.74 -18.43 31.97 Favored Glycine 0 N--CA 1.441 -1.014 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.5 m -87.75 124.27 33.42 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.255 0.55 . . . . 0.0 110.361 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.6 m -91.88 146.16 23.98 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.795 179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.9 t -74.22 129.63 38.18 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.28 0.562 . . . . 0.0 111.805 -179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 51.0 m -141.09 68.57 1.34 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 178.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 5.8 t90 -31.21 128.73 0.28 Allowed Pre-proline 0 N--CA 1.463 0.202 0 CA-C-N 114.306 -1.315 . . . . 0.0 112.892 -177.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -97.82 34.18 8.94 Favored 'Cis proline' 0 CA--C 1.538 0.69 0 C-N-CA 123.527 -1.447 . . . . 0.0 113.906 0.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 17.0 m -141.0 145.95 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 -179.225 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.427 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 79.9 m -83.66 128.56 34.62 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 178.042 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.8 t -112.05 173.73 6.22 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.129 -0.322 . . . . 0.0 110.129 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 31.8 ptt85 -89.64 137.43 32.34 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 . . . . . 0 C--N 1.317 -0.832 0 C-N-CA 120.336 -0.546 . . . . 0.0 110.816 -179.726 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 111.89 -0.484 . . . . 0.0 111.89 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 7.2 mp -74.1 136.86 75.85 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.728 -0.236 . . . . 0.0 110.428 179.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.68 135.94 43.87 Favored 'Trans proline' 0 N--CA 1.464 -0.264 0 C-N-CA 122.618 2.212 . . . . 0.0 112.019 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.466 HG12 ' N ' ' A' ' 5' ' ' CYS . 7.5 p -67.98 -47.14 80.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.145 0.497 . . . . 0.0 110.911 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.466 ' N ' HG12 ' A' ' 4' ' ' VAL . 12.8 m -86.54 164.69 16.76 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.394 178.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -167.92 -29.13 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.205 -0.998 . . . . 0.0 112.918 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.766 ' HG3' ' HA ' ' A' ' 14' ' ' CYS . 1.1 pm0 -62.79 142.55 58.14 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.56 0.695 . . . . 0.0 111.2 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.843 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.7 p -85.66 129.71 34.75 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.98 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.449 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 41.0 t -80.77 20.83 0.72 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.284 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.843 HG23 ' HB ' ' A' ' 8' ' ' THR . 53.4 t -58.68 -39.74 77.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 121.059 0.457 . . . . 0.0 110.583 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.12 23.78 33.37 Favored Glycine 0 N--CA 1.446 -0.665 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.055 179.025 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.13 53.48 44.32 Favored Glycine 0 C--N 1.334 0.449 0 C-N-CA 121.369 -0.443 . . . . 0.0 112.95 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 t -151.86 151.32 31.14 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.004 0.43 . . . . 0.0 111.739 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.766 ' HA ' ' HG3' ' A' ' 7' ' ' GLU . 84.4 m -142.34 134.66 27.74 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.189 179.165 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.481 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 71.5 m-80 -95.17 -46.24 6.86 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.933 0.397 . . . . 0.0 111.123 -179.239 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.551 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 7.7 m -64.41 121.2 71.15 Favored Pre-proline 0 C--O 1.238 0.469 0 CA-C-O 121.43 0.633 . . . . 0.0 111.77 -178.808 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -59.07 132.86 49.64 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.81 2.34 . . . . 0.0 112.191 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.68 -10.78 73.84 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.175 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.551 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 71.2 m -88.1 123.15 32.48 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.384 0.611 . . . . 0.0 110.163 179.61 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.6 m -88.97 143.3 26.95 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.184 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -72.85 119.05 16.55 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 30.2 m -135.15 70.67 1.43 Allowed 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.183 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.413 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 8.9 t90 -27.41 128.54 0.2 Allowed Pre-proline 0 N--CA 1.466 0.362 0 CA-C-N 114.036 -1.438 . . . . 0.0 112.916 -178.203 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.413 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 92.3 Cg_endo -96.37 29.53 15.24 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 C-N-CA 123.396 -1.501 . . . . 0.0 114.105 0.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.449 ' HA ' ' H ' ' A' ' 9' ' ' CYS . 9.3 m -145.89 148.06 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 -179.211 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HG2' ' A' ' 7' ' ' GLU . 72.7 m -83.58 141.25 31.71 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.836 178.041 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.2 t -146.46 -168.87 3.13 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.403 ' HD3' ' CG1' ' A' ' 4' ' ' VAL . 21.0 mmm180 -96.62 45.13 1.06 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.896 0.379 . . . . 0.0 110.187 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.331 -0.212 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.792 -179.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 N-CA-C 112.062 -0.415 . . . . 0.0 112.062 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.497 ' N ' HD13 ' A' ' 2' ' ' LEU . 7.1 mp -74.2 133.77 77.84 Favored Pre-proline 0 C--N 1.326 -0.428 0 N-CA-C 110.405 -0.22 . . . . 0.0 110.405 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 23.8 Cg_exo -63.93 118.71 5.64 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.492 2.128 . . . . 0.0 111.796 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 45.6 t -65.27 -37.4 80.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.118 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.793 ' HA ' HG22 ' A' ' 16' ' ' THR . 75.8 m -104.4 -55.22 2.39 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.579 -179.629 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 63.1 47.4 88.72 Favored Glycine 0 C--O 1.228 -0.228 0 CA-C-N 115.769 -0.651 . . . . 0.0 112.09 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.433 ' HG2' ' H ' ' A' ' 15' ' ' ASN . 6.6 tp10 -149.69 150.34 31.96 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.184 0.516 . . . . 0.0 110.229 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 12.6 p -109.92 127.94 55.05 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.041 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.485 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 20.5 t -90.7 38.46 0.95 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.278 0.561 . . . . 0.0 109.873 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.45 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.7 p -62.9 -36.8 77.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.239 -179.155 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.45 ' N ' HG13 ' A' ' 10' ' ' VAL . . . -98.47 28.05 16.68 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.662 179.371 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.07 40.97 97.8 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 121.271 -0.49 . . . . 0.0 112.933 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -151.75 160.06 43.72 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.578 0.228 . . . . 0.0 110.528 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.7 m -143.81 120.57 11.21 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.147 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.433 ' H ' ' HG2' ' A' ' 7' ' ' GLU . 48.8 m-80 -79.32 -35.61 40.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.672 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.793 HG22 ' HA ' ' A' ' 5' ' ' CYS . 0.2 OUTLIER -67.91 114.27 19.45 Favored Pre-proline 0 C--O 1.242 0.709 0 CA-C-O 121.252 0.549 . . . . 0.0 111.639 -179.112 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -59.37 135.8 67.64 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.765 2.31 . . . . 0.0 112.322 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.65 -6.39 73.87 Favored Glycine 0 N--CA 1.444 -0.821 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.698 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.491 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 84.2 m -89.76 132.5 35.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 117.461 0.63 . . . . 0.0 111.335 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 m -88.93 148.4 23.83 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.297 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.6 t -79.31 127.54 32.2 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.012 0.434 . . . . 0.0 111.285 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.6 m -137.93 67.84 1.41 Allowed 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.703 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 9.3 t90 -31.39 128.83 0.29 Allowed Pre-proline 0 N--CA 1.465 0.294 0 CA-C-N 114.356 -1.293 . . . . 0.0 112.793 -177.211 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -97.18 31.9 11.64 Favored 'Cis proline' 0 N--CA 1.456 -0.709 0 C-N-CA 123.554 -1.436 . . . . 0.0 113.772 0.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.487 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 16.1 m -136.64 141.79 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -178.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.485 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 80.7 m -85.0 135.02 34.2 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.608 178.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.2 t -149.05 142.37 25.14 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.557 0.694 . . . . 0.0 110.959 178.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -82.63 72.44 9.7 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.008 -0.997 . . . . 0.0 110.694 -179.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 31.5 t30 . . . . . 0 C--N 1.325 -0.467 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.026 -179.831 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.544 0 N-CA-C 112.076 -0.41 . . . . 0.0 112.076 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 14.1 mt -147.75 131.22 8.23 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-O 121.167 0.508 . . . . 0.0 110.945 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.99 52.56 3.08 Favored 'Trans proline' 0 CA--C 1.531 0.329 0 C-N-CA 123.575 2.85 . . . . 0.0 112.845 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 61.7 t -71.13 -45.19 72.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.286 0.565 . . . . 0.0 110.394 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.505 ' SG ' HG23 ' A' ' 16' ' ' THR . 55.8 m -105.06 169.89 8.18 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.866 179.317 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -159.18 28.1 0.39 Allowed Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.26 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.43 ' OE2' ' HB3' ' A' ' 5' ' ' CYS . 4.0 mp0 -77.5 140.0 39.71 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.499 ' HB ' HG22 ' A' ' 10' ' ' VAL . 2.2 p -74.89 123.55 25.27 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-O 121.443 0.64 . . . . 0.0 110.52 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.503 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 21.8 t -93.77 35.14 1.15 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.91 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.499 HG22 ' HB ' ' A' ' 8' ' ' THR . 44.5 t -62.31 -40.76 89.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.286 -179.635 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.05 24.68 23.61 Favored Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.629 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.91 47.55 90.07 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 121.34 -0.457 . . . . 0.0 113.287 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.8 t -150.89 155.9 40.11 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.854 0.359 . . . . 0.0 110.954 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 94.8 m -133.26 -44.02 0.85 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.756 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 73.76 -46.51 0.63 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.778 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.505 HG23 ' SG ' ' A' ' 5' ' ' CYS . 2.6 m -63.04 110.68 3.75 Favored Pre-proline 0 C--O 1.243 0.749 0 CA-C-O 121.511 0.672 . . . . 0.0 111.863 -179.227 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.62 131.77 37.24 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.573 2.182 . . . . 0.0 111.989 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.62 -22.85 37.07 Favored Glycine 0 N--CA 1.437 -1.272 0 C-N-CA 120.398 -0.906 . . . . 0.0 111.583 -179.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 15.3 m -98.43 134.7 41.05 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.342 0.591 . . . . 0.0 111.623 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.3 m -99.05 149.47 22.98 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.802 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 23.3 t -76.44 125.04 28.49 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.079 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 32.0 t -126.17 64.44 1.23 Allowed 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 178.365 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 5.1 t90 -26.74 128.48 0.19 Allowed Pre-proline 0 N--CA 1.467 0.417 0 CA-C-N 114.066 -1.425 . . . . 0.0 113.236 -177.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -95.34 30.03 14.64 Favored 'Cis proline' 0 CA--C 1.536 0.584 0 C-N-CA 123.451 -1.479 . . . . 0.0 113.964 0.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.7 m -139.15 137.17 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 121.558 0.694 . . . . 0.0 112.633 -179.498 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 79.2 m -81.99 140.05 34.19 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.475 178.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.3 t -151.03 172.88 15.03 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.802 0.334 . . . . 0.0 110.636 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 12.7 tpt180 -96.89 128.7 44.1 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.9 p30 . . . . . 0 C--N 1.321 -0.664 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.872 -179.95 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.035 -0.426 . . . . 0.0 112.035 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.485 HD12 ' HD2' ' A' ' 3' ' ' PRO . 46.5 tp -74.39 123.0 88.81 Favored Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 110.385 -0.228 . . . . 0.0 110.385 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.485 ' HD2' HD12 ' A' ' 2' ' ' LEU . 65.6 Cg_endo -73.78 49.99 1.98 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 123.019 2.48 . . . . 0.0 112.751 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.51 HG11 ' N ' ' A' ' 5' ' ' CYS . 12.8 p -79.45 -35.65 17.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.367 0.603 . . . . 0.0 109.964 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.542 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 59.6 m 60.26 -133.71 0.79 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 114.417 -1.265 . . . . 0.0 111.038 179.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.32 20.1 55.55 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.728 -179.438 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.616 ' HG2' HD22 ' A' ' 15' ' ' ASN . 1.1 mp0 -76.34 139.72 41.14 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 179.175 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.4 p -70.25 121.79 18.28 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-O 121.528 0.68 . . . . 0.0 110.498 179.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 18.9 t -87.96 40.98 0.97 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.903 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.1 m -62.36 -33.93 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.333 -179.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.84 22.45 39.55 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.177 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.47 45.69 94.12 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.837 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -151.87 155.74 38.73 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.012 0.434 . . . . 0.0 111.426 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 55.9 m -133.61 146.6 51.08 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 179.349 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.616 HD22 ' HG2' ' A' ' 7' ' ' GLU . 21.4 p30 -102.71 -35.07 8.81 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.303 -0.559 . . . . 0.0 112.247 -179.005 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.542 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 13.0 m -80.74 112.84 35.21 Favored Pre-proline 0 C--O 1.244 0.795 0 CA-C-O 121.542 0.687 . . . . 0.0 111.488 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 39.2 Cg_exo -59.52 129.06 29.42 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.677 2.251 . . . . 0.0 111.803 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.2 -23.21 19.19 Favored Glycine 0 N--CA 1.438 -1.194 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.433 ' SG ' ' HB3' ' A' ' 28' ' ' ARG . 42.2 m -95.16 127.08 40.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.306 0.574 . . . . 0.0 111.515 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.62 147.19 23.47 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.195 -179.52 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.2 t -71.3 123.94 23.42 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.201 0.524 . . . . 0.0 111.176 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 37.9 m -128.44 66.54 1.39 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 178.361 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.424 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 3.9 t90 -27.79 129.07 0.21 Allowed Pre-proline 0 N--CA 1.467 0.396 0 CA-C-N 113.904 -1.498 . . . . 0.0 113.051 -177.104 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 90.0 Cg_endo -95.3 31.34 12.61 Favored 'Cis proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.347 -1.522 . . . . 0.0 114.338 0.637 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.6 m -141.49 137.59 32.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 83.0 m -82.26 134.55 35.29 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.595 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.2 t -151.72 151.14 31.02 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.296 0.57 . . . . 0.0 110.879 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.433 ' HB3' ' SG ' ' A' ' 19' ' ' CYS . 6.7 ptm180 -84.3 56.27 3.71 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.781 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 15.6 p-10 . . . . . 0 C--N 1.326 -0.413 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.922 -179.957 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.226 -0.349 . . . . 0.0 112.226 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.423 HD13 ' HD2' ' A' ' 3' ' ' PRO . 29.9 tp -150.06 131.0 7.19 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HD2' HD13 ' A' ' 2' ' ' LEU . 51.8 Cg_endo -69.46 62.12 1.59 Allowed 'Trans proline' 0 CA--C 1.533 0.438 0 C-N-CA 123.146 2.564 . . . . 0.0 113.33 -179.227 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 46.9 t -68.92 -44.96 81.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.175 0.512 . . . . 0.0 110.408 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.699 ' SG ' HG21 ' A' ' 16' ' ' THR . 20.7 m -79.09 163.52 25.04 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.169 179.546 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -168.48 36.34 0.2 Allowed Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.967 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.462 ' H ' ' CD ' ' A' ' 7' ' ' GLU . 1.1 pm0 -85.62 143.22 28.56 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.117 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.405 ' HB ' HG22 ' A' ' 10' ' ' VAL . 1.4 p -72.0 125.41 27.18 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-O 121.684 0.754 . . . . 0.0 111.625 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.566 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.8 t -104.25 42.22 1.22 Allowed 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.164 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.405 HG22 ' HB ' ' A' ' 8' ' ' THR . 45.9 t -59.11 -40.94 82.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.967 -178.649 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.11 16.79 54.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.523 179.252 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.72 41.2 97.39 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 121.504 -0.379 . . . . 0.0 113.106 179.487 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.8 t -152.84 140.64 20.05 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-O 121.42 0.629 . . . . 0.0 112.26 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 91.1 m -152.49 148.9 27.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.613 -1.176 . . . . 0.0 109.087 178.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.543 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 4.5 m120 -115.71 11.64 15.76 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.864 -0.334 . . . . 0.0 111.281 -179.549 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.699 HG21 ' SG ' ' A' ' 5' ' ' CYS . 1.0 OUTLIER -81.12 107.58 8.08 Favored Pre-proline 0 C--O 1.24 0.601 0 CA-C-O 121.248 0.547 . . . . 0.0 110.995 -179.916 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.543 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 29.4 Cg_exo -60.91 131.81 39.11 Favored 'Trans proline' 0 CA--C 1.515 -0.431 0 C-N-CA 122.64 2.227 . . . . 0.0 112.684 -179.225 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.11 -18.16 56.75 Favored Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.221 -179.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 36.3 m -105.36 130.75 53.4 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.6 0.714 . . . . 0.0 111.668 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.6 m -97.98 148.47 23.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.141 -178.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.598 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 37.6 t -72.0 128.73 36.63 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.954 179.666 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.5 m -132.26 67.41 1.53 Allowed 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.408 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 3.7 t90 -26.61 128.67 0.19 Allowed Pre-proline 0 N--CA 1.467 0.385 0 CA-C-N 114.054 -1.43 . . . . 0.0 113.095 -177.203 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.408 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 85.4 Cg_endo -94.76 29.23 15.98 Favored 'Cis proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.464 -1.473 . . . . 0.0 114.261 0.595 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 6.7 m -143.04 137.16 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 CA-C-O 121.484 0.659 . . . . 0.0 112.653 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.598 ' SG ' ' HA ' ' A' ' 21' ' ' CYS . 61.2 m -83.56 140.83 32.01 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.876 178.441 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.9 t -152.44 165.22 35.74 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 120.878 0.37 . . . . 0.0 110.311 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -81.74 74.22 8.74 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.702 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 . . . . . 0 C--O 1.238 0.483 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.787 -179.738 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.514 0 N-CA-C 112.037 -0.425 . . . . 0.0 112.037 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -63.24 145.62 96.78 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-O 120.9 0.381 . . . . 0.0 110.947 179.327 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -68.33 121.45 8.42 Favored 'Trans proline' 0 N--CA 1.463 -0.296 0 C-N-CA 122.57 2.18 . . . . 0.0 112.016 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 39.2 t -71.91 -39.41 67.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.632 0.729 . . . . 0.0 110.167 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.581 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 2.7 m -138.46 156.43 47.55 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.586 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -134.64 39.06 1.74 Allowed Glycine 0 N--CA 1.449 -0.44 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -107.96 143.59 36.4 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.162 -0.519 . . . . 0.0 111.007 -179.366 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.657 HG21 HG13 ' A' ' 25' ' ' VAL . 3.2 p -89.8 126.84 35.83 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.563 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 17.3 t -83.99 45.21 1.07 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.05 0.452 . . . . 0.0 110.424 179.757 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 48.5 t -63.54 -39.89 87.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 120.993 0.425 . . . . 0.0 110.74 -179.143 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.73 22.38 25.07 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.738 -0.664 . . . . 0.0 112.948 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.98 39.81 94.67 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.335 -0.459 . . . . 0.0 113.269 179.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.7 t -152.25 158.31 42.64 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-O 120.773 0.32 . . . . 0.0 110.944 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -139.91 131.33 26.9 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -83.0 -46.42 12.89 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -178.35 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.581 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 4.5 m -70.38 113.61 19.49 Favored Pre-proline 0 C--O 1.246 0.915 0 CA-C-O 121.572 0.701 . . . . 0.0 112.343 -178.412 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -61.22 127.56 22.46 Favored 'Trans proline' 0 N--CA 1.459 -0.555 0 C-N-CA 122.673 2.249 . . . . 0.0 111.291 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 116.52 -26.3 8.63 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -178.157 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.7 m -89.69 130.12 36.02 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 121.338 0.59 . . . . 0.0 110.947 179.178 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 m -96.6 146.95 24.37 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.063 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.7 t -72.26 127.49 32.74 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.203 0.525 . . . . 0.0 111.465 -179.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 28.3 t -136.94 64.66 1.53 Allowed 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 178.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 4.1 t90 -29.21 128.61 0.23 Allowed Pre-proline 0 N--CA 1.466 0.353 0 CA-C-N 114.381 -1.281 . . . . 0.0 113.04 -177.144 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -97.31 34.26 8.96 Favored 'Cis proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.671 -1.387 . . . . 0.0 114.011 0.67 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.657 HG13 HG21 ' A' ' 8' ' ' THR . 17.6 m -140.82 146.96 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 O-C-N 121.898 -0.501 . . . . 0.0 112.33 -179.331 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 72.6 m -81.93 123.73 29.12 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 178.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.8 t -101.11 178.34 4.69 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 18.0 ptp180 -96.49 135.45 38.36 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 179.211 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 33.1 t30 . . . . . 0 C--N 1.319 -0.74 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.768 -179.603 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.445 0 N-CA-C 112.254 -0.338 . . . . 0.0 112.254 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 15.8 tp -82.53 135.55 46.45 Favored Pre-proline 0 C--N 1.323 -0.555 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.705 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 15.1 Cg_exo -69.95 53.42 1.15 Allowed 'Trans proline' 0 CA--C 1.535 0.571 0 C-N-CA 123.348 2.699 . . . . 0.0 113.88 -178.824 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 3.2 t -91.17 21.31 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.968 0.89 . . . . 0.0 109.419 178.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 27.1 m -61.85 160.97 11.08 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.906 -1.043 . . . . 0.0 112.157 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 159.9 -27.27 0.34 Allowed Glycine 0 C--N 1.315 -0.584 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.117 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -57.69 149.47 21.82 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 113.737 -1.232 . . . . 0.0 110.698 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 2.0 p -98.07 126.68 43.61 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.564 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 35.1 t -87.81 44.63 1.2 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.755 179.13 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.44 HG11 ' N ' ' A' ' 11' ' ' GLY . 7.2 p -62.38 -38.35 81.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.517 -178.734 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.44 ' N ' HG11 ' A' ' 10' ' ' VAL . . . -94.42 26.49 17.46 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.856 179.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.15 38.16 92.73 Favored Glycine 0 C--N 1.333 0.391 0 C-N-CA 121.31 -0.471 . . . . 0.0 112.949 179.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.9 t -152.51 163.11 40.22 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.6 m -145.02 120.12 10.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.027 179.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 33.5 t30 -78.94 -36.44 41.72 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.616 179.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 5.9 m -63.04 109.63 2.66 Favored Pre-proline 0 C--O 1.242 0.667 0 CA-C-O 121.414 0.626 . . . . 0.0 111.646 -179.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_exo -61.61 130.23 30.82 Favored 'Trans proline' 0 CA--C 1.515 -0.463 0 C-N-CA 122.844 2.362 . . . . 0.0 112.535 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.9 -20.02 52.27 Favored Glycine 0 N--CA 1.44 -1.062 0 CA-C-N 115.327 -0.852 . . . . 0.0 111.617 -179.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 72.0 m -89.81 123.93 34.22 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.321 0.581 . . . . 0.0 110.981 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.4 p -88.99 143.46 26.84 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.359 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.4 t -69.92 128.23 35.64 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.26 0.552 . . . . 0.0 112.005 -179.044 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 35.0 t -136.98 66.42 1.47 Allowed 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 6.8 t90 -29.46 128.62 0.24 Allowed Pre-proline 0 N--CA 1.464 0.269 0 CA-C-N 114.284 -1.325 . . . . 0.0 113.008 -176.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -97.0 32.47 10.96 Favored 'Cis proline' 0 N--CA 1.458 -0.599 0 C-N-CA 123.49 -1.463 . . . . 0.0 114.031 0.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 15.9 m -139.42 142.87 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 113.032 0.752 . . . . 0.0 113.032 -179.205 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 58.5 m -83.09 131.25 35.16 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.627 178.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 t -140.82 157.51 45.28 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.129 0.49 . . . . 0.0 111.062 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.71 81.48 8.19 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.02 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 32.1 t30 . . . . . 0 C--N 1.326 -0.449 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.645 179.799 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 N-CA-C 111.971 -0.451 . . . . 0.0 111.971 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.412 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 33.0 tp -75.65 122.12 86.48 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 17.7 Cg_exo -66.87 102.29 0.63 Allowed 'Trans proline' 0 C--O 1.233 0.244 0 C-N-CA 122.653 2.235 . . . . 0.0 112.177 -179.693 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 46.9 t -73.77 -43.74 53.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.17 0.51 . . . . 0.0 110.086 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 91.3 m 59.75 -113.0 0.6 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.905 -1.043 . . . . 0.0 111.649 179.299 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.83 14.52 80.8 Favored Glycine 0 N--CA 1.45 -0.395 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -178.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.604 ' OE1' ' HB3' ' A' ' 14' ' ' CYS . 64.6 mt-10 -71.87 139.49 48.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.056 -0.572 . . . . 0.0 110.075 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 17.3 p -75.34 123.75 25.9 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.131 0.491 . . . . 0.0 110.958 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.2 t -103.74 39.81 1.54 Allowed 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.434 179.7 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.439 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.1 p -59.16 -36.96 65.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.343 -178.766 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.439 ' N ' HG13 ' A' ' 10' ' ' VAL . . . -101.33 27.89 18.49 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.317 179.304 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.47 35.67 89.43 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 121.365 -0.445 . . . . 0.0 112.993 179.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.8 t -153.06 156.4 38.66 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 120.646 0.26 . . . . 0.0 110.838 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.604 ' HB3' ' OE1' ' A' ' 7' ' ' GLU . 61.0 m -150.05 -153.09 0.47 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.787 179.237 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.407 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 72.4 m-80 -133.12 -52.94 0.9 Allowed 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -178.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 51.3 m -66.34 108.47 2.33 Favored Pre-proline 0 C--O 1.249 1.047 0 N-CA-C 113.523 0.934 . . . . 0.0 113.523 -177.375 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.407 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 37.4 Cg_endo -65.6 125.48 14.44 Favored 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 122.461 2.107 . . . . 0.0 110.485 178.353 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.55 -27.38 6.03 Favored Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -177.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 14.2 m -89.86 129.41 36.23 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 120.15 -0.62 . . . . 0.0 110.067 178.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.511 ' HB ' ' OD1' ' A' ' 29' ' ' ASN . 3.7 m -88.14 144.86 26.23 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.533 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.2 t -72.98 122.68 22.11 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.12 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.0 m -127.73 67.28 1.33 Allowed 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 178.583 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.3 t90 -26.5 127.95 0.19 Allowed Pre-proline 0 N--CA 1.467 0.395 0 CA-C-N 113.921 -1.491 . . . . 0.0 113.058 -177.18 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 80.5 Cg_endo -95.56 31.55 12.3 Favored 'Cis proline' 0 N--CA 1.456 -0.707 0 C-N-CA 123.482 -1.466 . . . . 0.0 114.38 0.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.424 HG11 ' O ' ' A' ' 24' ' ' PRO . 6.0 m -145.03 138.06 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 N-CA-C 112.873 0.694 . . . . 0.0 112.873 -179.526 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.482 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 94.6 m -82.19 140.29 33.81 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.571 178.254 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t -148.11 158.84 44.29 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.041 0.448 . . . . 0.0 110.196 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 7.4 ptm180 -81.54 52.02 1.79 Allowed 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.196 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.511 ' OD1' ' HB ' ' A' ' 20' ' ' THR . 15.2 p-10 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.683 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.541 0 N-CA-C 111.975 -0.45 . . . . 0.0 111.975 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 48.9 tp -83.45 122.65 77.08 Favored Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 6.8 Cg_exo -73.41 48.25 1.51 Allowed 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 123.229 2.62 . . . . 0.0 112.802 -179.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.8 p -78.65 -42.25 25.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.641 0.734 . . . . 0.0 109.833 179.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.681 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 63.6 m -102.97 172.1 7.01 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.535 -1.211 . . . . 0.0 109.827 179.104 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 179.38 28.55 0.05 OUTLIER Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.535 -0.84 . . . . 0.0 112.519 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.681 ' OE2' ' HB3' ' A' ' 5' ' ' CYS . 1.3 pm0 -89.57 142.51 27.61 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.7 p -77.98 123.9 27.36 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-O 121.414 0.625 . . . . 0.0 110.855 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 28.2 t -90.52 39.97 1.0 Allowed 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.052 179.775 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.3 t -61.99 -40.31 86.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.653 -179.245 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.47 22.83 30.81 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.881 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.19 47.6 88.4 Favored Glycine 0 CA--C 1.52 0.362 0 C-N-CA 121.289 -0.482 . . . . 0.0 113.206 179.306 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.4 t -151.18 155.98 39.99 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 122.565 -0.373 . . . . 0.0 111.095 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 82.9 m -140.1 127.73 21.67 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.656 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -81.44 -41.18 22.22 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -179.202 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.47 HG21 ' SG ' ' A' ' 5' ' ' CYS . 15.5 m -75.82 109.46 8.15 Favored Pre-proline 0 C--O 1.246 0.885 0 CA-C-O 121.545 0.688 . . . . 0.0 112.223 -178.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 27.6 Cg_endo -61.96 131.19 33.83 Favored 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 122.564 2.176 . . . . 0.0 111.386 179.524 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 110.61 -29.32 9.13 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 -178.305 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.7 ' HA ' ' HB2' ' A' ' 28' ' ' ARG . 7.4 m -89.59 133.37 34.65 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.526 179.221 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.3 m -95.23 148.79 22.02 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.959 -178.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.3 t -70.07 126.6 30.15 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.875 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.7 m -134.22 67.96 1.5 Allowed 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.41 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 1.5 t90 -28.35 128.16 0.22 Allowed Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 113.976 -1.465 . . . . 0.0 112.989 -176.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.8 Cg_endo -96.71 32.52 10.92 Favored 'Cis proline' 0 CA--C 1.537 0.64 0 C-N-CA 123.595 -1.419 . . . . 0.0 114.151 0.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.2 m -143.71 141.78 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -179.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.436 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 65.8 m -82.68 132.54 35.18 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.234 178.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.2 t -152.46 164.72 37.0 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.014 0.435 . . . . 0.0 111.557 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.7 ' HB2' ' HA ' ' A' ' 19' ' ' CYS . 9.0 tpt180 177.36 -149.21 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.785 179.375 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 . . . . . 0 C--N 1.318 -0.794 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.665 179.735 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.572 ' HA2' ' HB ' ' A' ' 25' ' ' VAL . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.054 -0.418 . . . . 0.0 112.054 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.45 HD13 ' HD2' ' A' ' 3' ' ' PRO . 23.8 tp 69.01 131.68 0.04 OUTLIER Pre-proline 0 N--CA 1.466 0.348 0 C-N-CA 123.063 0.545 . . . . 0.0 110.941 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.45 ' HD2' HD13 ' A' ' 2' ' ' LEU . 57.8 Cg_endo -71.14 44.73 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 122.814 2.343 . . . . 0.0 112.715 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 3' ' ' PRO . 85.2 t -146.82 -47.61 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.398 -0.819 . . . . 0.0 108.89 179.491 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.418 ' HA ' HG22 ' A' ' 16' ' ' THR . 71.1 m -91.42 -50.08 5.99 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.992 -1.003 . . . . 0.0 110.657 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.82 -46.99 3.64 Favored Glycine 0 N--CA 1.451 -0.355 0 CA-C-N 115.244 -0.889 . . . . 0.0 112.573 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.644 ' HG3' ' HB3' ' A' ' 15' ' ' ASN . 47.3 mm-40 -62.81 145.05 55.88 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 122.028 0.918 . . . . 0.0 112.61 -179.458 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.575 ' HB ' HG22 ' A' ' 10' ' ' VAL . 5.9 p -110.22 127.85 55.18 Favored 'General case' 0 N--CA 1.439 -1.019 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.825 178.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 12.7 t -83.65 41.35 0.78 Allowed 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.919 0.39 . . . . 0.0 110.841 -179.403 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.575 HG22 ' HB ' ' A' ' 8' ' ' THR . 47.6 t -64.73 -42.01 93.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.174 0.511 . . . . 0.0 110.314 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.24 28.62 12.3 Favored Glycine 0 N--CA 1.45 -0.397 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.638 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.08 42.55 98.52 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 121.27 -0.49 . . . . 0.0 113.237 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.8 t -151.61 160.17 43.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.648 0.261 . . . . 0.0 110.756 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.7 m -146.03 124.75 12.57 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.191 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.644 ' HB3' ' HG3' ' A' ' 7' ' ' GLU . 28.2 t-20 -81.04 -46.73 14.58 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.657 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.458 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 0.2 OUTLIER -58.33 111.77 4.01 Favored Pre-proline 0 C--O 1.238 0.481 0 CA-C-O 121.221 0.534 . . . . 0.0 112.146 -178.857 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -62.24 130.59 31.0 Favored 'Trans proline' 0 N--CA 1.46 -0.448 0 C-N-CA 122.631 2.221 . . . . 0.0 111.63 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.38 -14.72 63.14 Favored Glycine 0 N--CA 1.442 -0.945 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.763 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.458 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 95.9 m -88.98 126.82 35.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.243 0.544 . . . . 0.0 110.816 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.87 148.76 23.69 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.412 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 t -75.48 128.6 35.67 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.127 0.489 . . . . 0.0 112.187 -178.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 57.6 m -139.99 69.13 1.35 Allowed 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 178.193 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 11.4 t90 -31.62 129.04 0.3 Allowed Pre-proline 0 N--CA 1.465 0.292 0 CA-C-N 114.227 -1.351 . . . . 0.0 112.886 -177.173 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -98.06 33.16 9.83 Favored 'Cis proline' 0 N--CA 1.457 -0.633 0 C-N-CA 123.71 -1.371 . . . . 0.0 113.75 0.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.572 ' HB ' ' HA2' ' A' ' 1' ' ' GLY . 24.6 m -139.43 145.85 26.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -178.837 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 61.3 m -84.63 138.26 32.8 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.7 t -133.15 151.39 51.98 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.057 0.456 . . . . 0.0 110.449 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 50.7 ttp180 -84.19 51.48 2.09 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.675 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 . . . . . 0 C--N 1.325 -0.497 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.267 179.892 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 . . . . . 0 N--CA 1.453 -0.315 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.7 ' HB ' HG23 ' A' ' 10' ' ' VAL . 18.8 p -71.72 122.43 20.61 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 120.909 0.385 . . . . 0.0 110.452 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.523 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 17.0 t -93.05 37.05 1.03 Allowed 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.981 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.7 HG23 ' HB ' ' A' ' 8' ' ' THR . 46.1 t -60.4 -41.14 86.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.777 -179.241 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.86 24.92 24.1 Favored Glycine 0 N--CA 1.451 -0.3 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.948 179.645 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.85 47.92 88.06 Favored Glycine 0 C--N 1.333 0.363 0 C-N-CA 121.223 -0.513 . . . . 0.0 113.326 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 t -150.97 154.1 36.46 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.872 0.368 . . . . 0.0 111.082 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 76.8 m -134.48 138.07 44.43 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.87 179.679 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -79.91 -53.99 6.23 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.889 -178.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.585 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 6.7 m -73.1 115.06 36.77 Favored Pre-proline 0 C--O 1.243 0.732 0 CA-C-O 121.368 0.604 . . . . 0.0 112.297 -178.321 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -63.69 121.86 9.75 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.529 2.153 . . . . 0.0 110.635 179.119 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.14 -16.11 13.16 Favored Glycine 0 N--CA 1.439 -1.112 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 -178.322 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.585 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 76.5 m -89.14 132.43 34.83 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 m -88.77 144.97 25.89 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.272 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.9 t -78.48 126.35 30.64 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.077 0.465 . . . . 0.0 110.811 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.0 m -132.66 67.93 1.52 Allowed 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.7 t90 -29.15 127.88 0.24 Allowed Pre-proline 0 N--CA 1.465 0.279 0 CA-C-N 114.06 -1.427 . . . . 0.0 112.841 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 91.3 Cg_endo -97.04 32.8 10.51 Favored 'Cis proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.582 -1.424 . . . . 0.0 114.053 0.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 10.8 m -140.68 139.39 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.523 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.3 m -83.36 137.82 33.79 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.649 178.788 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.1 t . . . . . 0 C--N 1.322 -0.591 0 CA-C-O 121.092 0.472 . . . . 0.0 110.227 178.817 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.447 ' OE2' ' HB3' ' A' ' 15' ' ' ASN . 20.7 mt-10 . . . . . 0 C--O 1.233 0.185 0 CA-C-O 120.798 0.332 . . . . 0.0 111.01 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 3.0 p -88.29 127.51 35.47 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 121.105 0.478 . . . . 0.0 110.825 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.561 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 15.0 t -91.28 40.52 1.03 Allowed 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.136 0.493 . . . . 0.0 109.84 179.465 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.6 p -61.81 -36.28 72.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.08 -179.129 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.56 24.23 31.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.829 -0.7 . . . . 0.0 112.72 179.412 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.5 41.59 97.23 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.257 -0.497 . . . . 0.0 113.181 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.8 t -151.48 152.58 33.2 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 121.011 0.434 . . . . 0.0 111.309 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 71.1 m -132.07 140.1 48.75 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.076 179.123 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.447 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 9.7 t30 -91.95 -47.91 7.04 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.609 -178.766 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' ' 17' ' ' PRO . 85.2 m -70.57 116.45 45.64 Favored Pre-proline 0 C--O 1.242 0.709 0 CA-C-O 121.322 0.582 . . . . 0.0 111.801 -179.244 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 26.1 Cg_exo -61.56 126.29 18.78 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.681 2.254 . . . . 0.0 111.019 179.524 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 110.62 -18.25 27.38 Favored Glycine 0 N--CA 1.44 -1.043 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -178.432 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.0 m -87.4 124.85 33.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.174 0.512 . . . . 0.0 110.273 179.45 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 m -89.35 145.52 25.3 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.854 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 53.7 t -77.03 126.81 31.58 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 121.173 0.511 . . . . 0.0 111.306 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -137.37 68.69 1.41 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.585 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.438 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.7 t90 -31.04 129.07 0.27 Allowed Pre-proline 0 N--CA 1.463 0.216 0 CA-C-N 114.111 -1.404 . . . . 0.0 112.832 -177.164 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.6 Cg_endo -97.08 33.24 10.01 Favored 'Cis proline' 0 N--CA 1.456 -0.678 0 C-N-CA 123.591 -1.421 . . . . 0.0 114.026 0.694 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 14.8 m -140.11 141.95 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 N-CA-C 113.222 0.823 . . . . 0.0 113.222 -179.121 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.561 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 84.1 m -84.01 135.47 34.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.03 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.2 t . . . . . 0 C--N 1.322 -0.616 0 CA-C-O 121.126 0.488 . . . . 0.0 110.226 179.044 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 . . . . . 0 N--CA 1.451 -0.419 0 CA-C-O 121.089 0.471 . . . . 0.0 110.133 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 p -77.34 125.48 29.4 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-O 121.313 0.577 . . . . 0.0 110.908 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.485 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 26.0 t -92.71 37.75 1.01 Allowed 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.784 -0.643 . . . . 0.0 109.616 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.1 p -62.02 -35.46 68.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.008 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.78 21.64 43.67 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.723 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.56 45.61 95.98 Favored Glycine 0 CA--C 1.519 0.34 0 C-N-CA 121.249 -0.501 . . . . 0.0 113.297 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.9 t -150.82 152.52 33.88 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.881 0.372 . . . . 0.0 111.108 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 90.1 m -130.48 140.44 50.53 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.799 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.5 t30 -89.5 -48.91 7.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.918 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.446 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 1.8 m -76.1 112.54 21.21 Favored Pre-proline 0 C--O 1.244 0.801 0 CA-C-O 121.426 0.631 . . . . 0.0 112.572 -178.064 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.446 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 19.3 Cg_endo -60.2 133.04 47.37 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.682 2.255 . . . . 0.0 111.481 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.51 -27.19 17.56 Favored Glycine 0 N--CA 1.438 -1.218 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 12.3 m -90.7 128.64 36.72 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.061 0.458 . . . . 0.0 110.232 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.5 t -90.83 160.98 15.46 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.929 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 46.1 t -80.67 131.45 35.47 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.55 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.2 m -138.38 68.77 1.39 Allowed 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 178.361 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 2.0 t90 -29.56 129.16 0.24 Allowed Pre-proline 0 N--CA 1.466 0.33 0 CA-C-N 114.062 -1.426 . . . . 0.0 113.015 -177.047 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 94.3 Cg_endo -96.66 33.26 10.02 Favored 'Cis proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.484 -1.465 . . . . 0.0 114.151 0.775 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 10.6 m -144.01 143.96 23.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.485 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.1 m -82.76 143.81 30.61 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.2 t . . . . . 0 C--N 1.326 -0.454 0 CA-C-O 121.371 0.605 . . . . 0.0 111.311 -179.864 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 . . . . . 0 N--CA 1.452 -0.326 0 CA-C-O 120.81 0.338 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.514 ' HB ' HG23 ' A' ' 10' ' ' VAL . 10.8 p -82.25 124.87 30.33 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.151 179.105 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 23.9 t -87.62 53.03 2.65 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.246 0.546 . . . . 0.0 110.725 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.514 HG23 ' HB ' ' A' ' 8' ' ' THR . 4.1 t -78.99 48.84 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-O 121.46 0.648 . . . . 0.0 110.781 -179.614 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.06 26.89 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.888 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 55.06 43.95 83.31 Favored Glycine 0 C--N 1.336 0.529 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.099 179.358 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.2 t -151.55 153.74 35.13 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.11 0.481 . . . . 0.0 111.545 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.4 m -142.33 134.34 27.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.186 -0.915 . . . . 0.0 108.578 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 62.0 m-80 -84.07 -45.18 13.32 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.591 0.234 . . . . 0.0 111.561 -178.571 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 4.1 m -69.94 113.66 19.26 Favored Pre-proline 0 C--O 1.244 0.811 0 CA-C-O 121.44 0.638 . . . . 0.0 112.002 -178.649 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -60.12 131.0 36.75 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.695 2.264 . . . . 0.0 111.345 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.48 -26.2 15.41 Favored Glycine 0 N--CA 1.439 -1.129 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -178.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.7 m -89.31 126.17 35.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.504 0.669 . . . . 0.0 111.112 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.3 m -94.07 147.55 23.03 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.597 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.1 t -72.38 114.87 10.97 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.074 0.464 . . . . 0.0 111.278 -179.51 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 36.8 m -123.43 64.47 1.01 Allowed 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 178.224 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.49 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 8.8 t90 -27.6 129.39 0.2 Allowed Pre-proline 0 N--CA 1.463 0.203 0 CA-C-N 113.798 -1.547 . . . . 0.0 113.104 -177.063 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 96.6 Cg_endo -94.71 27.89 18.05 Favored 'Cis proline' 0 N--CA 1.457 -0.668 0 C-N-CA 123.226 -1.573 . . . . 0.0 114.143 0.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.3 m -137.37 140.1 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -179.201 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 72.8 m -82.7 129.95 35.04 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.672 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.324 -0.535 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.962 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.593 ' HG2' ' HB3' ' A' ' 15' ' ' ASN . 2.8 mp0 . . . . . 0 N--CA 1.453 -0.3 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.3 p -73.31 124.24 25.33 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 120.844 0.354 . . . . 0.0 110.351 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.572 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 21.2 t -89.44 38.35 0.9 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.255 0.55 . . . . 0.0 110.019 179.669 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.01 -36.23 72.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.964 -179.283 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.04 25.59 26.96 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.746 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.14 45.29 95.53 Favored Glycine 0 C--N 1.331 0.277 0 C-N-CA 121.165 -0.54 . . . . 0.0 113.131 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.7 t -151.04 154.43 37.02 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.927 0.394 . . . . 0.0 111.065 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 98.8 m -130.98 139.58 50.03 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.813 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.593 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 30.4 t30 -85.26 -50.27 7.5 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.764 -179.211 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 5.6 m -80.59 109.1 11.64 Favored Pre-proline 0 C--O 1.251 1.174 0 CA-C-O 121.821 0.82 . . . . 0.0 112.584 -178.274 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.5 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 24.5 Cg_exo -61.4 127.08 20.85 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.686 2.257 . . . . 0.0 111.103 179.443 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.02 -29.73 5.47 Favored Glycine 0 N--CA 1.434 -1.458 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -178.039 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 19.0 m -88.99 143.1 27.09 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.256 -0.577 . . . . 0.0 110.529 179.061 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 m -97.08 149.33 22.08 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.559 -179.164 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.3 t -74.93 128.21 35.04 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.153 0.502 . . . . 0.0 111.15 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.0 m -133.84 67.79 1.51 Allowed 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.8 t90 -29.58 128.49 0.24 Allowed Pre-proline 0 N--CA 1.464 0.256 0 CA-C-N 114.118 -1.401 . . . . 0.0 112.811 -177.176 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.457 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 95.7 Cg_endo -96.78 34.13 9.15 Favored 'Cis proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.615 -1.41 . . . . 0.0 114.201 0.639 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.42 ' HA ' ' H ' ' A' ' 9' ' ' CYS . 10.8 m -143.11 139.97 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 -179.464 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.572 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 70.9 m -83.05 132.21 35.13 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.038 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.9 t . . . . . 0 C--N 1.325 -0.485 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.646 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.433 ' OE2' ' HB3' ' A' ' 15' ' ' ASN . 23.1 mt-10 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.749 0.309 . . . . 0.0 110.706 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 2.8 p -88.33 127.14 35.48 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-O 121.099 0.476 . . . . 0.0 110.989 179.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.532 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 18.1 t -91.79 40.43 1.04 Allowed 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.159 0.504 . . . . 0.0 109.881 179.396 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -62.12 -36.22 73.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.086 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.6 24.1 30.96 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.798 179.426 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.23 42.04 97.05 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.25 -0.5 . . . . 0.0 113.072 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.0 t -151.82 156.18 39.68 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.842 0.353 . . . . 0.0 111.023 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.9 m -135.8 136.88 41.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.302 179.386 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.433 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 9.8 t30 -87.48 -48.95 7.53 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.996 -178.762 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 88.4 m -70.98 118.38 65.0 Favored Pre-proline 0 C--O 1.241 0.647 0 CA-C-O 121.473 0.654 . . . . 0.0 111.946 -179.005 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -59.19 131.35 40.7 Favored 'Trans proline' 0 N--CA 1.458 -0.576 0 C-N-CA 122.717 2.278 . . . . 0.0 110.987 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 102.33 -13.64 56.96 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.369 -0.919 . . . . 0.0 111.505 -178.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.435 ' HB3' ' HB3' ' A' ' 26' ' ' CYS . 93.3 m -87.82 123.23 32.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.415 0.626 . . . . 0.0 110.561 179.573 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.25 141.49 28.49 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.675 179.722 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 45.8 t -73.65 120.9 19.89 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 121.104 0.478 . . . . 0.0 111.241 -179.487 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.1 t -129.03 64.85 1.46 Allowed 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.1 t90 -29.38 128.63 0.24 Allowed Pre-proline 0 N--CA 1.465 0.325 0 CA-C-N 114.26 -1.336 . . . . 0.0 112.978 -176.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.2 Cg_endo -96.64 33.53 9.75 Favored 'Cis proline' 0 CA--C 1.536 0.621 0 C-N-CA 123.542 -1.441 . . . . 0.0 114.149 0.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 15.3 m -140.93 141.77 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 112.96 0.726 . . . . 0.0 112.96 -179.328 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 77.3 m -82.35 136.34 35.01 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.771 178.344 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.4 t . . . . . 0 C--N 1.323 -0.559 0 CA-C-O 120.852 0.358 . . . . 0.0 110.587 179.731 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.462 ' HG3' ' H ' ' A' ' 15' ' ' ASN . 23.9 pm0 . . . . . 0 N--CA 1.448 -0.57 0 CA-C-O 121.191 0.52 . . . . 0.0 110.293 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.768 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.4 p -75.46 126.43 31.0 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.496 0.665 . . . . 0.0 111.429 -179.674 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.479 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 34.7 t -93.58 37.23 1.06 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.603 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.768 HG23 ' HB ' ' A' ' 8' ' ' THR . 48.0 t -60.91 -41.06 87.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.693 -179.16 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.37 23.22 22.93 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.753 179.424 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.94 45.16 95.54 Favored Glycine 0 CA--C 1.52 0.357 0 C-N-CA 121.394 -0.431 . . . . 0.0 113.288 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.9 t -150.85 151.98 33.04 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.046 0.45 . . . . 0.0 111.149 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 95.2 m -118.12 144.53 45.59 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.354 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.462 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 31.0 t30 -94.29 -48.53 6.13 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.366 -179.348 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.42 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 1.6 m -81.03 114.71 50.87 Favored Pre-proline 0 C--O 1.242 0.684 0 CA-C-O 121.334 0.588 . . . . 0.0 112.158 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 14.9 Cg_endo -56.95 137.92 83.89 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.686 2.257 . . . . 0.0 111.998 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 96.76 -23.28 36.1 Favored Glycine 0 N--CA 1.439 -1.147 0 C-N-CA 120.572 -0.823 . . . . 0.0 111.642 -178.785 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 7.3 m -90.64 131.89 36.08 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 120.404 -0.518 . . . . 0.0 110.913 179.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.9 t -89.87 158.28 17.52 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.823 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.2 t -79.29 129.17 34.2 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.216 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 29.6 m -134.79 67.24 1.51 Allowed 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 178.681 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 1.3 t90 -28.32 128.95 0.22 Allowed Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 114.11 -1.405 . . . . 0.0 113.091 -177.077 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 89.2 Cg_endo -95.64 31.69 12.1 Favored 'Cis proline' 0 N--CA 1.457 -0.642 0 C-N-CA 123.475 -1.469 . . . . 0.0 114.371 0.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.2 m -144.26 141.3 24.46 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 98.0 m -82.99 142.8 31.09 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.112 178.3 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.5 t . . . . . 0 C--N 1.326 -0.421 0 CA-C-O 121.092 0.472 . . . . 0.0 110.925 -179.706 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.234 0.278 0 CA-C-O 121.262 0.553 . . . . 0.0 111.009 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.655 ' HB ' HG23 ' A' ' 10' ' ' VAL . 7.9 p -69.12 126.66 30.48 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.202 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 35.9 t -86.66 47.21 1.45 Allowed 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.542 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.655 HG23 ' HB ' ' A' ' 8' ' ' THR . 17.8 t -76.15 69.63 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.505 0.669 . . . . 0.0 110.005 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 163.81 -20.58 0.15 Allowed Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.582 -0.736 . . . . 0.0 111.845 -179.044 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.87 42.89 4.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.873 -0.68 . . . . 0.0 111.593 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.9 t -152.11 154.42 35.87 Favored 'General case' 0 N--CA 1.446 -0.642 0 CA-C-O 120.67 0.271 . . . . 0.0 110.383 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 96.9 m -131.32 137.07 48.62 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.202 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 35.4 t30 -66.65 -56.54 10.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.082 -178.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 4.8 m -80.74 116.27 61.07 Favored Pre-proline 0 C--O 1.245 0.867 0 CA-C-O 121.622 0.725 . . . . 0.0 112.062 -178.738 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_exo -60.45 125.91 18.63 Favored 'Trans proline' 0 N--CA 1.46 -0.449 0 C-N-CA 122.543 2.162 . . . . 0.0 110.834 179.329 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.51 -22.31 8.87 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -178.216 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.2 m -88.6 133.86 34.05 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.932 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.1 m -88.87 146.28 25.05 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.451 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 t -80.07 103.4 9.93 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.472 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 61.3 m -103.82 60.88 0.74 Allowed 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.311 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.459 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 11.5 t90 -28.51 130.21 0.21 Allowed Pre-proline 0 N--CA 1.465 0.298 0 CA-C-N 113.492 -1.686 . . . . 0.0 112.703 -177.536 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.4 Cg_endo -93.96 33.07 10.04 Favored 'Cis proline' 0 N--CA 1.456 -0.7 0 C-N-CA 123.16 -1.6 . . . . 0.0 114.492 1.018 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.5 m -138.9 138.59 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 N-CA-C 112.724 0.638 . . . . 0.0 112.724 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 67.6 m -81.96 135.84 35.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.326 178.65 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.7 m . . . . . 0 C--N 1.322 -0.601 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -179.764 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 . . . . . 0 N--CA 1.447 -0.582 0 CA-C-O 121.182 0.515 . . . . 0.0 110.28 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 p -78.86 125.77 29.81 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.65 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 22.4 t -87.67 42.21 1.03 Allowed 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.423 0.63 . . . . 0.0 109.869 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.25 -34.84 71.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.865 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.93 22.56 40.37 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.552 179.318 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.99 45.9 94.5 Favored Glycine 0 C--N 1.332 0.328 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.12 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.3 t -151.36 155.56 38.92 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 120.933 0.397 . . . . 0.0 111.093 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 92.0 m -131.89 139.95 48.92 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.851 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -90.02 -47.29 7.94 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.629 -179.035 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 m -74.26 112.04 15.31 Favored Pre-proline 0 C--O 1.243 0.728 0 CA-C-O 121.328 0.585 . . . . 0.0 112.33 -178.31 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -60.76 131.56 38.19 Favored 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 122.625 2.217 . . . . 0.0 111.398 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.25 -28.72 11.25 Favored Glycine 0 N--CA 1.44 -1.083 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -178.221 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 6.5 m -91.52 128.44 37.35 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.165 0.507 . . . . 0.0 110.566 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 t -91.63 163.74 14.0 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.726 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.5 t -80.22 127.84 32.82 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.278 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 45.1 m -136.89 68.52 1.42 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 178.681 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.0 t90 -29.32 130.16 0.23 Allowed Pre-proline 0 N--CA 1.463 0.225 0 CA-C-N 114.133 -1.394 . . . . 0.0 113.064 -177.138 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.9 Cg_endo -95.76 31.28 12.66 Favored 'Cis proline' 0 N--CA 1.458 -0.604 0 C-N-CA 123.252 -1.562 . . . . 0.0 114.247 0.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.4 m -144.46 146.49 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -179.391 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 71.5 m -82.57 138.52 34.22 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.77 178.22 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.4 t . . . . . 0 C--N 1.325 -0.467 0 CA-C-O 120.724 0.297 . . . . 0.0 110.843 -179.664 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 89.3 mt-10 . . . . . 0 C--O 1.235 0.293 0 CA-C-O 121.234 0.54 . . . . 0.0 111.333 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.698 HG22 HG12 ' A' ' 25' ' ' VAL . 5.9 p -95.69 127.58 41.84 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.711 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.434 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 16.1 t -89.48 39.05 0.93 Allowed 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.169 0.509 . . . . 0.0 109.908 179.618 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.3 p -63.01 -35.17 70.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.938 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.82 23.27 36.22 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.434 179.187 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.99 41.14 99.31 Favored Glycine 0 C--N 1.333 0.366 0 C-N-CA 121.284 -0.484 . . . . 0.0 113.167 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.0 t -151.38 153.17 34.21 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 121.025 0.44 . . . . 0.0 111.467 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 76.9 m -138.26 137.11 37.17 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -92.9 -47.17 7.16 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.559 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.43 ' HA ' ' HD3' ' A' ' 17' ' ' PRO . 86.8 m -65.53 115.46 22.32 Favored Pre-proline 0 C--O 1.24 0.589 0 CA-C-O 121.437 0.637 . . . . 0.0 111.805 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 25.5 Cg_exo -61.83 127.13 20.61 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.674 2.25 . . . . 0.0 111.097 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.74 -18.43 31.97 Favored Glycine 0 N--CA 1.441 -1.014 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.5 m -87.75 124.27 33.42 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.255 0.55 . . . . 0.0 110.361 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.6 m -91.88 146.16 23.98 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.795 179.605 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.9 t -74.22 129.63 38.18 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.28 0.562 . . . . 0.0 111.805 -179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 51.0 m -141.09 68.57 1.34 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 178.505 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.533 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.8 t90 -31.21 128.73 0.28 Allowed Pre-proline 0 N--CA 1.463 0.202 0 CA-C-N 114.306 -1.315 . . . . 0.0 112.892 -177.039 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.533 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.7 Cg_endo -97.82 34.18 8.94 Favored 'Cis proline' 0 CA--C 1.538 0.69 0 C-N-CA 123.527 -1.447 . . . . 0.0 113.906 0.769 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.698 HG12 HG22 ' A' ' 8' ' ' THR . 17.0 m -141.0 145.95 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 -179.225 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.429 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 79.9 m -83.66 128.56 34.62 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 178.042 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.8 t . . . . . 0 C--N 1.324 -0.532 0 N-CA-C 110.129 -0.322 . . . . 0.0 110.129 179.873 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.787 ' HG3' ' HA ' ' A' ' 14' ' ' CYS . 1.1 pm0 . . . . . 0 C--O 1.237 0.421 0 CA-C-O 121.56 0.695 . . . . 0.0 111.2 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.803 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.7 p -85.66 129.71 34.75 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.98 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.508 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 41.0 t -80.77 20.83 0.72 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.284 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.803 HG23 ' HB ' ' A' ' 8' ' ' THR . 53.4 t -58.68 -39.74 77.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 121.059 0.457 . . . . 0.0 110.583 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.12 23.78 33.37 Favored Glycine 0 N--CA 1.446 -0.665 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.055 179.025 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.13 53.48 44.32 Favored Glycine 0 C--N 1.334 0.449 0 C-N-CA 121.369 -0.443 . . . . 0.0 112.95 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 t -151.86 151.32 31.14 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.004 0.43 . . . . 0.0 111.739 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.787 ' HA ' ' HG3' ' A' ' 7' ' ' GLU . 84.4 m -142.34 134.66 27.74 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.189 179.165 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.457 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 71.5 m-80 -95.17 -46.24 6.86 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.933 0.397 . . . . 0.0 111.123 -179.239 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.56 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 7.7 m -64.41 121.2 71.15 Favored Pre-proline 0 C--O 1.238 0.469 0 CA-C-O 121.43 0.633 . . . . 0.0 111.77 -178.808 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -59.07 132.86 49.64 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.81 2.34 . . . . 0.0 112.191 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.68 -10.78 73.84 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.175 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.56 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 71.2 m -88.1 123.15 32.48 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.384 0.611 . . . . 0.0 110.163 179.61 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.6 m -88.97 143.3 26.95 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.184 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -72.85 119.05 16.55 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 30.2 m -135.15 70.67 1.43 Allowed 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.183 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 8.9 t90 -27.41 128.54 0.2 Allowed Pre-proline 0 N--CA 1.466 0.362 0 CA-C-N 114.036 -1.438 . . . . 0.0 112.916 -178.203 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 92.3 Cg_endo -96.37 29.53 15.24 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 C-N-CA 123.396 -1.501 . . . . 0.0 114.105 0.647 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.508 ' HA ' ' H ' ' A' ' 9' ' ' CYS . 9.3 m -145.89 148.06 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 -179.211 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.554 ' SG ' ' HG2' ' A' ' 7' ' ' GLU . 72.7 m -83.58 141.25 31.71 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.836 178.041 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.2 t . . . . . 0 C--N 1.324 -0.511 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 -179.893 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.473 ' HG2' ' H ' ' A' ' 15' ' ' ASN . 6.6 tp10 . . . . . 0 C--O 1.235 0.336 0 CA-C-O 121.184 0.516 . . . . 0.0 110.229 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 12.6 p -109.92 127.94 55.05 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.041 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.49 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 20.5 t -90.7 38.46 0.95 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.278 0.561 . . . . 0.0 109.873 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -62.9 -36.8 77.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.239 -179.155 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.47 28.05 16.68 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.662 179.371 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.07 40.97 97.8 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 121.271 -0.49 . . . . 0.0 112.933 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -151.75 160.06 43.72 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.578 0.228 . . . . 0.0 110.528 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.7 m -143.81 120.57 11.21 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.147 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.473 ' H ' ' HG2' ' A' ' 7' ' ' GLU . 48.8 m-80 -79.32 -35.61 40.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.672 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.496 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 0.2 OUTLIER -67.91 114.27 19.45 Favored Pre-proline 0 C--O 1.242 0.709 0 CA-C-O 121.252 0.549 . . . . 0.0 111.639 -179.112 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -59.37 135.8 67.64 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.765 2.31 . . . . 0.0 112.322 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.65 -6.39 73.87 Favored Glycine 0 N--CA 1.444 -0.821 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.698 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.496 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 84.2 m -89.76 132.5 35.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 117.461 0.63 . . . . 0.0 111.335 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 m -88.93 148.4 23.83 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.297 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.6 t -79.31 127.54 32.2 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.012 0.434 . . . . 0.0 111.285 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.6 m -137.93 67.84 1.41 Allowed 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.703 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 9.3 t90 -31.39 128.83 0.29 Allowed Pre-proline 0 N--CA 1.465 0.294 0 CA-C-N 114.356 -1.293 . . . . 0.0 112.793 -177.211 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.2 Cg_endo -97.18 31.9 11.64 Favored 'Cis proline' 0 N--CA 1.456 -0.709 0 C-N-CA 123.554 -1.436 . . . . 0.0 113.772 0.305 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 16.1 m -136.64 141.79 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -178.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 80.7 m -85.0 135.02 34.2 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.608 178.419 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.2 t . . . . . 0 C--N 1.323 -0.569 0 CA-C-O 121.557 0.694 . . . . 0.0 110.959 178.971 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 . . . . . 0 CA--C 1.518 -0.287 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.685 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.2 p -74.89 123.55 25.27 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-O 121.443 0.64 . . . . 0.0 110.52 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.503 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 21.8 t -93.77 35.14 1.15 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.91 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.685 HG23 ' HB ' ' A' ' 8' ' ' THR . 44.5 t -62.31 -40.76 89.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.286 -179.635 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.05 24.68 23.61 Favored Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.629 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.91 47.55 90.07 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 121.34 -0.457 . . . . 0.0 113.287 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.8 t -150.89 155.9 40.11 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.854 0.359 . . . . 0.0 110.954 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 94.8 m -133.26 -44.02 0.85 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.756 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 73.76 -46.51 0.63 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.778 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.411 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 2.6 m -63.04 110.68 3.75 Favored Pre-proline 0 C--O 1.243 0.749 0 CA-C-O 121.511 0.672 . . . . 0.0 111.863 -179.227 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 25.2 Cg_endo -61.62 131.77 37.24 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.573 2.182 . . . . 0.0 111.989 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.62 -22.85 37.07 Favored Glycine 0 N--CA 1.437 -1.272 0 C-N-CA 120.398 -0.906 . . . . 0.0 111.583 -179.005 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 15.3 m -98.43 134.7 41.05 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.342 0.591 . . . . 0.0 111.623 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.3 m -99.05 149.47 22.98 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.802 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 23.3 t -76.44 125.04 28.49 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.079 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 32.0 t -126.17 64.44 1.23 Allowed 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 178.365 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.1 t90 -26.74 128.48 0.19 Allowed Pre-proline 0 N--CA 1.467 0.417 0 CA-C-N 114.066 -1.425 . . . . 0.0 113.236 -177.083 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 84.1 Cg_endo -95.34 30.03 14.64 Favored 'Cis proline' 0 CA--C 1.536 0.584 0 C-N-CA 123.451 -1.479 . . . . 0.0 113.964 0.658 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.7 m -139.15 137.17 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 121.558 0.694 . . . . 0.0 112.633 -179.498 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 79.2 m -81.99 140.05 34.19 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.475 178.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.3 t . . . . . 0 C--N 1.323 -0.563 0 CA-C-O 120.802 0.334 . . . . 0.0 110.636 -179.662 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.611 ' HG2' HD21 ' A' ' 15' ' ' ASN . 1.1 mp0 . . . . . 0 CA--C 1.515 -0.384 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.486 ' HB ' HG13 ' A' ' 10' ' ' VAL . 2.4 p -70.25 121.79 18.28 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-O 121.528 0.68 . . . . 0.0 110.498 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 18.9 t -87.96 40.98 0.97 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.903 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.486 HG13 ' HB ' ' A' ' 8' ' ' THR . 15.1 m -62.36 -33.93 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.333 -179.377 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.84 22.45 39.55 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.177 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.47 45.69 94.12 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.837 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -151.87 155.74 38.73 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.012 0.434 . . . . 0.0 111.426 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 55.9 m -133.61 146.6 51.08 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 179.349 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.611 HD21 ' HG2' ' A' ' 7' ' ' GLU . 21.4 p30 -102.71 -35.07 8.81 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.303 -0.559 . . . . 0.0 112.247 -179.005 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 13.0 m -80.74 112.84 35.21 Favored Pre-proline 0 C--O 1.244 0.795 0 CA-C-O 121.542 0.687 . . . . 0.0 111.488 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.411 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 39.2 Cg_exo -59.52 129.06 29.42 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.677 2.251 . . . . 0.0 111.803 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.2 -23.21 19.19 Favored Glycine 0 N--CA 1.438 -1.194 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.2 m -95.16 127.08 40.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.306 0.574 . . . . 0.0 111.515 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.62 147.19 23.47 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.195 -179.52 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.2 t -71.3 123.94 23.42 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.201 0.524 . . . . 0.0 111.176 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 37.9 m -128.44 66.54 1.39 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 178.361 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 3.9 t90 -27.79 129.07 0.21 Allowed Pre-proline 0 N--CA 1.467 0.396 0 CA-C-N 113.904 -1.498 . . . . 0.0 113.051 -177.104 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 90.0 Cg_endo -95.3 31.34 12.61 Favored 'Cis proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.347 -1.522 . . . . 0.0 114.338 0.637 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.6 m -141.49 137.59 32.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 83.0 m -82.26 134.55 35.29 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.595 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.2 t . . . . . 0 C--N 1.324 -0.529 0 CA-C-O 121.296 0.57 . . . . 0.0 110.879 179.492 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 . . . . . 0 N--CA 1.452 -0.363 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.566 ' HB ' HG23 ' A' ' 10' ' ' VAL . 1.4 p -72.0 125.41 27.18 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-O 121.684 0.754 . . . . 0.0 111.625 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.568 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.8 t -104.25 42.22 1.22 Allowed 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.164 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.566 HG23 ' HB ' ' A' ' 8' ' ' THR . 45.9 t -59.11 -40.94 82.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.967 -178.649 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.11 16.79 54.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.523 179.252 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.72 41.2 97.39 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 121.504 -0.379 . . . . 0.0 113.106 179.487 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.8 t -152.84 140.64 20.05 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-O 121.42 0.629 . . . . 0.0 112.26 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 91.1 m -152.49 148.9 27.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.613 -1.176 . . . . 0.0 109.087 178.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.536 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 75.4 m-20 -115.71 11.64 15.76 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.864 -0.334 . . . . 0.0 111.281 -179.549 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -81.12 107.58 8.08 Favored Pre-proline 0 C--O 1.24 0.601 0 CA-C-O 121.248 0.547 . . . . 0.0 110.995 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.536 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 29.4 Cg_exo -60.91 131.81 39.11 Favored 'Trans proline' 0 CA--C 1.515 -0.431 0 C-N-CA 122.64 2.227 . . . . 0.0 112.684 -179.225 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.11 -18.16 56.75 Favored Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.221 -179.697 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 36.3 m -105.36 130.75 53.4 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.6 0.714 . . . . 0.0 111.668 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.6 m -97.98 148.47 23.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.141 -178.8 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.604 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 37.6 t -72.0 128.73 36.63 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.954 179.666 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.5 m -132.26 67.41 1.53 Allowed 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.817 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 3.7 t90 -26.61 128.67 0.19 Allowed Pre-proline 0 N--CA 1.467 0.385 0 CA-C-N 114.054 -1.43 . . . . 0.0 113.095 -177.203 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.48 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 85.4 Cg_endo -94.76 29.23 15.98 Favored 'Cis proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.464 -1.473 . . . . 0.0 114.261 0.595 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 6.7 m -143.04 137.16 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 CA-C-O 121.484 0.659 . . . . 0.0 112.653 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.604 ' SG ' ' HA ' ' A' ' 21' ' ' CYS . 61.2 m -83.56 140.83 32.01 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.876 178.441 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.9 t . . . . . 0 N--CA 1.448 -0.526 0 CA-C-O 120.878 0.37 . . . . 0.0 110.311 179.84 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 . . . . . 0 C--O 1.237 0.416 0 CA-C-O 121.176 0.512 . . . . 0.0 111.007 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.669 HG22 HG12 ' A' ' 25' ' ' VAL . 3.2 p -89.8 126.84 35.83 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.563 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.417 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 17.3 t -83.99 45.21 1.07 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.05 0.452 . . . . 0.0 110.424 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.604 HG23 ' HB ' ' A' ' 8' ' ' THR . 48.5 t -63.54 -39.89 87.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 120.993 0.425 . . . . 0.0 110.74 -179.143 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.73 22.38 25.07 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.738 -0.664 . . . . 0.0 112.948 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.98 39.81 94.67 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.335 -0.459 . . . . 0.0 113.269 179.401 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.7 t -152.25 158.31 42.64 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-O 120.773 0.32 . . . . 0.0 110.944 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -139.91 131.33 26.9 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -83.0 -46.42 12.89 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -178.35 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 4.5 m -70.38 113.61 19.49 Favored Pre-proline 0 C--O 1.246 0.915 0 CA-C-O 121.572 0.701 . . . . 0.0 112.343 -178.412 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -61.22 127.56 22.46 Favored 'Trans proline' 0 N--CA 1.459 -0.555 0 C-N-CA 122.673 2.249 . . . . 0.0 111.291 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 116.52 -26.3 8.63 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -178.157 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.7 m -89.69 130.12 36.02 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 121.338 0.59 . . . . 0.0 110.947 179.178 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 m -96.6 146.95 24.37 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.063 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.7 t -72.26 127.49 32.74 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.203 0.525 . . . . 0.0 111.465 -179.491 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 28.3 t -136.94 64.66 1.53 Allowed 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 178.59 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.432 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.1 t90 -29.21 128.61 0.23 Allowed Pre-proline 0 N--CA 1.466 0.353 0 CA-C-N 114.381 -1.281 . . . . 0.0 113.04 -177.144 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.432 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 96.4 Cg_endo -97.31 34.26 8.96 Favored 'Cis proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.671 -1.387 . . . . 0.0 114.011 0.67 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.669 HG12 HG22 ' A' ' 8' ' ' THR . 17.6 m -140.82 146.96 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 O-C-N 121.898 -0.501 . . . . 0.0 112.33 -179.331 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 72.6 m -81.93 123.73 29.12 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 178.583 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.8 t . . . . . 0 C--N 1.323 -0.551 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.775 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 . . . . . 0 N--CA 1.452 -0.373 0 CA-C-O 121.259 0.552 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.489 HG22 HG12 ' A' ' 25' ' ' VAL . 2.0 p -98.07 126.68 43.61 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.564 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 35.1 t -87.81 44.63 1.2 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.755 179.13 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.2 p -62.38 -38.35 81.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.517 -178.734 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.42 26.49 17.46 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.856 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.15 38.16 92.73 Favored Glycine 0 C--N 1.333 0.391 0 C-N-CA 121.31 -0.471 . . . . 0.0 112.949 179.518 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.9 t -152.51 163.11 40.22 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.6 m -145.02 120.12 10.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.027 179.362 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 33.5 t30 -78.94 -36.44 41.72 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.616 179.692 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 5.9 m -63.04 109.63 2.66 Favored Pre-proline 0 C--O 1.242 0.667 0 CA-C-O 121.414 0.626 . . . . 0.0 111.646 -179.205 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_exo -61.61 130.23 30.82 Favored 'Trans proline' 0 CA--C 1.515 -0.463 0 C-N-CA 122.844 2.362 . . . . 0.0 112.535 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.9 -20.02 52.27 Favored Glycine 0 N--CA 1.44 -1.062 0 CA-C-N 115.327 -0.852 . . . . 0.0 111.617 -179.39 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 72.0 m -89.81 123.93 34.22 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.321 0.581 . . . . 0.0 110.981 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.4 p -88.99 143.46 26.84 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.359 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.4 t -69.92 128.23 35.64 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.26 0.552 . . . . 0.0 112.005 -179.044 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 35.0 t -136.98 66.42 1.47 Allowed 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.435 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 6.8 t90 -29.46 128.62 0.24 Allowed Pre-proline 0 N--CA 1.464 0.269 0 CA-C-N 114.284 -1.325 . . . . 0.0 113.008 -176.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 97.0 Cg_endo -97.0 32.47 10.96 Favored 'Cis proline' 0 N--CA 1.458 -0.599 0 C-N-CA 123.49 -1.463 . . . . 0.0 114.031 0.638 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.489 HG12 HG22 ' A' ' 8' ' ' THR . 15.9 m -139.42 142.87 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 113.032 0.752 . . . . 0.0 113.032 -179.205 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 58.5 m -83.09 131.25 35.16 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.627 178.438 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 t . . . . . 0 C--N 1.324 -0.51 0 CA-C-O 121.129 0.49 . . . . 0.0 111.062 -179.781 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.615 ' OE1' ' HB3' ' A' ' 14' ' ' CYS . 64.6 mt-10 . . . . . 0 N--CA 1.451 -0.399 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 17.3 p -75.34 123.75 25.9 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.131 0.491 . . . . 0.0 110.958 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.2 t -103.74 39.81 1.54 Allowed 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.434 179.7 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -59.16 -36.96 65.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.343 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.33 27.89 18.49 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.317 179.304 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.47 35.67 89.43 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 121.365 -0.445 . . . . 0.0 112.993 179.748 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.8 t -153.06 156.4 38.66 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 120.646 0.26 . . . . 0.0 110.838 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.615 ' HB3' ' OE1' ' A' ' 7' ' ' GLU . 61.0 m -150.05 -153.09 0.47 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.787 179.237 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.417 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 72.4 m-80 -133.12 -52.94 0.9 Allowed 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -178.559 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 51.3 m -66.34 108.47 2.33 Favored Pre-proline 0 C--O 1.249 1.047 0 N-CA-C 113.523 0.934 . . . . 0.0 113.523 -177.375 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.417 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 37.4 Cg_endo -65.6 125.48 14.44 Favored 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 122.461 2.107 . . . . 0.0 110.485 178.353 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.55 -27.38 6.03 Favored Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -177.774 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 14.2 m -89.86 129.41 36.23 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 120.15 -0.62 . . . . 0.0 110.067 178.733 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.7 m -88.14 144.86 26.23 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.533 -179.17 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.2 t -72.98 122.68 22.11 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.12 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.0 m -127.73 67.28 1.33 Allowed 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 178.583 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.516 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.3 t90 -26.5 127.95 0.19 Allowed Pre-proline 0 N--CA 1.467 0.395 0 CA-C-N 113.921 -1.491 . . . . 0.0 113.058 -177.18 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.516 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 80.5 Cg_endo -95.56 31.55 12.3 Favored 'Cis proline' 0 N--CA 1.456 -0.707 0 C-N-CA 123.482 -1.466 . . . . 0.0 114.38 0.864 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 6.0 m -145.03 138.06 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 N-CA-C 112.873 0.694 . . . . 0.0 112.873 -179.526 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.482 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 94.6 m -82.19 140.29 33.81 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.571 178.254 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.321 -0.646 0 CA-C-O 121.041 0.448 . . . . 0.0 110.196 179.387 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 . . . . . 0 N--CA 1.452 -0.368 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.724 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.7 p -77.98 123.9 27.36 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-O 121.414 0.625 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.438 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 28.2 t -90.52 39.97 1.0 Allowed 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.052 179.775 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.724 HG23 ' HB ' ' A' ' 8' ' ' THR . 47.3 t -61.99 -40.31 86.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.653 -179.245 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.47 22.83 30.81 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.881 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.19 47.6 88.4 Favored Glycine 0 CA--C 1.52 0.362 0 C-N-CA 121.289 -0.482 . . . . 0.0 113.206 179.306 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.4 t -151.18 155.98 39.99 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 122.565 -0.373 . . . . 0.0 111.095 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 82.9 m -140.1 127.73 21.67 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.656 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -81.44 -41.18 22.22 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -179.202 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.433 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 15.5 m -75.82 109.46 8.15 Favored Pre-proline 0 C--O 1.246 0.885 0 CA-C-O 121.545 0.688 . . . . 0.0 112.223 -178.52 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 27.6 Cg_endo -61.96 131.19 33.83 Favored 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 122.564 2.176 . . . . 0.0 111.386 179.524 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 110.61 -29.32 9.13 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 -178.305 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 7.4 m -89.59 133.37 34.65 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.526 179.221 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.3 m -95.23 148.79 22.02 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.959 -178.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.3 t -70.07 126.6 30.15 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.875 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.7 m -134.22 67.96 1.5 Allowed 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 1.5 t90 -28.35 128.16 0.22 Allowed Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 113.976 -1.465 . . . . 0.0 112.989 -176.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.8 Cg_endo -96.71 32.52 10.92 Favored 'Cis proline' 0 CA--C 1.537 0.64 0 C-N-CA 123.595 -1.419 . . . . 0.0 114.151 0.896 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.2 m -143.71 141.78 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -179.572 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.438 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 65.8 m -82.68 132.54 35.18 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.234 178.757 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.2 t . . . . . 0 C--O 1.239 0.508 0 CA-C-O 121.014 0.435 . . . . 0.0 111.557 -179.869 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.669 ' HG3' ' HB3' ' A' ' 15' ' ' ASN . 47.3 mm-40 . . . . . 0 C--O 1.239 0.539 0 CA-C-O 122.028 0.918 . . . . 0.0 112.61 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.697 HG22 HG12 ' A' ' 25' ' ' VAL . 5.9 p -110.22 127.85 55.18 Favored 'General case' 0 N--CA 1.439 -1.019 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.825 178.789 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 12.7 t -83.65 41.35 0.78 Allowed 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.919 0.39 . . . . 0.0 110.841 -179.403 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.621 HG23 ' HB ' ' A' ' 8' ' ' THR . 47.6 t -64.73 -42.01 93.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.174 0.511 . . . . 0.0 110.314 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.24 28.62 12.3 Favored Glycine 0 N--CA 1.45 -0.397 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.638 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.08 42.55 98.52 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 121.27 -0.49 . . . . 0.0 113.237 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.8 t -151.61 160.17 43.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.648 0.261 . . . . 0.0 110.756 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.7 m -146.03 124.75 12.57 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.191 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.669 ' HB3' ' HG3' ' A' ' 7' ' ' GLU . 28.2 t-20 -81.04 -46.73 14.58 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.657 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.465 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 0.2 OUTLIER -58.33 111.77 4.01 Favored Pre-proline 0 C--O 1.238 0.481 0 CA-C-O 121.221 0.534 . . . . 0.0 112.146 -178.857 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 24.7 Cg_exo -62.24 130.59 31.0 Favored 'Trans proline' 0 N--CA 1.46 -0.448 0 C-N-CA 122.631 2.221 . . . . 0.0 111.63 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.38 -14.72 63.14 Favored Glycine 0 N--CA 1.442 -0.945 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.763 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.465 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 95.9 m -88.98 126.82 35.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.243 0.544 . . . . 0.0 110.816 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.87 148.76 23.69 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.412 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 t -75.48 128.6 35.67 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.127 0.489 . . . . 0.0 112.187 -178.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 57.6 m -139.99 69.13 1.35 Allowed 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 178.193 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.528 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 11.4 t90 -31.62 129.04 0.3 Allowed Pre-proline 0 N--CA 1.465 0.292 0 CA-C-N 114.227 -1.351 . . . . 0.0 112.886 -177.173 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 97.6 Cg_endo -98.06 33.16 9.83 Favored 'Cis proline' 0 N--CA 1.457 -0.633 0 C-N-CA 123.71 -1.371 . . . . 0.0 113.75 0.557 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.697 HG12 HG22 ' A' ' 8' ' ' THR . 24.6 m -139.43 145.85 26.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -178.837 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 61.3 m -84.63 138.26 32.8 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.192 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.7 t . . . . . 0 C--N 1.324 -0.533 0 CA-C-O 121.057 0.456 . . . . 0.0 110.449 179.417 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 111.972 -0.451 . . . . 0.0 111.972 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 47.0 tp -75.8 123.05 88.16 Favored Pre-proline 0 C--N 1.326 -0.43 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -68.72 131.58 23.08 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.627 2.218 . . . . 0.0 111.868 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 46.6 t -70.11 -44.75 77.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.445 0.64 . . . . 0.0 110.29 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 1.6 m -95.55 156.18 16.43 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.644 179.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -162.34 17.87 0.16 Allowed Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.314 -0.946 . . . . 0.0 112.657 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -79.47 136.99 37.07 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.7 ' HB ' HG23 ' A' ' 10' ' ' VAL . 18.8 p -71.72 122.43 20.61 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 120.909 0.385 . . . . 0.0 110.452 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.523 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 17.0 t -93.05 37.05 1.03 Allowed 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.981 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.7 HG23 ' HB ' ' A' ' 8' ' ' THR . 46.1 t -60.4 -41.14 86.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.777 -179.241 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.86 24.92 24.1 Favored Glycine 0 N--CA 1.451 -0.3 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.948 179.645 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.85 47.92 88.06 Favored Glycine 0 C--N 1.333 0.363 0 C-N-CA 121.223 -0.513 . . . . 0.0 113.326 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 t -150.97 154.1 36.46 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.872 0.368 . . . . 0.0 111.082 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 76.8 m -134.48 138.07 44.43 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.87 179.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -79.91 -53.99 6.23 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.889 -178.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.585 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 6.7 m -73.1 115.06 36.77 Favored Pre-proline 0 C--O 1.243 0.732 0 CA-C-O 121.368 0.604 . . . . 0.0 112.297 -178.321 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -63.69 121.86 9.75 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.529 2.153 . . . . 0.0 110.635 179.119 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.14 -16.11 13.16 Favored Glycine 0 N--CA 1.439 -1.112 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 -178.322 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.585 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 76.5 m -89.14 132.43 34.83 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 m -88.77 144.97 25.89 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.272 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.9 t -78.48 126.35 30.64 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.077 0.465 . . . . 0.0 110.811 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.0 m -132.66 67.93 1.52 Allowed 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.7 t90 -29.15 127.88 0.24 Allowed Pre-proline 0 N--CA 1.465 0.279 0 CA-C-N 114.06 -1.427 . . . . 0.0 112.841 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 91.3 Cg_endo -97.04 32.8 10.51 Favored 'Cis proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.582 -1.424 . . . . 0.0 114.053 0.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 10.8 m -140.68 139.39 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.523 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.3 m -83.36 137.82 33.79 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.649 178.788 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.1 t -150.77 149.15 29.39 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.092 0.472 . . . . 0.0 110.227 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 39.8 ttt85 -100.17 125.16 46.26 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.096 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 5.9 m120 . . . . . 0 C--N 1.319 -0.739 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.474 -179.575 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.4 0 N-CA-C 111.87 -0.492 . . . . 0.0 111.87 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.677 HD12 ' HD2' ' A' ' 3' ' ' PRO . 46.9 tp -72.17 123.13 89.07 Favored Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.622 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.677 ' HD2' HD12 ' A' ' 2' ' ' LEU . 70.7 Cg_endo -74.73 48.49 1.93 Allowed 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.973 2.449 . . . . 0.0 112.367 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.36 -35.68 63.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.449 0.642 . . . . 0.0 110.653 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.7 m -137.42 -55.89 0.69 Allowed 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.102 -0.953 . . . . 0.0 110.035 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.76 -38.7 2.81 Favored Glycine 0 C--N 1.322 -0.234 0 CA-C-N 115.682 -0.69 . . . . 0.0 113.538 179.231 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.447 ' OE2' ' HB3' ' A' ' 15' ' ' ASN . 20.7 mt-10 -53.44 134.37 40.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.798 0.332 . . . . 0.0 111.01 -179.394 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 3.0 p -88.29 127.51 35.47 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 121.105 0.478 . . . . 0.0 110.825 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.561 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 15.0 t -91.28 40.52 1.03 Allowed 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.136 0.493 . . . . 0.0 109.84 179.465 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.6 p -61.81 -36.28 72.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.08 -179.129 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.56 24.23 31.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.829 -0.7 . . . . 0.0 112.72 179.412 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.5 41.59 97.23 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.257 -0.497 . . . . 0.0 113.181 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.8 t -151.48 152.58 33.2 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 121.011 0.434 . . . . 0.0 111.309 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 71.1 m -132.07 140.1 48.75 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.076 179.123 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.447 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 9.7 t30 -91.95 -47.91 7.04 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.609 -178.766 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' ' 17' ' ' PRO . 85.2 m -70.57 116.45 45.64 Favored Pre-proline 0 C--O 1.242 0.709 0 CA-C-O 121.322 0.582 . . . . 0.0 111.801 -179.244 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 26.1 Cg_exo -61.56 126.29 18.78 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.681 2.254 . . . . 0.0 111.019 179.524 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 110.62 -18.25 27.38 Favored Glycine 0 N--CA 1.44 -1.043 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -178.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.0 m -87.4 124.85 33.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.174 0.512 . . . . 0.0 110.273 179.45 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 m -89.35 145.52 25.3 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.854 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 53.7 t -77.03 126.81 31.58 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 121.173 0.511 . . . . 0.0 111.306 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -137.37 68.69 1.41 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.585 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.438 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.7 t90 -31.04 129.07 0.27 Allowed Pre-proline 0 N--CA 1.463 0.216 0 CA-C-N 114.111 -1.404 . . . . 0.0 112.832 -177.164 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.6 Cg_endo -97.08 33.24 10.01 Favored 'Cis proline' 0 N--CA 1.456 -0.678 0 C-N-CA 123.591 -1.421 . . . . 0.0 114.026 0.694 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 14.8 m -140.11 141.95 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 N-CA-C 113.222 0.823 . . . . 0.0 113.222 -179.121 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.561 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 84.1 m -84.01 135.47 34.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.03 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.2 t -150.72 146.69 26.6 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.126 0.488 . . . . 0.0 110.226 179.044 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.407 ' HG2' HH11 ' A' ' 28' ' ' ARG . 43.0 ttp85 -80.41 108.64 14.2 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.469 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 . . . . . 0 C--N 1.319 -0.738 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.852 -179.418 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.599 0 N-CA-C 111.971 -0.452 . . . . 0.0 111.971 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 14.6 mt -148.15 135.47 10.57 Favored Pre-proline 0 C--N 1.325 -0.47 0 CA-C-O 120.953 0.406 . . . . 0.0 110.838 179.589 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.15 52.63 3.16 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 123.441 2.76 . . . . 0.0 112.768 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 48.3 t -71.39 -45.49 68.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.432 0.634 . . . . 0.0 110.466 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.464 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 6.5 m -89.08 160.39 17.08 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.329 179.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -175.28 25.71 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.898 -0.668 . . . . 0.0 111.983 179.483 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -85.53 144.99 27.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.089 0.471 . . . . 0.0 110.133 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 p -77.34 125.48 29.4 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-O 121.313 0.577 . . . . 0.0 110.908 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.485 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 26.0 t -92.71 37.75 1.01 Allowed 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.784 -0.643 . . . . 0.0 109.616 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.1 p -62.02 -35.46 68.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.008 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.78 21.64 43.67 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.723 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.56 45.61 95.98 Favored Glycine 0 CA--C 1.519 0.34 0 C-N-CA 121.249 -0.501 . . . . 0.0 113.297 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.9 t -150.82 152.52 33.88 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.881 0.372 . . . . 0.0 111.108 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 90.1 m -130.48 140.44 50.53 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.799 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.5 t30 -89.5 -48.91 7.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.918 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.464 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 1.8 m -76.1 112.54 21.21 Favored Pre-proline 0 C--O 1.244 0.801 0 CA-C-O 121.426 0.631 . . . . 0.0 112.572 -178.064 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.446 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 19.3 Cg_endo -60.2 133.04 47.37 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.682 2.255 . . . . 0.0 111.481 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.51 -27.19 17.56 Favored Glycine 0 N--CA 1.438 -1.218 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 12.3 m -90.7 128.64 36.72 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.061 0.458 . . . . 0.0 110.232 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.5 t -90.83 160.98 15.46 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.929 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 46.1 t -80.67 131.45 35.47 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.55 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.2 m -138.38 68.77 1.39 Allowed 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 178.361 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 2.0 t90 -29.56 129.16 0.24 Allowed Pre-proline 0 N--CA 1.466 0.33 0 CA-C-N 114.062 -1.426 . . . . 0.0 113.015 -177.047 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 94.3 Cg_endo -96.66 33.26 10.02 Favored 'Cis proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.484 -1.465 . . . . 0.0 114.151 0.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 10.6 m -144.01 143.96 23.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.485 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.1 m -82.76 143.81 30.61 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.2 t -150.01 158.48 44.21 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.371 0.605 . . . . 0.0 111.311 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.442 ' HA ' ' HD2' ' A' ' 28' ' ' ARG . 29.8 tpt85 -81.22 52.44 1.81 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.003 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 . . . . . 0 C--N 1.323 -0.564 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.53 179.514 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.404 0 N-CA-C 112.125 -0.39 . . . . 0.0 112.125 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.6 tp -66.81 117.84 49.06 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 115.629 -0.285 . . . . 0.0 111.072 -179.805 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -76.92 58.98 6.28 Favored 'Trans proline' 0 N--CA 1.462 -0.349 0 C-N-CA 123.369 2.713 . . . . 0.0 111.718 179.52 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.7 p -55.57 -39.85 56.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.397 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.497 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 62.7 m -65.61 -52.87 48.76 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.683 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.61 10.17 63.27 Favored Glycine 0 C--N 1.322 -0.24 0 CA-C-N 115.078 -0.965 . . . . 0.0 113.234 179.375 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -73.63 138.97 45.16 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.81 0.338 . . . . 0.0 110.583 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.514 ' HB ' HG23 ' A' ' 10' ' ' VAL . 10.8 p -82.25 124.87 30.33 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.151 179.105 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 23.9 t -87.62 53.03 2.65 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.246 0.546 . . . . 0.0 110.725 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.514 HG23 ' HB ' ' A' ' 8' ' ' THR . 4.1 t -78.99 48.84 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-O 121.46 0.648 . . . . 0.0 110.781 -179.614 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.06 26.89 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.888 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 55.06 43.95 83.31 Favored Glycine 0 C--N 1.336 0.529 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.099 179.358 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.2 t -151.55 153.74 35.13 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.11 0.481 . . . . 0.0 111.545 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.4 m -142.33 134.34 27.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.186 -0.915 . . . . 0.0 108.578 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 62.0 m-80 -84.07 -45.18 13.32 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.591 0.234 . . . . 0.0 111.561 -178.571 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.497 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 4.1 m -69.94 113.66 19.26 Favored Pre-proline 0 C--O 1.244 0.811 0 CA-C-O 121.44 0.638 . . . . 0.0 112.002 -178.649 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -60.12 131.0 36.75 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.695 2.264 . . . . 0.0 111.345 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.48 -26.2 15.41 Favored Glycine 0 N--CA 1.439 -1.129 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -178.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.7 m -89.31 126.17 35.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.504 0.669 . . . . 0.0 111.112 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.3 m -94.07 147.55 23.03 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.597 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.1 t -72.38 114.87 10.97 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.074 0.464 . . . . 0.0 111.278 -179.51 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 36.8 m -123.43 64.47 1.01 Allowed 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 178.224 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.49 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 8.8 t90 -27.6 129.39 0.2 Allowed Pre-proline 0 N--CA 1.463 0.203 0 CA-C-N 113.798 -1.547 . . . . 0.0 113.104 -177.063 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 96.6 Cg_endo -94.71 27.89 18.05 Favored 'Cis proline' 0 N--CA 1.457 -0.668 0 C-N-CA 123.226 -1.573 . . . . 0.0 114.143 0.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.3 m -137.37 140.1 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -179.201 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 72.8 m -82.7 129.95 35.04 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.672 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t -150.71 161.45 42.6 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 52.0 ttp85 -75.21 104.3 5.72 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 3.8 m120 . . . . . 0 C--N 1.321 -0.64 0 CA-C-O 121.032 0.444 . . . . 0.0 111.216 -179.366 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.444 0 N-CA-C 111.899 -0.481 . . . . 0.0 111.899 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 4' ' ' VAL . 7.3 mp -67.0 128.41 93.86 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.798 0.299 . . . . 0.0 110.468 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -73.81 48.42 1.65 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.146 2.564 . . . . 0.0 112.828 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.431 HG23 ' HB3' ' A' ' 2' ' ' LEU . 23.8 t -101.68 -20.98 5.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.418 0.628 . . . . 0.0 109.813 179.698 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.587 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 1.6 m -62.87 154.24 30.72 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.167 -0.924 . . . . 0.0 111.657 -179.288 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -160.14 28.46 0.35 Allowed Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.535 179.173 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.593 ' HG2' ' HB3' ' A' ' 15' ' ' ASN . 2.8 mp0 -85.32 137.33 33.03 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.3 p -73.31 124.24 25.33 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 120.844 0.354 . . . . 0.0 110.351 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.572 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 21.2 t -89.44 38.35 0.9 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.255 0.55 . . . . 0.0 110.019 179.669 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.01 -36.23 72.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.964 -179.283 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.04 25.59 26.96 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.746 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.14 45.29 95.53 Favored Glycine 0 C--N 1.331 0.277 0 C-N-CA 121.165 -0.54 . . . . 0.0 113.131 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.7 t -151.04 154.43 37.02 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.927 0.394 . . . . 0.0 111.065 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 98.8 m -130.98 139.58 50.03 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.813 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.593 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 30.4 t30 -85.26 -50.27 7.5 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.764 -179.211 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.587 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 5.6 m -80.59 109.1 11.64 Favored Pre-proline 0 C--O 1.251 1.174 0 CA-C-O 121.821 0.82 . . . . 0.0 112.584 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.5 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 24.5 Cg_exo -61.4 127.08 20.85 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.686 2.257 . . . . 0.0 111.103 179.443 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.525 ' O ' ' HG3' ' A' ' 28' ' ' ARG . . . 122.02 -29.73 5.47 Favored Glycine 0 N--CA 1.434 -1.458 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -178.039 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.615 ' HA ' ' HB2' ' A' ' 28' ' ' ARG . 19.0 m -88.99 143.1 27.09 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.256 -0.577 . . . . 0.0 110.529 179.061 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 m -97.08 149.33 22.08 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.559 -179.164 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.3 t -74.93 128.21 35.04 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.153 0.502 . . . . 0.0 111.15 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.0 m -133.84 67.79 1.51 Allowed 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.8 t90 -29.58 128.49 0.24 Allowed Pre-proline 0 N--CA 1.464 0.256 0 CA-C-N 114.118 -1.401 . . . . 0.0 112.811 -177.176 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.457 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 95.7 Cg_endo -96.78 34.13 9.15 Favored 'Cis proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.615 -1.41 . . . . 0.0 114.201 0.639 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.42 ' HA ' ' H ' ' A' ' 9' ' ' CYS . 10.8 m -143.11 139.97 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 -179.464 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.572 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 70.9 m -83.05 132.21 35.13 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.038 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.9 t -152.01 168.41 25.32 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.646 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.615 ' HB2' ' HA ' ' A' ' 19' ' ' CYS . 0.3 OUTLIER -173.72 -160.53 0.11 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.046 0.45 . . . . 0.0 111.172 179.77 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 . . . . . 0 C--N 1.322 -0.595 0 CA-C-N 114.878 -1.056 . . . . 0.0 109.236 179.951 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.019 -0.432 . . . . 0.0 112.019 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.1 tp 63.41 94.07 0.05 OUTLIER Pre-proline 0 N--CA 1.464 0.236 0 C-N-CA 123.205 0.602 . . . . 0.0 111.404 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -71.31 120.45 6.99 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 122.333 2.022 . . . . 0.0 111.68 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 32.4 t -66.12 -40.93 88.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.324 0.583 . . . . 0.0 110.998 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.442 ' HB2' ' O ' ' A' ' 26' ' ' CYS . 81.4 m -89.31 -49.96 6.4 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.769 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.77 -38.25 3.19 Favored Glycine 0 C--N 1.319 -0.414 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.749 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.433 ' OE2' ' HB3' ' A' ' 15' ' ' ASN . 23.1 mt-10 -58.11 135.18 56.98 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.749 0.309 . . . . 0.0 110.706 -179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 2.8 p -88.33 127.14 35.48 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-O 121.099 0.476 . . . . 0.0 110.989 179.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.532 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 18.1 t -91.79 40.43 1.04 Allowed 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.159 0.504 . . . . 0.0 109.881 179.396 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -62.12 -36.22 73.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.086 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.6 24.1 30.96 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.798 179.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.23 42.04 97.05 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.25 -0.5 . . . . 0.0 113.072 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.0 t -151.82 156.18 39.68 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.842 0.353 . . . . 0.0 111.023 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.9 m -135.8 136.88 41.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.302 179.386 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.433 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 9.8 t30 -87.48 -48.95 7.53 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.996 -178.762 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 88.4 m -70.98 118.38 65.0 Favored Pre-proline 0 C--O 1.241 0.647 0 CA-C-O 121.473 0.654 . . . . 0.0 111.946 -179.005 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -59.19 131.35 40.7 Favored 'Trans proline' 0 N--CA 1.458 -0.576 0 C-N-CA 122.717 2.278 . . . . 0.0 110.987 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 102.33 -13.64 56.96 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.369 -0.919 . . . . 0.0 111.505 -178.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.435 ' HB3' ' HB3' ' A' ' 26' ' ' CYS . 93.3 m -87.82 123.23 32.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.415 0.626 . . . . 0.0 110.561 179.573 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.25 141.49 28.49 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.675 179.722 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 45.8 t -73.65 120.9 19.89 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 121.104 0.478 . . . . 0.0 111.241 -179.487 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.1 t -129.03 64.85 1.46 Allowed 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.1 t90 -29.38 128.63 0.24 Allowed Pre-proline 0 N--CA 1.465 0.325 0 CA-C-N 114.26 -1.336 . . . . 0.0 112.978 -176.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.2 Cg_endo -96.64 33.53 9.75 Favored 'Cis proline' 0 CA--C 1.536 0.621 0 C-N-CA 123.542 -1.441 . . . . 0.0 114.149 0.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 15.3 m -140.93 141.77 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 112.96 0.726 . . . . 0.0 112.96 -179.328 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 77.3 m -82.35 136.34 35.01 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.771 178.344 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.4 t -150.84 167.02 28.75 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.852 0.358 . . . . 0.0 110.587 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 21.9 mmt85 -82.06 74.69 9.03 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.346 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 . . . . . 0 C--N 1.324 -0.524 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.476 -179.643 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 36.2 tp -160.74 127.77 2.6 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -67.29 135.72 37.81 Favored 'Trans proline' 0 N--CA 1.462 -0.341 0 C-N-CA 122.586 2.191 . . . . 0.0 111.835 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.527 HG13 ' SG ' ' A' ' 5' ' ' CYS . 7.7 p -65.92 -44.13 92.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.425 0.631 . . . . 0.0 110.635 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.562 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 4.6 m -94.75 157.02 16.13 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.844 178.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -172.98 24.82 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.099 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.462 ' HG3' ' H ' ' A' ' 15' ' ' ASN . 23.9 pm0 -83.15 144.86 29.55 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.191 0.52 . . . . 0.0 110.293 179.761 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.768 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.4 p -75.46 126.43 31.0 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.496 0.665 . . . . 0.0 111.429 -179.674 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.479 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 34.7 t -93.58 37.23 1.06 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.603 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.768 HG23 ' HB ' ' A' ' 8' ' ' THR . 48.0 t -60.91 -41.06 87.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.693 -179.16 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.37 23.22 22.93 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.753 179.424 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.94 45.16 95.54 Favored Glycine 0 CA--C 1.52 0.357 0 C-N-CA 121.394 -0.431 . . . . 0.0 113.288 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.9 t -150.85 151.98 33.04 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.046 0.45 . . . . 0.0 111.149 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 95.2 m -118.12 144.53 45.59 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.354 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.462 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 31.0 t30 -94.29 -48.53 6.13 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.366 -179.348 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.562 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 1.6 m -81.03 114.71 50.87 Favored Pre-proline 0 C--O 1.242 0.684 0 CA-C-O 121.334 0.588 . . . . 0.0 112.158 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 14.9 Cg_endo -56.95 137.92 83.89 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.686 2.257 . . . . 0.0 111.998 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 96.76 -23.28 36.1 Favored Glycine 0 N--CA 1.439 -1.147 0 C-N-CA 120.572 -0.823 . . . . 0.0 111.642 -178.785 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 7.3 m -90.64 131.89 36.08 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 120.404 -0.518 . . . . 0.0 110.913 179.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.9 t -89.87 158.28 17.52 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.823 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.2 t -79.29 129.17 34.2 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.216 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 29.6 m -134.79 67.24 1.51 Allowed 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 178.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 1.3 t90 -28.32 128.95 0.22 Allowed Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 114.11 -1.405 . . . . 0.0 113.091 -177.077 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 89.2 Cg_endo -95.64 31.69 12.1 Favored 'Cis proline' 0 N--CA 1.457 -0.642 0 C-N-CA 123.475 -1.469 . . . . 0.0 114.371 0.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.2 m -144.26 141.3 24.46 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 98.0 m -82.99 142.8 31.09 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.112 178.3 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.5 t -150.12 171.4 16.95 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.092 0.472 . . . . 0.0 110.925 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 19.9 tpp85 -95.53 117.22 30.02 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.881 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 35.5 t30 . . . . . 0 C--N 1.321 -0.635 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.711 -179.993 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.61 0 N-CA-C 112.136 -0.386 . . . . 0.0 112.136 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.586 ' HG ' ' HD3' ' A' ' 3' ' ' PRO . 3.6 pp -68.42 -34.3 5.59 Favored Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 114.443 1.275 . . . . 0.0 114.443 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.601 ' O ' ' HD3' ' A' ' 28' ' ' ARG . 59.2 Cg_endo -75.35 61.4 5.93 Favored 'Trans proline' 0 C--N 1.354 0.846 0 C-N-CA 122.101 1.868 . . . . 0.0 112.78 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 41.5 t -68.07 -47.47 78.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.208 0.528 . . . . 0.0 109.755 179.687 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.787 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 96.2 m 62.2 -168.82 0.19 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 114.561 -1.199 . . . . 0.0 112.527 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 146.16 -10.23 1.55 Allowed Glycine 0 N--CA 1.449 -0.492 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.541 -179.154 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.438 ' H ' ' CD ' ' A' ' 7' ' ' GLU . 0.8 OUTLIER -62.92 145.25 55.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.262 0.553 . . . . 0.0 111.009 179.933 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.655 ' HB ' HG23 ' A' ' 10' ' ' VAL . 7.9 p -69.12 126.66 30.48 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.202 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 35.9 t -86.66 47.21 1.45 Allowed 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.542 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.655 HG23 ' HB ' ' A' ' 8' ' ' THR . 17.8 t -76.15 69.63 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.505 0.669 . . . . 0.0 110.005 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 163.81 -20.58 0.15 Allowed Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.582 -0.736 . . . . 0.0 111.845 -179.044 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.87 42.89 4.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.873 -0.68 . . . . 0.0 111.593 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.9 t -152.11 154.42 35.87 Favored 'General case' 0 N--CA 1.446 -0.642 0 CA-C-O 120.67 0.271 . . . . 0.0 110.383 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 96.9 m -131.32 137.07 48.62 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.202 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 35.4 t30 -66.65 -56.54 10.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.082 -178.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.787 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 4.8 m -80.74 116.27 61.07 Favored Pre-proline 0 C--O 1.245 0.867 0 CA-C-O 121.622 0.725 . . . . 0.0 112.062 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_exo -60.45 125.91 18.63 Favored 'Trans proline' 0 N--CA 1.46 -0.449 0 C-N-CA 122.543 2.162 . . . . 0.0 110.834 179.329 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.51 -22.31 8.87 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -178.216 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.2 m -88.6 133.86 34.05 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.932 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.1 m -88.87 146.28 25.05 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.451 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 t -80.07 103.4 9.93 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.472 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 61.3 m -103.82 60.88 0.74 Allowed 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.311 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.459 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 11.5 t90 -28.51 130.21 0.21 Allowed Pre-proline 0 N--CA 1.465 0.298 0 CA-C-N 113.492 -1.686 . . . . 0.0 112.703 -177.536 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.4 Cg_endo -93.96 33.07 10.04 Favored 'Cis proline' 0 N--CA 1.456 -0.7 0 C-N-CA 123.16 -1.6 . . . . 0.0 114.492 1.018 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.5 m -138.9 138.59 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 N-CA-C 112.724 0.638 . . . . 0.0 112.724 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 67.6 m -81.96 135.84 35.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.326 178.65 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.546 ' HB ' ' OD1' ' A' ' 29' ' ' ASN . 10.7 m -150.74 149.82 30.26 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.601 ' HD3' ' O ' ' A' ' 3' ' ' PRO . 32.9 ptt180 -80.85 45.27 0.8 Allowed 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.206 0.526 . . . . 0.0 110.92 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.546 ' OD1' ' HB ' ' A' ' 27' ' ' THR . 15.3 p-10 . . . . . 0 C--N 1.322 -0.622 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.577 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.101 -0.4 . . . . 0.0 112.101 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 2' ' ' LEU . 3.0 mm? -68.34 146.04 97.69 Favored Pre-proline 0 C--N 1.325 -0.5 0 CA-C-O 120.862 0.363 . . . . 0.0 111.075 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.77 53.71 3.76 Favored 'Trans proline' 0 CA--C 1.529 0.237 0 C-N-CA 123.285 2.657 . . . . 0.0 112.726 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 47.2 t -68.08 -47.37 78.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.268 0.556 . . . . 0.0 110.342 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.3 m -85.26 155.25 21.46 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.195 179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -177.89 26.38 0.06 OUTLIER Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.968 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -88.38 144.51 26.34 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-O 121.182 0.515 . . . . 0.0 110.28 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 p -78.86 125.77 29.81 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.65 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 22.4 t -87.67 42.21 1.03 Allowed 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.423 0.63 . . . . 0.0 109.869 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.25 -34.84 71.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.865 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.93 22.56 40.37 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.552 179.318 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.99 45.9 94.5 Favored Glycine 0 C--N 1.332 0.328 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.12 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.3 t -151.36 155.56 38.92 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 120.933 0.397 . . . . 0.0 111.093 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 92.0 m -131.89 139.95 48.92 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.851 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -90.02 -47.29 7.94 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.629 -179.035 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 m -74.26 112.04 15.31 Favored Pre-proline 0 C--O 1.243 0.728 0 CA-C-O 121.328 0.585 . . . . 0.0 112.33 -178.31 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -60.76 131.56 38.19 Favored 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 122.625 2.217 . . . . 0.0 111.398 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.25 -28.72 11.25 Favored Glycine 0 N--CA 1.44 -1.083 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -178.221 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 6.5 m -91.52 128.44 37.35 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.165 0.507 . . . . 0.0 110.566 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 t -91.63 163.74 14.0 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.726 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.5 t -80.22 127.84 32.82 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.278 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 45.1 m -136.89 68.52 1.42 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 178.681 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.0 t90 -29.32 130.16 0.23 Allowed Pre-proline 0 N--CA 1.463 0.225 0 CA-C-N 114.133 -1.394 . . . . 0.0 113.064 -177.138 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.9 Cg_endo -95.76 31.28 12.66 Favored 'Cis proline' 0 N--CA 1.458 -0.604 0 C-N-CA 123.252 -1.562 . . . . 0.0 114.247 0.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.4 m -144.46 146.49 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -179.391 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 71.5 m -82.57 138.52 34.22 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.77 178.22 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.4 t -151.06 -171.45 3.94 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.724 0.297 . . . . 0.0 110.843 -179.664 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.9 ptp85 -89.76 136.68 32.89 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.6 t30 . . . . . 0 C--N 1.317 -0.806 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.553 -179.488 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.422 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.364 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.422 ' HB2' ' O ' ' A' ' 1' ' ' GLY . 9.8 mp 71.12 141.48 0.08 OUTLIER Pre-proline 0 N--CA 1.468 0.425 0 C-N-CA 123.228 0.611 . . . . 0.0 111.473 -179.725 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 18.2 Cg_exo -66.03 121.57 8.93 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 122.33 2.02 . . . . 0.0 111.477 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.1 m -64.44 -31.62 54.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.808 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 67.5 m -136.64 -52.95 0.71 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.954 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.4 -41.79 3.04 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.393 -0.821 . . . . 0.0 112.883 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 89.3 mt-10 -55.72 138.1 48.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.234 0.54 . . . . 0.0 111.333 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.698 HG22 HG12 ' A' ' 25' ' ' VAL . 5.9 p -95.69 127.58 41.84 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.711 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.434 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 16.1 t -89.48 39.05 0.93 Allowed 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.169 0.509 . . . . 0.0 109.908 179.618 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.3 p -63.01 -35.17 70.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.938 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.82 23.27 36.22 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.434 179.187 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.99 41.14 99.31 Favored Glycine 0 C--N 1.333 0.366 0 C-N-CA 121.284 -0.484 . . . . 0.0 113.167 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.0 t -151.38 153.17 34.21 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 121.025 0.44 . . . . 0.0 111.467 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 76.9 m -138.26 137.11 37.17 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -92.9 -47.17 7.16 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.559 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.43 ' HA ' ' HD3' ' A' ' 17' ' ' PRO . 86.8 m -65.53 115.46 22.32 Favored Pre-proline 0 C--O 1.24 0.589 0 CA-C-O 121.437 0.637 . . . . 0.0 111.805 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 25.5 Cg_exo -61.83 127.13 20.61 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.674 2.25 . . . . 0.0 111.097 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.74 -18.43 31.97 Favored Glycine 0 N--CA 1.441 -1.014 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.5 m -87.75 124.27 33.42 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.255 0.55 . . . . 0.0 110.361 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.6 m -91.88 146.16 23.98 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.795 179.605 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.9 t -74.22 129.63 38.18 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.28 0.562 . . . . 0.0 111.805 -179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 51.0 m -141.09 68.57 1.34 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 178.505 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.533 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.8 t90 -31.21 128.73 0.28 Allowed Pre-proline 0 N--CA 1.463 0.202 0 CA-C-N 114.306 -1.315 . . . . 0.0 112.892 -177.039 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.533 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.7 Cg_endo -97.82 34.18 8.94 Favored 'Cis proline' 0 CA--C 1.538 0.69 0 C-N-CA 123.527 -1.447 . . . . 0.0 113.906 0.769 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.698 HG12 HG22 ' A' ' 8' ' ' THR . 17.0 m -141.0 145.95 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 -179.225 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.429 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 79.9 m -83.66 128.56 34.62 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 178.042 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.8 t -112.05 173.73 6.22 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.129 -0.322 . . . . 0.0 110.129 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 31.8 ptt85 -89.64 137.43 32.34 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 . . . . . 0 C--N 1.317 -0.832 0 C-N-CA 120.336 -0.546 . . . . 0.0 110.816 -179.726 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 111.89 -0.484 . . . . 0.0 111.89 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 7.2 mp -74.1 136.86 75.85 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.728 -0.236 . . . . 0.0 110.428 179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.68 135.94 43.87 Favored 'Trans proline' 0 N--CA 1.464 -0.264 0 C-N-CA 122.618 2.212 . . . . 0.0 112.019 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.505 HG22 HG21 ' A' ' 16' ' ' THR . 7.5 p -67.98 -47.14 80.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.145 0.497 . . . . 0.0 110.911 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.8 m -86.54 164.69 16.76 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.394 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -167.92 -29.13 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.205 -0.998 . . . . 0.0 112.918 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.787 ' HG3' ' HA ' ' A' ' 14' ' ' CYS . 1.1 pm0 -62.79 142.55 58.14 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.56 0.695 . . . . 0.0 111.2 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.803 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.7 p -85.66 129.71 34.75 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.98 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.508 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 41.0 t -80.77 20.83 0.72 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.284 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.803 HG23 ' HB ' ' A' ' 8' ' ' THR . 53.4 t -58.68 -39.74 77.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 121.059 0.457 . . . . 0.0 110.583 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.12 23.78 33.37 Favored Glycine 0 N--CA 1.446 -0.665 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.055 179.025 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.13 53.48 44.32 Favored Glycine 0 C--N 1.334 0.449 0 C-N-CA 121.369 -0.443 . . . . 0.0 112.95 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 t -151.86 151.32 31.14 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.004 0.43 . . . . 0.0 111.739 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.787 ' HA ' ' HG3' ' A' ' 7' ' ' GLU . 84.4 m -142.34 134.66 27.74 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.189 179.165 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.457 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 71.5 m-80 -95.17 -46.24 6.86 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.933 0.397 . . . . 0.0 111.123 -179.239 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.56 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 7.7 m -64.41 121.2 71.15 Favored Pre-proline 0 C--O 1.238 0.469 0 CA-C-O 121.43 0.633 . . . . 0.0 111.77 -178.808 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -59.07 132.86 49.64 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.81 2.34 . . . . 0.0 112.191 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.68 -10.78 73.84 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.175 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.56 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 71.2 m -88.1 123.15 32.48 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.384 0.611 . . . . 0.0 110.163 179.61 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.6 m -88.97 143.3 26.95 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.184 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -72.85 119.05 16.55 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 30.2 m -135.15 70.67 1.43 Allowed 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.183 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 8.9 t90 -27.41 128.54 0.2 Allowed Pre-proline 0 N--CA 1.466 0.362 0 CA-C-N 114.036 -1.438 . . . . 0.0 112.916 -178.203 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 92.3 Cg_endo -96.37 29.53 15.24 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 C-N-CA 123.396 -1.501 . . . . 0.0 114.105 0.647 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.508 ' HA ' ' H ' ' A' ' 9' ' ' CYS . 9.3 m -145.89 148.06 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 -179.211 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.554 ' SG ' ' HG2' ' A' ' 7' ' ' GLU . 72.7 m -83.58 141.25 31.71 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.836 178.041 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.2 t -146.46 -168.87 3.13 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.404 ' HD3' ' CG1' ' A' ' 4' ' ' VAL . 21.0 mmm180 -96.62 45.13 1.06 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.896 0.379 . . . . 0.0 110.187 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 49.2 t30 . . . . . 0 C--N 1.331 -0.212 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.792 -179.464 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 N-CA-C 112.062 -0.415 . . . . 0.0 112.062 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.451 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 7.1 mp -74.2 133.77 77.84 Favored Pre-proline 0 C--N 1.326 -0.428 0 N-CA-C 110.405 -0.22 . . . . 0.0 110.405 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 23.8 Cg_exo -63.93 118.71 5.64 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.492 2.128 . . . . 0.0 111.796 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 45.6 t -65.27 -37.4 80.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.118 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.811 ' HA ' HG21 ' A' ' 16' ' ' THR . 75.8 m -104.4 -55.22 2.39 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.579 -179.629 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 63.1 47.4 88.72 Favored Glycine 0 C--O 1.228 -0.228 0 CA-C-N 115.769 -0.651 . . . . 0.0 112.09 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.473 ' HG2' ' H ' ' A' ' 15' ' ' ASN . 6.6 tp10 -149.69 150.34 31.96 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.184 0.516 . . . . 0.0 110.229 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 12.6 p -109.92 127.94 55.05 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.041 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.49 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 20.5 t -90.7 38.46 0.95 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.278 0.561 . . . . 0.0 109.873 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -62.9 -36.8 77.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.239 -179.155 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.47 28.05 16.68 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.662 179.371 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.07 40.97 97.8 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 121.271 -0.49 . . . . 0.0 112.933 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -151.75 160.06 43.72 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.578 0.228 . . . . 0.0 110.528 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.7 m -143.81 120.57 11.21 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.147 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.473 ' H ' ' HG2' ' A' ' 7' ' ' GLU . 48.8 m-80 -79.32 -35.61 40.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.672 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.811 HG21 ' HA ' ' A' ' 5' ' ' CYS . 0.2 OUTLIER -67.91 114.27 19.45 Favored Pre-proline 0 C--O 1.242 0.709 0 CA-C-O 121.252 0.549 . . . . 0.0 111.639 -179.112 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -59.37 135.8 67.64 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.765 2.31 . . . . 0.0 112.322 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.65 -6.39 73.87 Favored Glycine 0 N--CA 1.444 -0.821 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.698 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.496 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 84.2 m -89.76 132.5 35.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 117.461 0.63 . . . . 0.0 111.335 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 m -88.93 148.4 23.83 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.297 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.6 t -79.31 127.54 32.2 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.012 0.434 . . . . 0.0 111.285 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.6 m -137.93 67.84 1.41 Allowed 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.703 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 9.3 t90 -31.39 128.83 0.29 Allowed Pre-proline 0 N--CA 1.465 0.294 0 CA-C-N 114.356 -1.293 . . . . 0.0 112.793 -177.211 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.2 Cg_endo -97.18 31.9 11.64 Favored 'Cis proline' 0 N--CA 1.456 -0.709 0 C-N-CA 123.554 -1.436 . . . . 0.0 113.772 0.305 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 16.1 m -136.64 141.79 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -178.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 80.7 m -85.0 135.02 34.2 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.608 178.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.2 t -149.05 142.37 25.14 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.557 0.694 . . . . 0.0 110.959 178.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -82.63 72.44 9.7 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.008 -0.997 . . . . 0.0 110.694 -179.218 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 31.5 t30 . . . . . 0 C--N 1.325 -0.467 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.026 -179.831 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.544 0 N-CA-C 112.076 -0.41 . . . . 0.0 112.076 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 14.1 mt -147.75 131.22 8.23 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-O 121.167 0.508 . . . . 0.0 110.945 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.99 52.56 3.08 Favored 'Trans proline' 0 CA--C 1.531 0.329 0 C-N-CA 123.575 2.85 . . . . 0.0 112.845 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 61.7 t -71.13 -45.19 72.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.286 0.565 . . . . 0.0 110.394 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.431 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 55.8 m -105.06 169.89 8.18 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.866 179.317 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -159.18 28.1 0.39 Allowed Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.26 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.431 ' OE2' ' HB3' ' A' ' 5' ' ' CYS . 4.0 mp0 -77.5 140.0 39.71 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.685 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.2 p -74.89 123.55 25.27 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-O 121.443 0.64 . . . . 0.0 110.52 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.503 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 21.8 t -93.77 35.14 1.15 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.91 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.685 HG23 ' HB ' ' A' ' 8' ' ' THR . 44.5 t -62.31 -40.76 89.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.286 -179.635 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.05 24.68 23.61 Favored Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.629 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.91 47.55 90.07 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 121.34 -0.457 . . . . 0.0 113.287 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.8 t -150.89 155.9 40.11 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.854 0.359 . . . . 0.0 110.954 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 94.8 m -133.26 -44.02 0.85 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.756 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 73.76 -46.51 0.63 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.778 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.411 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 2.6 m -63.04 110.68 3.75 Favored Pre-proline 0 C--O 1.243 0.749 0 CA-C-O 121.511 0.672 . . . . 0.0 111.863 -179.227 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 25.2 Cg_endo -61.62 131.77 37.24 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.573 2.182 . . . . 0.0 111.989 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.62 -22.85 37.07 Favored Glycine 0 N--CA 1.437 -1.272 0 C-N-CA 120.398 -0.906 . . . . 0.0 111.583 -179.005 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 15.3 m -98.43 134.7 41.05 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.342 0.591 . . . . 0.0 111.623 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.3 m -99.05 149.47 22.98 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.802 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 23.3 t -76.44 125.04 28.49 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.079 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 32.0 t -126.17 64.44 1.23 Allowed 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 178.365 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.1 t90 -26.74 128.48 0.19 Allowed Pre-proline 0 N--CA 1.467 0.417 0 CA-C-N 114.066 -1.425 . . . . 0.0 113.236 -177.083 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 84.1 Cg_endo -95.34 30.03 14.64 Favored 'Cis proline' 0 CA--C 1.536 0.584 0 C-N-CA 123.451 -1.479 . . . . 0.0 113.964 0.658 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.7 m -139.15 137.17 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 121.558 0.694 . . . . 0.0 112.633 -179.498 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 79.2 m -81.99 140.05 34.19 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.475 178.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.3 t -151.03 172.88 15.03 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.802 0.334 . . . . 0.0 110.636 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 12.7 tpt180 -96.89 128.7 44.1 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.281 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.9 p30 . . . . . 0 C--N 1.321 -0.664 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.872 -179.95 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.035 -0.426 . . . . 0.0 112.035 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.669 HD12 ' HD2' ' A' ' 3' ' ' PRO . 46.5 tp -74.39 123.0 88.81 Favored Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 110.385 -0.228 . . . . 0.0 110.385 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.669 ' HD2' HD12 ' A' ' 2' ' ' LEU . 65.6 Cg_endo -73.78 49.99 1.98 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 123.019 2.48 . . . . 0.0 112.751 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.8 p -79.45 -35.65 17.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.367 0.603 . . . . 0.0 109.964 179.694 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.544 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 59.6 m 60.26 -133.71 0.79 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 114.417 -1.265 . . . . 0.0 111.038 179.218 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.32 20.1 55.55 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.728 -179.438 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.611 ' HG2' HD21 ' A' ' 15' ' ' ASN . 1.1 mp0 -76.34 139.72 41.14 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 179.175 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.486 ' HB ' HG13 ' A' ' 10' ' ' VAL . 2.4 p -70.25 121.79 18.28 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-O 121.528 0.68 . . . . 0.0 110.498 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 18.9 t -87.96 40.98 0.97 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.903 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.486 HG13 ' HB ' ' A' ' 8' ' ' THR . 15.1 m -62.36 -33.93 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.333 -179.377 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.84 22.45 39.55 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.177 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.47 45.69 94.12 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.837 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -151.87 155.74 38.73 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.012 0.434 . . . . 0.0 111.426 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 55.9 m -133.61 146.6 51.08 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 179.349 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.611 HD21 ' HG2' ' A' ' 7' ' ' GLU . 21.4 p30 -102.71 -35.07 8.81 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.303 -0.559 . . . . 0.0 112.247 -179.005 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.544 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 13.0 m -80.74 112.84 35.21 Favored Pre-proline 0 C--O 1.244 0.795 0 CA-C-O 121.542 0.687 . . . . 0.0 111.488 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.411 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 39.2 Cg_exo -59.52 129.06 29.42 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.677 2.251 . . . . 0.0 111.803 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.2 -23.21 19.19 Favored Glycine 0 N--CA 1.438 -1.194 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.431 ' SG ' ' HB3' ' A' ' 28' ' ' ARG . 42.2 m -95.16 127.08 40.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.306 0.574 . . . . 0.0 111.515 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.62 147.19 23.47 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.195 -179.52 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.2 t -71.3 123.94 23.42 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.201 0.524 . . . . 0.0 111.176 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 37.9 m -128.44 66.54 1.39 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 178.361 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 3.9 t90 -27.79 129.07 0.21 Allowed Pre-proline 0 N--CA 1.467 0.396 0 CA-C-N 113.904 -1.498 . . . . 0.0 113.051 -177.104 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 90.0 Cg_endo -95.3 31.34 12.61 Favored 'Cis proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.347 -1.522 . . . . 0.0 114.338 0.637 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.6 m -141.49 137.59 32.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 83.0 m -82.26 134.55 35.29 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.595 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.2 t -151.72 151.14 31.02 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.296 0.57 . . . . 0.0 110.879 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.431 ' HB3' ' SG ' ' A' ' 19' ' ' CYS . 6.7 ptm180 -84.3 56.27 3.71 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.781 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 15.6 p-10 . . . . . 0 C--N 1.326 -0.413 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.922 -179.957 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.505 ' H3 ' ' HD2' ' A' ' 28' ' ' ARG . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.226 -0.349 . . . . 0.0 112.226 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.681 HD12 ' HD2' ' A' ' 3' ' ' PRO . 29.9 tp -150.06 131.0 7.19 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.681 ' HD2' HD12 ' A' ' 2' ' ' LEU . 51.8 Cg_endo -69.46 62.12 1.59 Allowed 'Trans proline' 0 CA--C 1.533 0.438 0 C-N-CA 123.146 2.564 . . . . 0.0 113.33 -179.227 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 46.9 t -68.92 -44.96 81.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.175 0.512 . . . . 0.0 110.408 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.447 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 20.7 m -79.09 163.52 25.04 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.169 179.546 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -168.48 36.34 0.2 Allowed Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.967 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.548 ' H ' ' CD ' ' A' ' 7' ' ' GLU . 1.1 pm0 -85.62 143.22 28.56 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.117 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.566 ' HB ' HG23 ' A' ' 10' ' ' VAL . 1.4 p -72.0 125.41 27.18 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-O 121.684 0.754 . . . . 0.0 111.625 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.568 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.8 t -104.25 42.22 1.22 Allowed 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.164 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.566 HG23 ' HB ' ' A' ' 8' ' ' THR . 45.9 t -59.11 -40.94 82.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.967 -178.649 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.11 16.79 54.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.523 179.252 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.72 41.2 97.39 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 121.504 -0.379 . . . . 0.0 113.106 179.487 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.8 t -152.84 140.64 20.05 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-O 121.42 0.629 . . . . 0.0 112.26 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 91.1 m -152.49 148.9 27.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.613 -1.176 . . . . 0.0 109.087 178.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.536 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 75.4 m-20 -115.71 11.64 15.76 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.864 -0.334 . . . . 0.0 111.281 -179.549 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -81.12 107.58 8.08 Favored Pre-proline 0 C--O 1.24 0.601 0 CA-C-O 121.248 0.547 . . . . 0.0 110.995 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.536 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 29.4 Cg_exo -60.91 131.81 39.11 Favored 'Trans proline' 0 CA--C 1.515 -0.431 0 C-N-CA 122.64 2.227 . . . . 0.0 112.684 -179.225 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.11 -18.16 56.75 Favored Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.221 -179.697 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 36.3 m -105.36 130.75 53.4 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.6 0.714 . . . . 0.0 111.668 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.6 m -97.98 148.47 23.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.141 -178.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.604 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 37.6 t -72.0 128.73 36.63 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.954 179.666 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.5 m -132.26 67.41 1.53 Allowed 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 3.7 t90 -26.61 128.67 0.19 Allowed Pre-proline 0 N--CA 1.467 0.385 0 CA-C-N 114.054 -1.43 . . . . 0.0 113.095 -177.203 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.48 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 85.4 Cg_endo -94.76 29.23 15.98 Favored 'Cis proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.464 -1.473 . . . . 0.0 114.261 0.595 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 6.7 m -143.04 137.16 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 CA-C-O 121.484 0.659 . . . . 0.0 112.653 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.604 ' SG ' ' HA ' ' A' ' 21' ' ' CYS . 61.2 m -83.56 140.83 32.01 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.876 178.441 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.9 t -152.44 165.22 35.74 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 120.878 0.37 . . . . 0.0 110.311 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.505 ' HD2' ' H3 ' ' A' ' 1' ' ' GLY . 0.3 OUTLIER -81.74 74.22 8.74 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.702 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 . . . . . 0 C--O 1.238 0.483 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.787 -179.738 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.514 0 N-CA-C 112.037 -0.425 . . . . 0.0 112.037 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -63.24 145.62 96.78 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-O 120.9 0.381 . . . . 0.0 110.947 179.327 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -68.33 121.45 8.42 Favored 'Trans proline' 0 N--CA 1.463 -0.296 0 C-N-CA 122.57 2.18 . . . . 0.0 112.016 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 39.2 t -71.91 -39.41 67.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.632 0.729 . . . . 0.0 110.167 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.581 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 2.7 m -138.46 156.43 47.55 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.586 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -134.64 39.06 1.74 Allowed Glycine 0 N--CA 1.449 -0.44 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -107.96 143.59 36.4 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.162 -0.519 . . . . 0.0 111.007 -179.366 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.669 HG22 HG12 ' A' ' 25' ' ' VAL . 3.2 p -89.8 126.84 35.83 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.563 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.417 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 17.3 t -83.99 45.21 1.07 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.05 0.452 . . . . 0.0 110.424 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.604 HG23 ' HB ' ' A' ' 8' ' ' THR . 48.5 t -63.54 -39.89 87.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 120.993 0.425 . . . . 0.0 110.74 -179.143 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.73 22.38 25.07 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.738 -0.664 . . . . 0.0 112.948 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.98 39.81 94.67 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.335 -0.459 . . . . 0.0 113.269 179.401 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.7 t -152.25 158.31 42.64 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-O 120.773 0.32 . . . . 0.0 110.944 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -139.91 131.33 26.9 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -83.0 -46.42 12.89 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -178.35 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.581 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 4.5 m -70.38 113.61 19.49 Favored Pre-proline 0 C--O 1.246 0.915 0 CA-C-O 121.572 0.701 . . . . 0.0 112.343 -178.412 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -61.22 127.56 22.46 Favored 'Trans proline' 0 N--CA 1.459 -0.555 0 C-N-CA 122.673 2.249 . . . . 0.0 111.291 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 116.52 -26.3 8.63 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -178.157 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.7 m -89.69 130.12 36.02 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 121.338 0.59 . . . . 0.0 110.947 179.178 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 m -96.6 146.95 24.37 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.063 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.7 t -72.26 127.49 32.74 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.203 0.525 . . . . 0.0 111.465 -179.491 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 28.3 t -136.94 64.66 1.53 Allowed 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 178.59 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.432 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.1 t90 -29.21 128.61 0.23 Allowed Pre-proline 0 N--CA 1.466 0.353 0 CA-C-N 114.381 -1.281 . . . . 0.0 113.04 -177.144 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.432 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 96.4 Cg_endo -97.31 34.26 8.96 Favored 'Cis proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.671 -1.387 . . . . 0.0 114.011 0.67 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.669 HG12 HG22 ' A' ' 8' ' ' THR . 17.6 m -140.82 146.96 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 O-C-N 121.898 -0.501 . . . . 0.0 112.33 -179.331 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 72.6 m -81.93 123.73 29.12 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 178.583 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.8 t -101.11 178.34 4.69 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 18.0 ptp180 -96.49 135.45 38.36 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 179.211 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 33.1 t30 . . . . . 0 C--N 1.319 -0.74 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.768 -179.603 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.405 ' HA3' ' HA3' ' A' ' 18' ' ' GLY . . . . . . . . 0 N--CA 1.449 -0.445 0 N-CA-C 112.254 -0.338 . . . . 0.0 112.254 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 15.8 tp -82.53 135.55 46.45 Favored Pre-proline 0 C--N 1.323 -0.555 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.705 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 15.1 Cg_exo -69.95 53.42 1.15 Allowed 'Trans proline' 0 CA--C 1.535 0.571 0 C-N-CA 123.348 2.699 . . . . 0.0 113.88 -178.824 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 3.2 t -91.17 21.31 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.968 0.89 . . . . 0.0 109.419 178.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 27.1 m -61.85 160.97 11.08 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.906 -1.043 . . . . 0.0 112.157 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 159.9 -27.27 0.34 Allowed Glycine 0 C--N 1.315 -0.584 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.117 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -57.69 149.47 21.82 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 113.737 -1.232 . . . . 0.0 110.698 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.489 HG22 HG12 ' A' ' 25' ' ' VAL . 2.0 p -98.07 126.68 43.61 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.564 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 35.1 t -87.81 44.63 1.2 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.755 179.13 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.2 p -62.38 -38.35 81.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.517 -178.734 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.42 26.49 17.46 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.856 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.15 38.16 92.73 Favored Glycine 0 C--N 1.333 0.391 0 C-N-CA 121.31 -0.471 . . . . 0.0 112.949 179.518 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.9 t -152.51 163.11 40.22 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.6 m -145.02 120.12 10.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.027 179.362 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 33.5 t30 -78.94 -36.44 41.72 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.616 179.692 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 5.9 m -63.04 109.63 2.66 Favored Pre-proline 0 C--O 1.242 0.667 0 CA-C-O 121.414 0.626 . . . . 0.0 111.646 -179.205 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_exo -61.61 130.23 30.82 Favored 'Trans proline' 0 CA--C 1.515 -0.463 0 C-N-CA 122.844 2.362 . . . . 0.0 112.535 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.405 ' HA3' ' HA3' ' A' ' 1' ' ' GLY . . . 97.9 -20.02 52.27 Favored Glycine 0 N--CA 1.44 -1.062 0 CA-C-N 115.327 -0.852 . . . . 0.0 111.617 -179.39 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 72.0 m -89.81 123.93 34.22 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.321 0.581 . . . . 0.0 110.981 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.4 p -88.99 143.46 26.84 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.359 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.4 t -69.92 128.23 35.64 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.26 0.552 . . . . 0.0 112.005 -179.044 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 35.0 t -136.98 66.42 1.47 Allowed 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.435 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 6.8 t90 -29.46 128.62 0.24 Allowed Pre-proline 0 N--CA 1.464 0.269 0 CA-C-N 114.284 -1.325 . . . . 0.0 113.008 -176.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 97.0 Cg_endo -97.0 32.47 10.96 Favored 'Cis proline' 0 N--CA 1.458 -0.599 0 C-N-CA 123.49 -1.463 . . . . 0.0 114.031 0.638 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.489 HG12 HG22 ' A' ' 8' ' ' THR . 15.9 m -139.42 142.87 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 113.032 0.752 . . . . 0.0 113.032 -179.205 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 58.5 m -83.09 131.25 35.16 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.627 178.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 t -140.82 157.51 45.28 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.129 0.49 . . . . 0.0 111.062 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.71 81.48 8.19 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.02 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 32.1 t30 . . . . . 0 C--N 1.326 -0.449 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.645 179.799 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 N-CA-C 111.971 -0.451 . . . . 0.0 111.971 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.429 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 33.0 tp -75.65 122.12 86.48 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 17.7 Cg_exo -66.87 102.29 0.63 Allowed 'Trans proline' 0 C--O 1.233 0.244 0 C-N-CA 122.653 2.235 . . . . 0.0 112.177 -179.693 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 46.9 t -73.77 -43.74 53.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.17 0.51 . . . . 0.0 110.086 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 91.3 m 59.75 -113.0 0.6 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.905 -1.043 . . . . 0.0 111.649 179.299 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.83 14.52 80.8 Favored Glycine 0 N--CA 1.45 -0.395 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -178.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.615 ' OE1' ' HB3' ' A' ' 14' ' ' CYS . 64.6 mt-10 -71.87 139.49 48.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.056 -0.572 . . . . 0.0 110.075 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 17.3 p -75.34 123.75 25.9 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.131 0.491 . . . . 0.0 110.958 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.2 t -103.74 39.81 1.54 Allowed 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.434 179.7 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -59.16 -36.96 65.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.343 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.33 27.89 18.49 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.317 179.304 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.47 35.67 89.43 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 121.365 -0.445 . . . . 0.0 112.993 179.748 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.8 t -153.06 156.4 38.66 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 120.646 0.26 . . . . 0.0 110.838 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.615 ' HB3' ' OE1' ' A' ' 7' ' ' GLU . 61.0 m -150.05 -153.09 0.47 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.787 179.237 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.417 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 72.4 m-80 -133.12 -52.94 0.9 Allowed 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -178.559 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 51.3 m -66.34 108.47 2.33 Favored Pre-proline 0 C--O 1.249 1.047 0 N-CA-C 113.523 0.934 . . . . 0.0 113.523 -177.375 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.417 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 37.4 Cg_endo -65.6 125.48 14.44 Favored 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 122.461 2.107 . . . . 0.0 110.485 178.353 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.55 -27.38 6.03 Favored Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -177.774 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 14.2 m -89.86 129.41 36.23 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 120.15 -0.62 . . . . 0.0 110.067 178.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.518 ' HB ' ' OD1' ' A' ' 29' ' ' ASN . 3.7 m -88.14 144.86 26.23 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.533 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.2 t -72.98 122.68 22.11 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.12 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.0 m -127.73 67.28 1.33 Allowed 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 178.583 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.516 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.3 t90 -26.5 127.95 0.19 Allowed Pre-proline 0 N--CA 1.467 0.395 0 CA-C-N 113.921 -1.491 . . . . 0.0 113.058 -177.18 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.516 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 80.5 Cg_endo -95.56 31.55 12.3 Favored 'Cis proline' 0 N--CA 1.456 -0.707 0 C-N-CA 123.482 -1.466 . . . . 0.0 114.38 0.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 6.0 m -145.03 138.06 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 N-CA-C 112.873 0.694 . . . . 0.0 112.873 -179.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.482 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 94.6 m -82.19 140.29 33.81 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.571 178.254 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t -148.11 158.84 44.29 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.041 0.448 . . . . 0.0 110.196 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 7.4 ptm180 -81.54 52.02 1.79 Allowed 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.196 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.518 ' OD1' ' HB ' ' A' ' 20' ' ' THR . 15.2 p-10 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.683 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.541 0 N-CA-C 111.975 -0.45 . . . . 0.0 111.975 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.439 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 48.9 tp -83.45 122.65 77.08 Favored Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 6.8 Cg_exo -73.41 48.25 1.51 Allowed 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 123.229 2.62 . . . . 0.0 112.802 -179.753 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.8 p -78.65 -42.25 25.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.641 0.734 . . . . 0.0 109.833 179.436 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.692 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 63.6 m -102.97 172.1 7.01 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.535 -1.211 . . . . 0.0 109.827 179.104 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 179.38 28.55 0.05 OUTLIER Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.535 -0.84 . . . . 0.0 112.519 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.692 ' OE2' ' HB3' ' A' ' 5' ' ' CYS . 1.3 pm0 -89.57 142.51 27.61 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.724 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.7 p -77.98 123.9 27.36 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-O 121.414 0.625 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.438 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 28.2 t -90.52 39.97 1.0 Allowed 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.052 179.775 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.724 HG23 ' HB ' ' A' ' 8' ' ' THR . 47.3 t -61.99 -40.31 86.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.653 -179.245 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.47 22.83 30.81 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.881 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.19 47.6 88.4 Favored Glycine 0 CA--C 1.52 0.362 0 C-N-CA 121.289 -0.482 . . . . 0.0 113.206 179.306 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.4 t -151.18 155.98 39.99 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 122.565 -0.373 . . . . 0.0 111.095 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 82.9 m -140.1 127.73 21.67 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.656 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -81.44 -41.18 22.22 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -179.202 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.433 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 15.5 m -75.82 109.46 8.15 Favored Pre-proline 0 C--O 1.246 0.885 0 CA-C-O 121.545 0.688 . . . . 0.0 112.223 -178.52 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 27.6 Cg_endo -61.96 131.19 33.83 Favored 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 122.564 2.176 . . . . 0.0 111.386 179.524 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 110.61 -29.32 9.13 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 -178.305 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.734 ' HA ' ' HB2' ' A' ' 28' ' ' ARG . 7.4 m -89.59 133.37 34.65 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.526 179.221 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.3 m -95.23 148.79 22.02 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.959 -178.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.3 t -70.07 126.6 30.15 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.875 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.7 m -134.22 67.96 1.5 Allowed 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 1.5 t90 -28.35 128.16 0.22 Allowed Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 113.976 -1.465 . . . . 0.0 112.989 -176.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.8 Cg_endo -96.71 32.52 10.92 Favored 'Cis proline' 0 CA--C 1.537 0.64 0 C-N-CA 123.595 -1.419 . . . . 0.0 114.151 0.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.2 m -143.71 141.78 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -179.572 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.438 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 65.8 m -82.68 132.54 35.18 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.234 178.757 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.2 t -152.46 164.72 37.0 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.014 0.435 . . . . 0.0 111.557 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.734 ' HB2' ' HA ' ' A' ' 19' ' ' CYS . 9.0 tpt180 177.36 -149.21 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.785 179.375 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 . . . . . 0 C--N 1.318 -0.794 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.665 179.735 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.587 ' HA2' ' HB ' ' A' ' 25' ' ' VAL . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.054 -0.418 . . . . 0.0 112.054 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.652 HD12 ' HD2' ' A' ' 3' ' ' PRO . 23.8 tp 69.01 131.68 0.04 OUTLIER Pre-proline 0 N--CA 1.466 0.348 0 C-N-CA 123.063 0.545 . . . . 0.0 110.941 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.652 ' HD2' HD12 ' A' ' 2' ' ' LEU . 57.8 Cg_endo -71.14 44.73 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 122.814 2.343 . . . . 0.0 112.715 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 85.2 t -146.82 -47.61 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.398 -0.819 . . . . 0.0 108.89 179.491 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.485 ' HA ' HG21 ' A' ' 16' ' ' THR . 71.1 m -91.42 -50.08 5.99 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.992 -1.003 . . . . 0.0 110.657 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.82 -46.99 3.64 Favored Glycine 0 N--CA 1.451 -0.355 0 CA-C-N 115.244 -0.889 . . . . 0.0 112.573 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.669 ' HG3' ' HB3' ' A' ' 15' ' ' ASN . 47.3 mm-40 -62.81 145.05 55.88 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 122.028 0.918 . . . . 0.0 112.61 -179.458 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.697 HG22 HG12 ' A' ' 25' ' ' VAL . 5.9 p -110.22 127.85 55.18 Favored 'General case' 0 N--CA 1.439 -1.019 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.825 178.789 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 12.7 t -83.65 41.35 0.78 Allowed 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.919 0.39 . . . . 0.0 110.841 -179.403 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.621 HG23 ' HB ' ' A' ' 8' ' ' THR . 47.6 t -64.73 -42.01 93.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.174 0.511 . . . . 0.0 110.314 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.24 28.62 12.3 Favored Glycine 0 N--CA 1.45 -0.397 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.638 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.08 42.55 98.52 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 121.27 -0.49 . . . . 0.0 113.237 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.8 t -151.61 160.17 43.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.648 0.261 . . . . 0.0 110.756 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.7 m -146.03 124.75 12.57 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.191 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.669 ' HB3' ' HG3' ' A' ' 7' ' ' GLU . 28.2 t-20 -81.04 -46.73 14.58 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.657 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.485 HG21 ' HA ' ' A' ' 5' ' ' CYS . 0.2 OUTLIER -58.33 111.77 4.01 Favored Pre-proline 0 C--O 1.238 0.481 0 CA-C-O 121.221 0.534 . . . . 0.0 112.146 -178.857 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 24.7 Cg_exo -62.24 130.59 31.0 Favored 'Trans proline' 0 N--CA 1.46 -0.448 0 C-N-CA 122.631 2.221 . . . . 0.0 111.63 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.38 -14.72 63.14 Favored Glycine 0 N--CA 1.442 -0.945 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.763 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.465 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 95.9 m -88.98 126.82 35.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.243 0.544 . . . . 0.0 110.816 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.87 148.76 23.69 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.412 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 t -75.48 128.6 35.67 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.127 0.489 . . . . 0.0 112.187 -178.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 57.6 m -139.99 69.13 1.35 Allowed 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 178.193 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.528 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 11.4 t90 -31.62 129.04 0.3 Allowed Pre-proline 0 N--CA 1.465 0.292 0 CA-C-N 114.227 -1.351 . . . . 0.0 112.886 -177.173 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 97.6 Cg_endo -98.06 33.16 9.83 Favored 'Cis proline' 0 N--CA 1.457 -0.633 0 C-N-CA 123.71 -1.371 . . . . 0.0 113.75 0.557 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.697 HG12 HG22 ' A' ' 8' ' ' THR . 24.6 m -139.43 145.85 26.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -178.837 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 61.3 m -84.63 138.26 32.8 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.192 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.7 t -133.15 151.39 51.98 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.057 0.456 . . . . 0.0 110.449 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 50.7 ttp180 -84.19 51.48 2.09 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.675 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 52.2 t30 . . . . . 0 C--N 1.325 -0.497 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.267 179.892 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 . . . . . 0 N--CA 1.453 -0.315 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.7 ' HB ' HG23 ' A' ' 10' ' ' VAL . 18.8 p -71.72 122.43 20.61 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 120.909 0.385 . . . . 0.0 110.452 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.523 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 17.0 t -93.05 37.05 1.03 Allowed 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.981 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.7 HG23 ' HB ' ' A' ' 8' ' ' THR . 46.1 t -60.4 -41.14 86.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.777 -179.241 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.86 24.92 24.1 Favored Glycine 0 N--CA 1.451 -0.3 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.948 179.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.85 47.92 88.06 Favored Glycine 0 C--N 1.333 0.363 0 C-N-CA 121.223 -0.513 . . . . 0.0 113.326 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 t -150.97 154.1 36.46 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.872 0.368 . . . . 0.0 111.082 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 76.8 m -134.48 138.07 44.43 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.87 179.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -79.91 -53.99 6.23 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.889 -178.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.585 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 6.7 m -73.1 115.06 36.77 Favored Pre-proline 0 C--O 1.243 0.732 0 CA-C-O 121.368 0.604 . . . . 0.0 112.297 -178.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -63.69 121.86 9.75 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.529 2.153 . . . . 0.0 110.635 179.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.14 -16.11 13.16 Favored Glycine 0 N--CA 1.439 -1.112 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 -178.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.585 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 76.5 m -89.14 132.43 34.83 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 m -88.77 144.97 25.89 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.272 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.9 t -78.48 126.35 30.64 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.077 0.465 . . . . 0.0 110.811 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.0 m -132.66 67.93 1.52 Allowed 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.7 t90 -29.15 127.88 0.24 Allowed Pre-proline 0 N--CA 1.465 0.279 0 CA-C-N 114.06 -1.427 . . . . 0.0 112.841 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 91.3 Cg_endo -97.04 32.8 10.51 Favored 'Cis proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.582 -1.424 . . . . 0.0 114.053 0.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 10.8 m -140.68 139.39 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.523 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.3 m -83.36 137.82 33.79 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.649 178.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.1 t . . . . . 0 C--N 1.322 -0.591 0 CA-C-O 121.092 0.472 . . . . 0.0 110.227 178.817 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.447 ' OE2' ' HB3' ' A' ' 15' ' ' ASN . 20.7 mt-10 . . . . . 0 C--O 1.233 0.185 0 CA-C-O 120.798 0.332 . . . . 0.0 111.01 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 3.0 p -88.29 127.51 35.47 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 121.105 0.478 . . . . 0.0 110.825 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.561 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 15.0 t -91.28 40.52 1.03 Allowed 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.136 0.493 . . . . 0.0 109.84 179.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.6 p -61.81 -36.28 72.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.08 -179.129 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.56 24.23 31.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.829 -0.7 . . . . 0.0 112.72 179.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.5 41.59 97.23 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.257 -0.497 . . . . 0.0 113.181 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.8 t -151.48 152.58 33.2 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 121.011 0.434 . . . . 0.0 111.309 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 71.1 m -132.07 140.1 48.75 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.076 179.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.447 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 9.7 t30 -91.95 -47.91 7.04 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.609 -178.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' ' 17' ' ' PRO . 85.2 m -70.57 116.45 45.64 Favored Pre-proline 0 C--O 1.242 0.709 0 CA-C-O 121.322 0.582 . . . . 0.0 111.801 -179.244 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 26.1 Cg_exo -61.56 126.29 18.78 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.681 2.254 . . . . 0.0 111.019 179.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 110.62 -18.25 27.38 Favored Glycine 0 N--CA 1.44 -1.043 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -178.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.0 m -87.4 124.85 33.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.174 0.512 . . . . 0.0 110.273 179.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 m -89.35 145.52 25.3 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.854 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 53.7 t -77.03 126.81 31.58 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 121.173 0.511 . . . . 0.0 111.306 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -137.37 68.69 1.41 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.438 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.7 t90 -31.04 129.07 0.27 Allowed Pre-proline 0 N--CA 1.463 0.216 0 CA-C-N 114.111 -1.404 . . . . 0.0 112.832 -177.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.6 Cg_endo -97.08 33.24 10.01 Favored 'Cis proline' 0 N--CA 1.456 -0.678 0 C-N-CA 123.591 -1.421 . . . . 0.0 114.026 0.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 14.8 m -140.11 141.95 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 N-CA-C 113.222 0.823 . . . . 0.0 113.222 -179.121 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.561 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 84.1 m -84.01 135.47 34.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.03 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.2 t . . . . . 0 C--N 1.322 -0.616 0 CA-C-O 121.126 0.488 . . . . 0.0 110.226 179.044 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 . . . . . 0 N--CA 1.451 -0.419 0 CA-C-O 121.089 0.471 . . . . 0.0 110.133 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 p -77.34 125.48 29.4 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-O 121.313 0.577 . . . . 0.0 110.908 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.485 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 26.0 t -92.71 37.75 1.01 Allowed 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.784 -0.643 . . . . 0.0 109.616 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.1 p -62.02 -35.46 68.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.008 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.78 21.64 43.67 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.723 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.56 45.61 95.98 Favored Glycine 0 CA--C 1.519 0.34 0 C-N-CA 121.249 -0.501 . . . . 0.0 113.297 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.9 t -150.82 152.52 33.88 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.881 0.372 . . . . 0.0 111.108 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 90.1 m -130.48 140.44 50.53 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.799 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.5 t30 -89.5 -48.91 7.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.918 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.446 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 1.8 m -76.1 112.54 21.21 Favored Pre-proline 0 C--O 1.244 0.801 0 CA-C-O 121.426 0.631 . . . . 0.0 112.572 -178.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.446 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 19.3 Cg_endo -60.2 133.04 47.37 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.682 2.255 . . . . 0.0 111.481 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.51 -27.19 17.56 Favored Glycine 0 N--CA 1.438 -1.218 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 12.3 m -90.7 128.64 36.72 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.061 0.458 . . . . 0.0 110.232 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.5 t -90.83 160.98 15.46 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.929 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 46.1 t -80.67 131.45 35.47 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.55 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.2 m -138.38 68.77 1.39 Allowed 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 178.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 2.0 t90 -29.56 129.16 0.24 Allowed Pre-proline 0 N--CA 1.466 0.33 0 CA-C-N 114.062 -1.426 . . . . 0.0 113.015 -177.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 94.3 Cg_endo -96.66 33.26 10.02 Favored 'Cis proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.484 -1.465 . . . . 0.0 114.151 0.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 10.6 m -144.01 143.96 23.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.485 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.1 m -82.76 143.81 30.61 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.2 t . . . . . 0 C--N 1.326 -0.454 0 CA-C-O 121.371 0.605 . . . . 0.0 111.311 -179.864 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 . . . . . 0 N--CA 1.452 -0.326 0 CA-C-O 120.81 0.338 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.514 ' HB ' HG23 ' A' ' 10' ' ' VAL . 10.8 p -82.25 124.87 30.33 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.151 179.105 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 23.9 t -87.62 53.03 2.65 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.246 0.546 . . . . 0.0 110.725 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.514 HG23 ' HB ' ' A' ' 8' ' ' THR . 4.1 t -78.99 48.84 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-O 121.46 0.648 . . . . 0.0 110.781 -179.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.06 26.89 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.888 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 55.06 43.95 83.31 Favored Glycine 0 C--N 1.336 0.529 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.099 179.358 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.2 t -151.55 153.74 35.13 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.11 0.481 . . . . 0.0 111.545 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.4 m -142.33 134.34 27.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.186 -0.915 . . . . 0.0 108.578 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 62.0 m-80 -84.07 -45.18 13.32 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.591 0.234 . . . . 0.0 111.561 -178.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 4.1 m -69.94 113.66 19.26 Favored Pre-proline 0 C--O 1.244 0.811 0 CA-C-O 121.44 0.638 . . . . 0.0 112.002 -178.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -60.12 131.0 36.75 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.695 2.264 . . . . 0.0 111.345 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.48 -26.2 15.41 Favored Glycine 0 N--CA 1.439 -1.129 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -178.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.7 m -89.31 126.17 35.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.504 0.669 . . . . 0.0 111.112 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.3 m -94.07 147.55 23.03 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.597 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.1 t -72.38 114.87 10.97 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.074 0.464 . . . . 0.0 111.278 -179.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 36.8 m -123.43 64.47 1.01 Allowed 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 178.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.49 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 8.8 t90 -27.6 129.39 0.2 Allowed Pre-proline 0 N--CA 1.463 0.203 0 CA-C-N 113.798 -1.547 . . . . 0.0 113.104 -177.063 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 96.6 Cg_endo -94.71 27.89 18.05 Favored 'Cis proline' 0 N--CA 1.457 -0.668 0 C-N-CA 123.226 -1.573 . . . . 0.0 114.143 0.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.3 m -137.37 140.1 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -179.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 72.8 m -82.7 129.95 35.04 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.672 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.324 -0.535 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.962 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.593 ' HG2' ' HB3' ' A' ' 15' ' ' ASN . 2.8 mp0 . . . . . 0 N--CA 1.453 -0.3 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.3 p -73.31 124.24 25.33 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 120.844 0.354 . . . . 0.0 110.351 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.572 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 21.2 t -89.44 38.35 0.9 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.255 0.55 . . . . 0.0 110.019 179.669 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.01 -36.23 72.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.964 -179.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.04 25.59 26.96 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.746 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.14 45.29 95.53 Favored Glycine 0 C--N 1.331 0.277 0 C-N-CA 121.165 -0.54 . . . . 0.0 113.131 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.7 t -151.04 154.43 37.02 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.927 0.394 . . . . 0.0 111.065 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 98.8 m -130.98 139.58 50.03 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.813 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.593 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 30.4 t30 -85.26 -50.27 7.5 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.764 -179.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 5.6 m -80.59 109.1 11.64 Favored Pre-proline 0 C--O 1.251 1.174 0 CA-C-O 121.821 0.82 . . . . 0.0 112.584 -178.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.5 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 24.5 Cg_exo -61.4 127.08 20.85 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.686 2.257 . . . . 0.0 111.103 179.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.02 -29.73 5.47 Favored Glycine 0 N--CA 1.434 -1.458 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -178.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 19.0 m -88.99 143.1 27.09 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.256 -0.577 . . . . 0.0 110.529 179.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 m -97.08 149.33 22.08 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.559 -179.164 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.3 t -74.93 128.21 35.04 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.153 0.502 . . . . 0.0 111.15 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.0 m -133.84 67.79 1.51 Allowed 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.8 t90 -29.58 128.49 0.24 Allowed Pre-proline 0 N--CA 1.464 0.256 0 CA-C-N 114.118 -1.401 . . . . 0.0 112.811 -177.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.457 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 95.7 Cg_endo -96.78 34.13 9.15 Favored 'Cis proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.615 -1.41 . . . . 0.0 114.201 0.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.42 ' HA ' ' H ' ' A' ' 9' ' ' CYS . 10.8 m -143.11 139.97 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 -179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.572 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 70.9 m -83.05 132.21 35.13 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.038 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.9 t . . . . . 0 C--N 1.325 -0.485 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.646 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.433 ' OE2' ' HB3' ' A' ' 15' ' ' ASN . 23.1 mt-10 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.749 0.309 . . . . 0.0 110.706 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 2.8 p -88.33 127.14 35.48 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-O 121.099 0.476 . . . . 0.0 110.989 179.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.532 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 18.1 t -91.79 40.43 1.04 Allowed 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.159 0.504 . . . . 0.0 109.881 179.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -62.12 -36.22 73.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.086 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.6 24.1 30.96 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.798 179.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.23 42.04 97.05 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.25 -0.5 . . . . 0.0 113.072 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.0 t -151.82 156.18 39.68 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.842 0.353 . . . . 0.0 111.023 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.9 m -135.8 136.88 41.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.302 179.386 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.433 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 9.8 t30 -87.48 -48.95 7.53 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.996 -178.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 88.4 m -70.98 118.38 65.0 Favored Pre-proline 0 C--O 1.241 0.647 0 CA-C-O 121.473 0.654 . . . . 0.0 111.946 -179.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -59.19 131.35 40.7 Favored 'Trans proline' 0 N--CA 1.458 -0.576 0 C-N-CA 122.717 2.278 . . . . 0.0 110.987 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 102.33 -13.64 56.96 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.369 -0.919 . . . . 0.0 111.505 -178.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.435 ' HB3' ' HB3' ' A' ' 26' ' ' CYS . 93.3 m -87.82 123.23 32.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.415 0.626 . . . . 0.0 110.561 179.573 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.25 141.49 28.49 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.675 179.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 45.8 t -73.65 120.9 19.89 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 121.104 0.478 . . . . 0.0 111.241 -179.487 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.1 t -129.03 64.85 1.46 Allowed 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.1 t90 -29.38 128.63 0.24 Allowed Pre-proline 0 N--CA 1.465 0.325 0 CA-C-N 114.26 -1.336 . . . . 0.0 112.978 -176.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.2 Cg_endo -96.64 33.53 9.75 Favored 'Cis proline' 0 CA--C 1.536 0.621 0 C-N-CA 123.542 -1.441 . . . . 0.0 114.149 0.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 15.3 m -140.93 141.77 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 112.96 0.726 . . . . 0.0 112.96 -179.328 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 77.3 m -82.35 136.34 35.01 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.771 178.344 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.4 t . . . . . 0 C--N 1.323 -0.559 0 CA-C-O 120.852 0.358 . . . . 0.0 110.587 179.731 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.462 ' HG3' ' H ' ' A' ' 15' ' ' ASN . 23.9 pm0 . . . . . 0 N--CA 1.448 -0.57 0 CA-C-O 121.191 0.52 . . . . 0.0 110.293 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.768 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.4 p -75.46 126.43 31.0 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.496 0.665 . . . . 0.0 111.429 -179.674 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.479 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 34.7 t -93.58 37.23 1.06 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.603 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.768 HG23 ' HB ' ' A' ' 8' ' ' THR . 48.0 t -60.91 -41.06 87.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.693 -179.16 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.37 23.22 22.93 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.753 179.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.94 45.16 95.54 Favored Glycine 0 CA--C 1.52 0.357 0 C-N-CA 121.394 -0.431 . . . . 0.0 113.288 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.9 t -150.85 151.98 33.04 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.046 0.45 . . . . 0.0 111.149 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 95.2 m -118.12 144.53 45.59 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.354 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.462 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 31.0 t30 -94.29 -48.53 6.13 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.366 -179.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.42 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 1.6 m -81.03 114.71 50.87 Favored Pre-proline 0 C--O 1.242 0.684 0 CA-C-O 121.334 0.588 . . . . 0.0 112.158 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 14.9 Cg_endo -56.95 137.92 83.89 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.686 2.257 . . . . 0.0 111.998 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 96.76 -23.28 36.1 Favored Glycine 0 N--CA 1.439 -1.147 0 C-N-CA 120.572 -0.823 . . . . 0.0 111.642 -178.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 7.3 m -90.64 131.89 36.08 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 120.404 -0.518 . . . . 0.0 110.913 179.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.9 t -89.87 158.28 17.52 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.823 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.2 t -79.29 129.17 34.2 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.216 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 29.6 m -134.79 67.24 1.51 Allowed 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 178.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 1.3 t90 -28.32 128.95 0.22 Allowed Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 114.11 -1.405 . . . . 0.0 113.091 -177.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 89.2 Cg_endo -95.64 31.69 12.1 Favored 'Cis proline' 0 N--CA 1.457 -0.642 0 C-N-CA 123.475 -1.469 . . . . 0.0 114.371 0.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.2 m -144.26 141.3 24.46 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 98.0 m -82.99 142.8 31.09 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.112 178.3 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.5 t . . . . . 0 C--N 1.326 -0.421 0 CA-C-O 121.092 0.472 . . . . 0.0 110.925 -179.706 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.234 0.278 0 CA-C-O 121.262 0.553 . . . . 0.0 111.009 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.655 ' HB ' HG23 ' A' ' 10' ' ' VAL . 7.9 p -69.12 126.66 30.48 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.202 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 35.9 t -86.66 47.21 1.45 Allowed 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.542 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.655 HG23 ' HB ' ' A' ' 8' ' ' THR . 17.8 t -76.15 69.63 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.505 0.669 . . . . 0.0 110.005 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 163.81 -20.58 0.15 Allowed Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.582 -0.736 . . . . 0.0 111.845 -179.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.87 42.89 4.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.873 -0.68 . . . . 0.0 111.593 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.9 t -152.11 154.42 35.87 Favored 'General case' 0 N--CA 1.446 -0.642 0 CA-C-O 120.67 0.271 . . . . 0.0 110.383 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 96.9 m -131.32 137.07 48.62 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.202 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 35.4 t30 -66.65 -56.54 10.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.082 -178.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 4.8 m -80.74 116.27 61.07 Favored Pre-proline 0 C--O 1.245 0.867 0 CA-C-O 121.622 0.725 . . . . 0.0 112.062 -178.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_exo -60.45 125.91 18.63 Favored 'Trans proline' 0 N--CA 1.46 -0.449 0 C-N-CA 122.543 2.162 . . . . 0.0 110.834 179.329 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.51 -22.31 8.87 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -178.216 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.2 m -88.6 133.86 34.05 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.932 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.1 m -88.87 146.28 25.05 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.451 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 t -80.07 103.4 9.93 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.472 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 61.3 m -103.82 60.88 0.74 Allowed 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.459 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 11.5 t90 -28.51 130.21 0.21 Allowed Pre-proline 0 N--CA 1.465 0.298 0 CA-C-N 113.492 -1.686 . . . . 0.0 112.703 -177.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.4 Cg_endo -93.96 33.07 10.04 Favored 'Cis proline' 0 N--CA 1.456 -0.7 0 C-N-CA 123.16 -1.6 . . . . 0.0 114.492 1.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.5 m -138.9 138.59 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 N-CA-C 112.724 0.638 . . . . 0.0 112.724 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 67.6 m -81.96 135.84 35.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.326 178.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.7 m . . . . . 0 C--N 1.322 -0.601 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -179.764 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 . . . . . 0 N--CA 1.447 -0.582 0 CA-C-O 121.182 0.515 . . . . 0.0 110.28 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 p -78.86 125.77 29.81 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.65 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 22.4 t -87.67 42.21 1.03 Allowed 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.423 0.63 . . . . 0.0 109.869 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.25 -34.84 71.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.865 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.93 22.56 40.37 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.552 179.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.99 45.9 94.5 Favored Glycine 0 C--N 1.332 0.328 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.12 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.3 t -151.36 155.56 38.92 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 120.933 0.397 . . . . 0.0 111.093 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 92.0 m -131.89 139.95 48.92 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.851 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -90.02 -47.29 7.94 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.629 -179.035 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 m -74.26 112.04 15.31 Favored Pre-proline 0 C--O 1.243 0.728 0 CA-C-O 121.328 0.585 . . . . 0.0 112.33 -178.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -60.76 131.56 38.19 Favored 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 122.625 2.217 . . . . 0.0 111.398 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.25 -28.72 11.25 Favored Glycine 0 N--CA 1.44 -1.083 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -178.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 6.5 m -91.52 128.44 37.35 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.165 0.507 . . . . 0.0 110.566 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 t -91.63 163.74 14.0 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.726 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.5 t -80.22 127.84 32.82 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.278 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 45.1 m -136.89 68.52 1.42 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 178.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.0 t90 -29.32 130.16 0.23 Allowed Pre-proline 0 N--CA 1.463 0.225 0 CA-C-N 114.133 -1.394 . . . . 0.0 113.064 -177.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.9 Cg_endo -95.76 31.28 12.66 Favored 'Cis proline' 0 N--CA 1.458 -0.604 0 C-N-CA 123.252 -1.562 . . . . 0.0 114.247 0.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.4 m -144.46 146.49 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -179.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 71.5 m -82.57 138.52 34.22 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.77 178.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.4 t . . . . . 0 C--N 1.325 -0.467 0 CA-C-O 120.724 0.297 . . . . 0.0 110.843 -179.664 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 89.3 mt-10 . . . . . 0 C--O 1.235 0.293 0 CA-C-O 121.234 0.54 . . . . 0.0 111.333 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.698 HG22 HG12 ' A' ' 25' ' ' VAL . 5.9 p -95.69 127.58 41.84 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.711 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.434 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 16.1 t -89.48 39.05 0.93 Allowed 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.169 0.509 . . . . 0.0 109.908 179.618 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.3 p -63.01 -35.17 70.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.938 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.82 23.27 36.22 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.434 179.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.99 41.14 99.31 Favored Glycine 0 C--N 1.333 0.366 0 C-N-CA 121.284 -0.484 . . . . 0.0 113.167 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.0 t -151.38 153.17 34.21 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 121.025 0.44 . . . . 0.0 111.467 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 76.9 m -138.26 137.11 37.17 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -92.9 -47.17 7.16 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.559 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.43 ' HA ' ' HD3' ' A' ' 17' ' ' PRO . 86.8 m -65.53 115.46 22.32 Favored Pre-proline 0 C--O 1.24 0.589 0 CA-C-O 121.437 0.637 . . . . 0.0 111.805 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 25.5 Cg_exo -61.83 127.13 20.61 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.674 2.25 . . . . 0.0 111.097 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.74 -18.43 31.97 Favored Glycine 0 N--CA 1.441 -1.014 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.5 m -87.75 124.27 33.42 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.255 0.55 . . . . 0.0 110.361 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.6 m -91.88 146.16 23.98 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.795 179.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.9 t -74.22 129.63 38.18 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.28 0.562 . . . . 0.0 111.805 -179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 51.0 m -141.09 68.57 1.34 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 178.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.533 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.8 t90 -31.21 128.73 0.28 Allowed Pre-proline 0 N--CA 1.463 0.202 0 CA-C-N 114.306 -1.315 . . . . 0.0 112.892 -177.039 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.533 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.7 Cg_endo -97.82 34.18 8.94 Favored 'Cis proline' 0 CA--C 1.538 0.69 0 C-N-CA 123.527 -1.447 . . . . 0.0 113.906 0.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.698 HG12 HG22 ' A' ' 8' ' ' THR . 17.0 m -141.0 145.95 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 -179.225 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.429 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 79.9 m -83.66 128.56 34.62 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 178.042 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.8 t . . . . . 0 C--N 1.324 -0.532 0 N-CA-C 110.129 -0.322 . . . . 0.0 110.129 179.873 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.787 ' HG3' ' HA ' ' A' ' 14' ' ' CYS . 1.1 pm0 . . . . . 0 C--O 1.237 0.421 0 CA-C-O 121.56 0.695 . . . . 0.0 111.2 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.803 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.7 p -85.66 129.71 34.75 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.98 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.508 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 41.0 t -80.77 20.83 0.72 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.284 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.803 HG23 ' HB ' ' A' ' 8' ' ' THR . 53.4 t -58.68 -39.74 77.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 121.059 0.457 . . . . 0.0 110.583 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.12 23.78 33.37 Favored Glycine 0 N--CA 1.446 -0.665 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.055 179.025 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.13 53.48 44.32 Favored Glycine 0 C--N 1.334 0.449 0 C-N-CA 121.369 -0.443 . . . . 0.0 112.95 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 t -151.86 151.32 31.14 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.004 0.43 . . . . 0.0 111.739 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.787 ' HA ' ' HG3' ' A' ' 7' ' ' GLU . 84.4 m -142.34 134.66 27.74 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.189 179.165 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.457 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 71.5 m-80 -95.17 -46.24 6.86 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.933 0.397 . . . . 0.0 111.123 -179.239 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.56 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 7.7 m -64.41 121.2 71.15 Favored Pre-proline 0 C--O 1.238 0.469 0 CA-C-O 121.43 0.633 . . . . 0.0 111.77 -178.808 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -59.07 132.86 49.64 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.81 2.34 . . . . 0.0 112.191 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.68 -10.78 73.84 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.175 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.56 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 71.2 m -88.1 123.15 32.48 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.384 0.611 . . . . 0.0 110.163 179.61 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.6 m -88.97 143.3 26.95 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.184 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -72.85 119.05 16.55 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 30.2 m -135.15 70.67 1.43 Allowed 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.183 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 8.9 t90 -27.41 128.54 0.2 Allowed Pre-proline 0 N--CA 1.466 0.362 0 CA-C-N 114.036 -1.438 . . . . 0.0 112.916 -178.203 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 92.3 Cg_endo -96.37 29.53 15.24 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 C-N-CA 123.396 -1.501 . . . . 0.0 114.105 0.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.508 ' HA ' ' H ' ' A' ' 9' ' ' CYS . 9.3 m -145.89 148.06 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 -179.211 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.554 ' SG ' ' HG2' ' A' ' 7' ' ' GLU . 72.7 m -83.58 141.25 31.71 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.836 178.041 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.2 t . . . . . 0 C--N 1.324 -0.511 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 -179.893 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.473 ' HG2' ' H ' ' A' ' 15' ' ' ASN . 6.6 tp10 . . . . . 0 C--O 1.235 0.336 0 CA-C-O 121.184 0.516 . . . . 0.0 110.229 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 12.6 p -109.92 127.94 55.05 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.041 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.49 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 20.5 t -90.7 38.46 0.95 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.278 0.561 . . . . 0.0 109.873 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -62.9 -36.8 77.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.239 -179.155 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.47 28.05 16.68 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.662 179.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.07 40.97 97.8 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 121.271 -0.49 . . . . 0.0 112.933 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -151.75 160.06 43.72 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.578 0.228 . . . . 0.0 110.528 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.7 m -143.81 120.57 11.21 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.147 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.473 ' H ' ' HG2' ' A' ' 7' ' ' GLU . 48.8 m-80 -79.32 -35.61 40.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.672 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.496 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 0.2 OUTLIER -67.91 114.27 19.45 Favored Pre-proline 0 C--O 1.242 0.709 0 CA-C-O 121.252 0.549 . . . . 0.0 111.639 -179.112 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -59.37 135.8 67.64 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.765 2.31 . . . . 0.0 112.322 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.65 -6.39 73.87 Favored Glycine 0 N--CA 1.444 -0.821 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.698 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.496 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 84.2 m -89.76 132.5 35.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 117.461 0.63 . . . . 0.0 111.335 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 m -88.93 148.4 23.83 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.297 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.6 t -79.31 127.54 32.2 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.012 0.434 . . . . 0.0 111.285 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.6 m -137.93 67.84 1.41 Allowed 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.703 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 9.3 t90 -31.39 128.83 0.29 Allowed Pre-proline 0 N--CA 1.465 0.294 0 CA-C-N 114.356 -1.293 . . . . 0.0 112.793 -177.211 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.2 Cg_endo -97.18 31.9 11.64 Favored 'Cis proline' 0 N--CA 1.456 -0.709 0 C-N-CA 123.554 -1.436 . . . . 0.0 113.772 0.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 16.1 m -136.64 141.79 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -178.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 80.7 m -85.0 135.02 34.2 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.608 178.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.2 t . . . . . 0 C--N 1.323 -0.569 0 CA-C-O 121.557 0.694 . . . . 0.0 110.959 178.971 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 . . . . . 0 CA--C 1.518 -0.287 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.685 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.2 p -74.89 123.55 25.27 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-O 121.443 0.64 . . . . 0.0 110.52 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.503 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 21.8 t -93.77 35.14 1.15 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.91 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.685 HG23 ' HB ' ' A' ' 8' ' ' THR . 44.5 t -62.31 -40.76 89.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.286 -179.635 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.05 24.68 23.61 Favored Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.629 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.91 47.55 90.07 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 121.34 -0.457 . . . . 0.0 113.287 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.8 t -150.89 155.9 40.11 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.854 0.359 . . . . 0.0 110.954 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 94.8 m -133.26 -44.02 0.85 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.756 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 73.76 -46.51 0.63 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.778 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.411 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 2.6 m -63.04 110.68 3.75 Favored Pre-proline 0 C--O 1.243 0.749 0 CA-C-O 121.511 0.672 . . . . 0.0 111.863 -179.227 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 25.2 Cg_endo -61.62 131.77 37.24 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.573 2.182 . . . . 0.0 111.989 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.62 -22.85 37.07 Favored Glycine 0 N--CA 1.437 -1.272 0 C-N-CA 120.398 -0.906 . . . . 0.0 111.583 -179.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 15.3 m -98.43 134.7 41.05 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.342 0.591 . . . . 0.0 111.623 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.3 m -99.05 149.47 22.98 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.802 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 23.3 t -76.44 125.04 28.49 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.079 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 32.0 t -126.17 64.44 1.23 Allowed 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 178.365 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.1 t90 -26.74 128.48 0.19 Allowed Pre-proline 0 N--CA 1.467 0.417 0 CA-C-N 114.066 -1.425 . . . . 0.0 113.236 -177.083 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 84.1 Cg_endo -95.34 30.03 14.64 Favored 'Cis proline' 0 CA--C 1.536 0.584 0 C-N-CA 123.451 -1.479 . . . . 0.0 113.964 0.658 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.7 m -139.15 137.17 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 121.558 0.694 . . . . 0.0 112.633 -179.498 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 79.2 m -81.99 140.05 34.19 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.475 178.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.3 t . . . . . 0 C--N 1.323 -0.563 0 CA-C-O 120.802 0.334 . . . . 0.0 110.636 -179.662 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.611 ' HG2' HD21 ' A' ' 15' ' ' ASN . 1.1 mp0 . . . . . 0 CA--C 1.515 -0.384 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.486 ' HB ' HG13 ' A' ' 10' ' ' VAL . 2.4 p -70.25 121.79 18.28 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-O 121.528 0.68 . . . . 0.0 110.498 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 18.9 t -87.96 40.98 0.97 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.903 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.486 HG13 ' HB ' ' A' ' 8' ' ' THR . 15.1 m -62.36 -33.93 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.333 -179.377 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.84 22.45 39.55 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.177 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.47 45.69 94.12 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.837 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -151.87 155.74 38.73 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.012 0.434 . . . . 0.0 111.426 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 55.9 m -133.61 146.6 51.08 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 179.349 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.611 HD21 ' HG2' ' A' ' 7' ' ' GLU . 21.4 p30 -102.71 -35.07 8.81 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.303 -0.559 . . . . 0.0 112.247 -179.005 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 13.0 m -80.74 112.84 35.21 Favored Pre-proline 0 C--O 1.244 0.795 0 CA-C-O 121.542 0.687 . . . . 0.0 111.488 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.411 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 39.2 Cg_exo -59.52 129.06 29.42 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.677 2.251 . . . . 0.0 111.803 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.2 -23.21 19.19 Favored Glycine 0 N--CA 1.438 -1.194 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.2 m -95.16 127.08 40.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.306 0.574 . . . . 0.0 111.515 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.62 147.19 23.47 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.195 -179.52 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.2 t -71.3 123.94 23.42 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.201 0.524 . . . . 0.0 111.176 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 37.9 m -128.44 66.54 1.39 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 178.361 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 3.9 t90 -27.79 129.07 0.21 Allowed Pre-proline 0 N--CA 1.467 0.396 0 CA-C-N 113.904 -1.498 . . . . 0.0 113.051 -177.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 90.0 Cg_endo -95.3 31.34 12.61 Favored 'Cis proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.347 -1.522 . . . . 0.0 114.338 0.637 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.6 m -141.49 137.59 32.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 83.0 m -82.26 134.55 35.29 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.595 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.2 t . . . . . 0 C--N 1.324 -0.529 0 CA-C-O 121.296 0.57 . . . . 0.0 110.879 179.492 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 . . . . . 0 N--CA 1.452 -0.363 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.566 ' HB ' HG23 ' A' ' 10' ' ' VAL . 1.4 p -72.0 125.41 27.18 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-O 121.684 0.754 . . . . 0.0 111.625 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.568 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.8 t -104.25 42.22 1.22 Allowed 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.164 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.566 HG23 ' HB ' ' A' ' 8' ' ' THR . 45.9 t -59.11 -40.94 82.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.967 -178.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.11 16.79 54.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.523 179.252 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.72 41.2 97.39 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 121.504 -0.379 . . . . 0.0 113.106 179.487 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.8 t -152.84 140.64 20.05 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-O 121.42 0.629 . . . . 0.0 112.26 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 91.1 m -152.49 148.9 27.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.613 -1.176 . . . . 0.0 109.087 178.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.536 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 4.5 m120 -115.71 11.64 15.76 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.864 -0.334 . . . . 0.0 111.281 -179.549 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -81.12 107.58 8.08 Favored Pre-proline 0 C--O 1.24 0.601 0 CA-C-O 121.248 0.547 . . . . 0.0 110.995 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.536 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 29.4 Cg_exo -60.91 131.81 39.11 Favored 'Trans proline' 0 CA--C 1.515 -0.431 0 C-N-CA 122.64 2.227 . . . . 0.0 112.684 -179.225 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.11 -18.16 56.75 Favored Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.221 -179.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 36.3 m -105.36 130.75 53.4 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.6 0.714 . . . . 0.0 111.668 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.6 m -97.98 148.47 23.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.141 -178.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.604 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 37.6 t -72.0 128.73 36.63 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.954 179.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.5 m -132.26 67.41 1.53 Allowed 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 3.7 t90 -26.61 128.67 0.19 Allowed Pre-proline 0 N--CA 1.467 0.385 0 CA-C-N 114.054 -1.43 . . . . 0.0 113.095 -177.203 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.48 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 85.4 Cg_endo -94.76 29.23 15.98 Favored 'Cis proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.464 -1.473 . . . . 0.0 114.261 0.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 6.7 m -143.04 137.16 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 CA-C-O 121.484 0.659 . . . . 0.0 112.653 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.604 ' SG ' ' HA ' ' A' ' 21' ' ' CYS . 61.2 m -83.56 140.83 32.01 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.876 178.441 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.9 t . . . . . 0 N--CA 1.448 -0.526 0 CA-C-O 120.878 0.37 . . . . 0.0 110.311 179.84 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 . . . . . 0 C--O 1.237 0.416 0 CA-C-O 121.176 0.512 . . . . 0.0 111.007 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.669 HG22 HG12 ' A' ' 25' ' ' VAL . 3.2 p -89.8 126.84 35.83 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.563 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.417 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 17.3 t -83.99 45.21 1.07 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.05 0.452 . . . . 0.0 110.424 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.604 HG23 ' HB ' ' A' ' 8' ' ' THR . 48.5 t -63.54 -39.89 87.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 120.993 0.425 . . . . 0.0 110.74 -179.143 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.73 22.38 25.07 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.738 -0.664 . . . . 0.0 112.948 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.98 39.81 94.67 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.335 -0.459 . . . . 0.0 113.269 179.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.7 t -152.25 158.31 42.64 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-O 120.773 0.32 . . . . 0.0 110.944 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -139.91 131.33 26.9 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -83.0 -46.42 12.89 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -178.35 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 4.5 m -70.38 113.61 19.49 Favored Pre-proline 0 C--O 1.246 0.915 0 CA-C-O 121.572 0.701 . . . . 0.0 112.343 -178.412 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -61.22 127.56 22.46 Favored 'Trans proline' 0 N--CA 1.459 -0.555 0 C-N-CA 122.673 2.249 . . . . 0.0 111.291 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 116.52 -26.3 8.63 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -178.157 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.7 m -89.69 130.12 36.02 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 121.338 0.59 . . . . 0.0 110.947 179.178 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 m -96.6 146.95 24.37 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.063 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.7 t -72.26 127.49 32.74 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.203 0.525 . . . . 0.0 111.465 -179.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 28.3 t -136.94 64.66 1.53 Allowed 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 178.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.432 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.1 t90 -29.21 128.61 0.23 Allowed Pre-proline 0 N--CA 1.466 0.353 0 CA-C-N 114.381 -1.281 . . . . 0.0 113.04 -177.144 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.432 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 96.4 Cg_endo -97.31 34.26 8.96 Favored 'Cis proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.671 -1.387 . . . . 0.0 114.011 0.67 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.669 HG12 HG22 ' A' ' 8' ' ' THR . 17.6 m -140.82 146.96 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 O-C-N 121.898 -0.501 . . . . 0.0 112.33 -179.331 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 72.6 m -81.93 123.73 29.12 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 178.583 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.8 t . . . . . 0 C--N 1.323 -0.551 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.775 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 . . . . . 0 N--CA 1.452 -0.373 0 CA-C-O 121.259 0.552 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.489 HG22 HG12 ' A' ' 25' ' ' VAL . 2.0 p -98.07 126.68 43.61 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.564 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 35.1 t -87.81 44.63 1.2 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.755 179.13 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.2 p -62.38 -38.35 81.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.517 -178.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.42 26.49 17.46 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.856 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.15 38.16 92.73 Favored Glycine 0 C--N 1.333 0.391 0 C-N-CA 121.31 -0.471 . . . . 0.0 112.949 179.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.9 t -152.51 163.11 40.22 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.6 m -145.02 120.12 10.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.027 179.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 33.5 t30 -78.94 -36.44 41.72 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.616 179.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 5.9 m -63.04 109.63 2.66 Favored Pre-proline 0 C--O 1.242 0.667 0 CA-C-O 121.414 0.626 . . . . 0.0 111.646 -179.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_exo -61.61 130.23 30.82 Favored 'Trans proline' 0 CA--C 1.515 -0.463 0 C-N-CA 122.844 2.362 . . . . 0.0 112.535 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.9 -20.02 52.27 Favored Glycine 0 N--CA 1.44 -1.062 0 CA-C-N 115.327 -0.852 . . . . 0.0 111.617 -179.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 72.0 m -89.81 123.93 34.22 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.321 0.581 . . . . 0.0 110.981 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.4 p -88.99 143.46 26.84 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.359 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.4 t -69.92 128.23 35.64 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.26 0.552 . . . . 0.0 112.005 -179.044 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 35.0 t -136.98 66.42 1.47 Allowed 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.435 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 6.8 t90 -29.46 128.62 0.24 Allowed Pre-proline 0 N--CA 1.464 0.269 0 CA-C-N 114.284 -1.325 . . . . 0.0 113.008 -176.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 97.0 Cg_endo -97.0 32.47 10.96 Favored 'Cis proline' 0 N--CA 1.458 -0.599 0 C-N-CA 123.49 -1.463 . . . . 0.0 114.031 0.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.489 HG12 HG22 ' A' ' 8' ' ' THR . 15.9 m -139.42 142.87 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 113.032 0.752 . . . . 0.0 113.032 -179.205 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 58.5 m -83.09 131.25 35.16 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.627 178.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 t . . . . . 0 C--N 1.324 -0.51 0 CA-C-O 121.129 0.49 . . . . 0.0 111.062 -179.781 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.615 ' OE1' ' HB3' ' A' ' 14' ' ' CYS . 64.6 mt-10 . . . . . 0 N--CA 1.451 -0.399 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 17.3 p -75.34 123.75 25.9 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.131 0.491 . . . . 0.0 110.958 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.2 t -103.74 39.81 1.54 Allowed 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.434 179.7 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -59.16 -36.96 65.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.343 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.33 27.89 18.49 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.317 179.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.47 35.67 89.43 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 121.365 -0.445 . . . . 0.0 112.993 179.748 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.8 t -153.06 156.4 38.66 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 120.646 0.26 . . . . 0.0 110.838 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.615 ' HB3' ' OE1' ' A' ' 7' ' ' GLU . 61.0 m -150.05 -153.09 0.47 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.787 179.237 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.417 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 72.4 m-80 -133.12 -52.94 0.9 Allowed 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -178.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 51.3 m -66.34 108.47 2.33 Favored Pre-proline 0 C--O 1.249 1.047 0 N-CA-C 113.523 0.934 . . . . 0.0 113.523 -177.375 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.417 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 37.4 Cg_endo -65.6 125.48 14.44 Favored 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 122.461 2.107 . . . . 0.0 110.485 178.353 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.55 -27.38 6.03 Favored Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -177.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 14.2 m -89.86 129.41 36.23 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 120.15 -0.62 . . . . 0.0 110.067 178.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.7 m -88.14 144.86 26.23 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.533 -179.17 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.2 t -72.98 122.68 22.11 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.12 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.0 m -127.73 67.28 1.33 Allowed 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 178.583 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.516 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.3 t90 -26.5 127.95 0.19 Allowed Pre-proline 0 N--CA 1.467 0.395 0 CA-C-N 113.921 -1.491 . . . . 0.0 113.058 -177.18 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.516 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 80.5 Cg_endo -95.56 31.55 12.3 Favored 'Cis proline' 0 N--CA 1.456 -0.707 0 C-N-CA 123.482 -1.466 . . . . 0.0 114.38 0.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 6.0 m -145.03 138.06 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 N-CA-C 112.873 0.694 . . . . 0.0 112.873 -179.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.482 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 94.6 m -82.19 140.29 33.81 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.571 178.254 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.321 -0.646 0 CA-C-O 121.041 0.448 . . . . 0.0 110.196 179.387 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 . . . . . 0 N--CA 1.452 -0.368 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.724 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.7 p -77.98 123.9 27.36 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-O 121.414 0.625 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.438 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 28.2 t -90.52 39.97 1.0 Allowed 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.052 179.775 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.724 HG23 ' HB ' ' A' ' 8' ' ' THR . 47.3 t -61.99 -40.31 86.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.653 -179.245 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.47 22.83 30.81 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.881 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.19 47.6 88.4 Favored Glycine 0 CA--C 1.52 0.362 0 C-N-CA 121.289 -0.482 . . . . 0.0 113.206 179.306 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.4 t -151.18 155.98 39.99 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 122.565 -0.373 . . . . 0.0 111.095 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 82.9 m -140.1 127.73 21.67 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.656 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -81.44 -41.18 22.22 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -179.202 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.433 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 15.5 m -75.82 109.46 8.15 Favored Pre-proline 0 C--O 1.246 0.885 0 CA-C-O 121.545 0.688 . . . . 0.0 112.223 -178.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 27.6 Cg_endo -61.96 131.19 33.83 Favored 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 122.564 2.176 . . . . 0.0 111.386 179.524 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 110.61 -29.32 9.13 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 -178.305 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 7.4 m -89.59 133.37 34.65 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.526 179.221 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.3 m -95.23 148.79 22.02 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.959 -178.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.3 t -70.07 126.6 30.15 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.875 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.7 m -134.22 67.96 1.5 Allowed 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 1.5 t90 -28.35 128.16 0.22 Allowed Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 113.976 -1.465 . . . . 0.0 112.989 -176.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.8 Cg_endo -96.71 32.52 10.92 Favored 'Cis proline' 0 CA--C 1.537 0.64 0 C-N-CA 123.595 -1.419 . . . . 0.0 114.151 0.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.2 m -143.71 141.78 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -179.572 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.438 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 65.8 m -82.68 132.54 35.18 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.234 178.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.2 t . . . . . 0 C--O 1.239 0.508 0 CA-C-O 121.014 0.435 . . . . 0.0 111.557 -179.869 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.669 ' HG3' ' HB3' ' A' ' 15' ' ' ASN . 47.3 mm-40 . . . . . 0 C--O 1.239 0.539 0 CA-C-O 122.028 0.918 . . . . 0.0 112.61 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.697 HG22 HG12 ' A' ' 25' ' ' VAL . 5.9 p -110.22 127.85 55.18 Favored 'General case' 0 N--CA 1.439 -1.019 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.825 178.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 12.7 t -83.65 41.35 0.78 Allowed 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.919 0.39 . . . . 0.0 110.841 -179.403 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.621 HG23 ' HB ' ' A' ' 8' ' ' THR . 47.6 t -64.73 -42.01 93.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.174 0.511 . . . . 0.0 110.314 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.24 28.62 12.3 Favored Glycine 0 N--CA 1.45 -0.397 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.638 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.08 42.55 98.52 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 121.27 -0.49 . . . . 0.0 113.237 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.8 t -151.61 160.17 43.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.648 0.261 . . . . 0.0 110.756 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.7 m -146.03 124.75 12.57 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.191 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.669 ' HB3' ' HG3' ' A' ' 7' ' ' GLU . 28.2 t-20 -81.04 -46.73 14.58 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.657 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.465 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 0.2 OUTLIER -58.33 111.77 4.01 Favored Pre-proline 0 C--O 1.238 0.481 0 CA-C-O 121.221 0.534 . . . . 0.0 112.146 -178.857 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 24.7 Cg_exo -62.24 130.59 31.0 Favored 'Trans proline' 0 N--CA 1.46 -0.448 0 C-N-CA 122.631 2.221 . . . . 0.0 111.63 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.38 -14.72 63.14 Favored Glycine 0 N--CA 1.442 -0.945 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.763 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.465 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 95.9 m -88.98 126.82 35.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.243 0.544 . . . . 0.0 110.816 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.87 148.76 23.69 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.412 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 t -75.48 128.6 35.67 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.127 0.489 . . . . 0.0 112.187 -178.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 57.6 m -139.99 69.13 1.35 Allowed 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 178.193 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.528 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 11.4 t90 -31.62 129.04 0.3 Allowed Pre-proline 0 N--CA 1.465 0.292 0 CA-C-N 114.227 -1.351 . . . . 0.0 112.886 -177.173 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 97.6 Cg_endo -98.06 33.16 9.83 Favored 'Cis proline' 0 N--CA 1.457 -0.633 0 C-N-CA 123.71 -1.371 . . . . 0.0 113.75 0.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.697 HG12 HG22 ' A' ' 8' ' ' THR . 24.6 m -139.43 145.85 26.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -178.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 61.3 m -84.63 138.26 32.8 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.7 t . . . . . 0 C--N 1.324 -0.533 0 CA-C-O 121.057 0.456 . . . . 0.0 110.449 179.417 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 111.972 -0.451 . . . . 0.0 111.972 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 47.0 tp -75.8 123.05 88.16 Favored Pre-proline 0 C--N 1.326 -0.43 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -68.72 131.58 23.08 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.627 2.218 . . . . 0.0 111.868 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 46.6 t -70.11 -44.75 77.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.445 0.64 . . . . 0.0 110.29 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 1.6 m -95.55 156.18 16.43 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.644 179.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -162.34 17.87 0.16 Allowed Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.314 -0.946 . . . . 0.0 112.657 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -79.47 136.99 37.07 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.7 ' HB ' HG23 ' A' ' 10' ' ' VAL . 18.8 p -71.72 122.43 20.61 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 120.909 0.385 . . . . 0.0 110.452 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.523 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 17.0 t -93.05 37.05 1.03 Allowed 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.981 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.7 HG23 ' HB ' ' A' ' 8' ' ' THR . 46.1 t -60.4 -41.14 86.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.777 -179.241 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.86 24.92 24.1 Favored Glycine 0 N--CA 1.451 -0.3 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.948 179.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.85 47.92 88.06 Favored Glycine 0 C--N 1.333 0.363 0 C-N-CA 121.223 -0.513 . . . . 0.0 113.326 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 t -150.97 154.1 36.46 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.872 0.368 . . . . 0.0 111.082 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 76.8 m -134.48 138.07 44.43 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.87 179.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -79.91 -53.99 6.23 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.889 -178.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.585 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 6.7 m -73.1 115.06 36.77 Favored Pre-proline 0 C--O 1.243 0.732 0 CA-C-O 121.368 0.604 . . . . 0.0 112.297 -178.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -63.69 121.86 9.75 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.529 2.153 . . . . 0.0 110.635 179.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.14 -16.11 13.16 Favored Glycine 0 N--CA 1.439 -1.112 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 -178.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.585 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 76.5 m -89.14 132.43 34.83 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 m -88.77 144.97 25.89 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.272 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.9 t -78.48 126.35 30.64 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.077 0.465 . . . . 0.0 110.811 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.0 m -132.66 67.93 1.52 Allowed 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.7 t90 -29.15 127.88 0.24 Allowed Pre-proline 0 N--CA 1.465 0.279 0 CA-C-N 114.06 -1.427 . . . . 0.0 112.841 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 91.3 Cg_endo -97.04 32.8 10.51 Favored 'Cis proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.582 -1.424 . . . . 0.0 114.053 0.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 10.8 m -140.68 139.39 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 113.057 0.762 . . . . 0.0 113.057 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.523 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.3 m -83.36 137.82 33.79 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.649 178.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.1 t -150.77 149.15 29.39 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.092 0.472 . . . . 0.0 110.227 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 39.8 ttt85 -100.17 125.16 46.26 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.096 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 5.9 m120 . . . . . 0 C--N 1.319 -0.739 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.474 -179.575 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.4 0 N-CA-C 111.87 -0.492 . . . . 0.0 111.87 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.677 HD12 ' HD2' ' A' ' 3' ' ' PRO . 46.9 tp -72.17 123.13 89.07 Favored Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.622 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.677 ' HD2' HD12 ' A' ' 2' ' ' LEU . 70.7 Cg_endo -74.73 48.49 1.93 Allowed 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.973 2.449 . . . . 0.0 112.367 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.36 -35.68 63.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.449 0.642 . . . . 0.0 110.653 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.7 m -137.42 -55.89 0.69 Allowed 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.102 -0.953 . . . . 0.0 110.035 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.76 -38.7 2.81 Favored Glycine 0 C--N 1.322 -0.234 0 CA-C-N 115.682 -0.69 . . . . 0.0 113.538 179.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.447 ' OE2' ' HB3' ' A' ' 15' ' ' ASN . 20.7 mt-10 -53.44 134.37 40.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.798 0.332 . . . . 0.0 111.01 -179.394 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 3.0 p -88.29 127.51 35.47 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 121.105 0.478 . . . . 0.0 110.825 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.561 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 15.0 t -91.28 40.52 1.03 Allowed 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.136 0.493 . . . . 0.0 109.84 179.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.6 p -61.81 -36.28 72.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.08 -179.129 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.56 24.23 31.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.829 -0.7 . . . . 0.0 112.72 179.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.5 41.59 97.23 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.257 -0.497 . . . . 0.0 113.181 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.8 t -151.48 152.58 33.2 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 121.011 0.434 . . . . 0.0 111.309 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 71.1 m -132.07 140.1 48.75 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.076 179.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.447 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 9.7 t30 -91.95 -47.91 7.04 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.609 -178.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' ' 17' ' ' PRO . 85.2 m -70.57 116.45 45.64 Favored Pre-proline 0 C--O 1.242 0.709 0 CA-C-O 121.322 0.582 . . . . 0.0 111.801 -179.244 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 26.1 Cg_exo -61.56 126.29 18.78 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.681 2.254 . . . . 0.0 111.019 179.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 110.62 -18.25 27.38 Favored Glycine 0 N--CA 1.44 -1.043 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -178.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.0 m -87.4 124.85 33.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.174 0.512 . . . . 0.0 110.273 179.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 m -89.35 145.52 25.3 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.854 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 53.7 t -77.03 126.81 31.58 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 121.173 0.511 . . . . 0.0 111.306 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -137.37 68.69 1.41 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.438 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.7 t90 -31.04 129.07 0.27 Allowed Pre-proline 0 N--CA 1.463 0.216 0 CA-C-N 114.111 -1.404 . . . . 0.0 112.832 -177.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.6 Cg_endo -97.08 33.24 10.01 Favored 'Cis proline' 0 N--CA 1.456 -0.678 0 C-N-CA 123.591 -1.421 . . . . 0.0 114.026 0.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 14.8 m -140.11 141.95 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 N-CA-C 113.222 0.823 . . . . 0.0 113.222 -179.121 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.561 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 84.1 m -84.01 135.47 34.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.03 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.2 t -150.72 146.69 26.6 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.126 0.488 . . . . 0.0 110.226 179.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.407 ' HG2' HH11 ' A' ' 28' ' ' ARG . 43.0 ttp85 -80.41 108.64 14.2 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.469 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 . . . . . 0 C--N 1.319 -0.738 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.852 -179.418 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.599 0 N-CA-C 111.971 -0.452 . . . . 0.0 111.971 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 14.6 mt -148.15 135.47 10.57 Favored Pre-proline 0 C--N 1.325 -0.47 0 CA-C-O 120.953 0.406 . . . . 0.0 110.838 179.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.15 52.63 3.16 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 123.441 2.76 . . . . 0.0 112.768 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 48.3 t -71.39 -45.49 68.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.432 0.634 . . . . 0.0 110.466 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.464 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 6.5 m -89.08 160.39 17.08 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.329 179.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -175.28 25.71 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.898 -0.668 . . . . 0.0 111.983 179.483 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -85.53 144.99 27.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.089 0.471 . . . . 0.0 110.133 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 p -77.34 125.48 29.4 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-O 121.313 0.577 . . . . 0.0 110.908 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.485 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 26.0 t -92.71 37.75 1.01 Allowed 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.784 -0.643 . . . . 0.0 109.616 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.1 p -62.02 -35.46 68.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.008 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.78 21.64 43.67 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.723 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.56 45.61 95.98 Favored Glycine 0 CA--C 1.519 0.34 0 C-N-CA 121.249 -0.501 . . . . 0.0 113.297 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.9 t -150.82 152.52 33.88 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.881 0.372 . . . . 0.0 111.108 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 90.1 m -130.48 140.44 50.53 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.799 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.5 t30 -89.5 -48.91 7.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.918 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.464 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 1.8 m -76.1 112.54 21.21 Favored Pre-proline 0 C--O 1.244 0.801 0 CA-C-O 121.426 0.631 . . . . 0.0 112.572 -178.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.446 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 19.3 Cg_endo -60.2 133.04 47.37 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.682 2.255 . . . . 0.0 111.481 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.51 -27.19 17.56 Favored Glycine 0 N--CA 1.438 -1.218 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -178.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 12.3 m -90.7 128.64 36.72 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.061 0.458 . . . . 0.0 110.232 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.5 t -90.83 160.98 15.46 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.929 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 46.1 t -80.67 131.45 35.47 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.55 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.2 m -138.38 68.77 1.39 Allowed 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 178.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 2.0 t90 -29.56 129.16 0.24 Allowed Pre-proline 0 N--CA 1.466 0.33 0 CA-C-N 114.062 -1.426 . . . . 0.0 113.015 -177.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 94.3 Cg_endo -96.66 33.26 10.02 Favored 'Cis proline' 0 N--CA 1.458 -0.594 0 C-N-CA 123.484 -1.465 . . . . 0.0 114.151 0.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 10.6 m -144.01 143.96 23.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.485 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.1 m -82.76 143.81 30.61 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.2 t -150.01 158.48 44.21 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.371 0.605 . . . . 0.0 111.311 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.442 ' HA ' ' HD2' ' A' ' 28' ' ' ARG . 29.8 tpt85 -81.22 52.44 1.81 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.003 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 . . . . . 0 C--N 1.323 -0.564 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.53 179.514 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.404 0 N-CA-C 112.125 -0.39 . . . . 0.0 112.125 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.6 tp -66.81 117.84 49.06 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 115.629 -0.285 . . . . 0.0 111.072 -179.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -76.92 58.98 6.28 Favored 'Trans proline' 0 N--CA 1.462 -0.349 0 C-N-CA 123.369 2.713 . . . . 0.0 111.718 179.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.7 p -55.57 -39.85 56.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.397 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.497 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 62.7 m -65.61 -52.87 48.76 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.683 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.61 10.17 63.27 Favored Glycine 0 C--N 1.322 -0.24 0 CA-C-N 115.078 -0.965 . . . . 0.0 113.234 179.375 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -73.63 138.97 45.16 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.81 0.338 . . . . 0.0 110.583 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.514 ' HB ' HG23 ' A' ' 10' ' ' VAL . 10.8 p -82.25 124.87 30.33 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.151 179.105 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 23.9 t -87.62 53.03 2.65 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.246 0.546 . . . . 0.0 110.725 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.514 HG23 ' HB ' ' A' ' 8' ' ' THR . 4.1 t -78.99 48.84 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-O 121.46 0.648 . . . . 0.0 110.781 -179.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.06 26.89 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.888 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 55.06 43.95 83.31 Favored Glycine 0 C--N 1.336 0.529 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.099 179.358 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.2 t -151.55 153.74 35.13 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.11 0.481 . . . . 0.0 111.545 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.4 m -142.33 134.34 27.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.186 -0.915 . . . . 0.0 108.578 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 62.0 m-80 -84.07 -45.18 13.32 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.591 0.234 . . . . 0.0 111.561 -178.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.497 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 4.1 m -69.94 113.66 19.26 Favored Pre-proline 0 C--O 1.244 0.811 0 CA-C-O 121.44 0.638 . . . . 0.0 112.002 -178.649 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -60.12 131.0 36.75 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.695 2.264 . . . . 0.0 111.345 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.48 -26.2 15.41 Favored Glycine 0 N--CA 1.439 -1.129 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -178.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.7 m -89.31 126.17 35.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.504 0.669 . . . . 0.0 111.112 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.3 m -94.07 147.55 23.03 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.597 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.1 t -72.38 114.87 10.97 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.074 0.464 . . . . 0.0 111.278 -179.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 36.8 m -123.43 64.47 1.01 Allowed 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 178.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.49 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 8.8 t90 -27.6 129.39 0.2 Allowed Pre-proline 0 N--CA 1.463 0.203 0 CA-C-N 113.798 -1.547 . . . . 0.0 113.104 -177.063 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 96.6 Cg_endo -94.71 27.89 18.05 Favored 'Cis proline' 0 N--CA 1.457 -0.668 0 C-N-CA 123.226 -1.573 . . . . 0.0 114.143 0.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.3 m -137.37 140.1 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -179.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 72.8 m -82.7 129.95 35.04 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.672 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t -150.71 161.45 42.6 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 52.0 ttp85 -75.21 104.3 5.72 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 3.8 m120 . . . . . 0 C--N 1.321 -0.64 0 CA-C-O 121.032 0.444 . . . . 0.0 111.216 -179.366 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.444 0 N-CA-C 111.899 -0.481 . . . . 0.0 111.899 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 4' ' ' VAL . 7.3 mp -67.0 128.41 93.86 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.798 0.299 . . . . 0.0 110.468 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -73.81 48.42 1.65 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.146 2.564 . . . . 0.0 112.828 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.431 HG23 ' HB3' ' A' ' 2' ' ' LEU . 23.8 t -101.68 -20.98 5.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.418 0.628 . . . . 0.0 109.813 179.698 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.587 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 1.6 m -62.87 154.24 30.72 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.167 -0.924 . . . . 0.0 111.657 -179.288 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -160.14 28.46 0.35 Allowed Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.535 179.173 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.593 ' HG2' ' HB3' ' A' ' 15' ' ' ASN . 2.8 mp0 -85.32 137.33 33.03 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.3 p -73.31 124.24 25.33 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 120.844 0.354 . . . . 0.0 110.351 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.572 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 21.2 t -89.44 38.35 0.9 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.255 0.55 . . . . 0.0 110.019 179.669 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.01 -36.23 72.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.964 -179.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.04 25.59 26.96 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.746 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.14 45.29 95.53 Favored Glycine 0 C--N 1.331 0.277 0 C-N-CA 121.165 -0.54 . . . . 0.0 113.131 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.7 t -151.04 154.43 37.02 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.927 0.394 . . . . 0.0 111.065 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 98.8 m -130.98 139.58 50.03 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.813 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.593 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 30.4 t30 -85.26 -50.27 7.5 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.764 -179.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.587 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 5.6 m -80.59 109.1 11.64 Favored Pre-proline 0 C--O 1.251 1.174 0 CA-C-O 121.821 0.82 . . . . 0.0 112.584 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.5 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 24.5 Cg_exo -61.4 127.08 20.85 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 122.686 2.257 . . . . 0.0 111.103 179.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.525 ' O ' ' HG3' ' A' ' 28' ' ' ARG . . . 122.02 -29.73 5.47 Favored Glycine 0 N--CA 1.434 -1.458 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -178.039 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.615 ' HA ' ' HB2' ' A' ' 28' ' ' ARG . 19.0 m -88.99 143.1 27.09 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.256 -0.577 . . . . 0.0 110.529 179.061 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 m -97.08 149.33 22.08 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.559 -179.164 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.3 t -74.93 128.21 35.04 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.153 0.502 . . . . 0.0 111.15 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.0 m -133.84 67.79 1.51 Allowed 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.8 t90 -29.58 128.49 0.24 Allowed Pre-proline 0 N--CA 1.464 0.256 0 CA-C-N 114.118 -1.401 . . . . 0.0 112.811 -177.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.457 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 95.7 Cg_endo -96.78 34.13 9.15 Favored 'Cis proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.615 -1.41 . . . . 0.0 114.201 0.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.42 ' HA ' ' H ' ' A' ' 9' ' ' CYS . 10.8 m -143.11 139.97 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 -179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.572 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 70.9 m -83.05 132.21 35.13 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.038 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.9 t -152.01 168.41 25.32 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.615 ' HB2' ' HA ' ' A' ' 19' ' ' CYS . 0.3 OUTLIER -173.72 -160.53 0.11 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.046 0.45 . . . . 0.0 111.172 179.77 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 . . . . . 0 C--N 1.322 -0.595 0 CA-C-N 114.878 -1.056 . . . . 0.0 109.236 179.951 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.019 -0.432 . . . . 0.0 112.019 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.1 tp 63.41 94.07 0.05 OUTLIER Pre-proline 0 N--CA 1.464 0.236 0 C-N-CA 123.205 0.602 . . . . 0.0 111.404 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -71.31 120.45 6.99 Favored 'Trans proline' 0 N--CA 1.459 -0.529 0 C-N-CA 122.333 2.022 . . . . 0.0 111.68 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 32.4 t -66.12 -40.93 88.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.324 0.583 . . . . 0.0 110.998 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.442 ' HB2' ' O ' ' A' ' 26' ' ' CYS . 81.4 m -89.31 -49.96 6.4 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.769 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.77 -38.25 3.19 Favored Glycine 0 C--N 1.319 -0.414 0 CA-C-N 115.277 -0.874 . . . . 0.0 112.749 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.433 ' OE2' ' HB3' ' A' ' 15' ' ' ASN . 23.1 mt-10 -58.11 135.18 56.98 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.749 0.309 . . . . 0.0 110.706 -179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 2.8 p -88.33 127.14 35.48 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-O 121.099 0.476 . . . . 0.0 110.989 179.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.532 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 18.1 t -91.79 40.43 1.04 Allowed 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.159 0.504 . . . . 0.0 109.881 179.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -62.12 -36.22 73.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.086 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.6 24.1 30.96 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.798 179.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.23 42.04 97.05 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 121.25 -0.5 . . . . 0.0 113.072 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.0 t -151.82 156.18 39.68 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.842 0.353 . . . . 0.0 111.023 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.9 m -135.8 136.88 41.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.302 179.386 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.433 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 9.8 t30 -87.48 -48.95 7.53 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.996 -178.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 88.4 m -70.98 118.38 65.0 Favored Pre-proline 0 C--O 1.241 0.647 0 CA-C-O 121.473 0.654 . . . . 0.0 111.946 -179.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -59.19 131.35 40.7 Favored 'Trans proline' 0 N--CA 1.458 -0.576 0 C-N-CA 122.717 2.278 . . . . 0.0 110.987 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 102.33 -13.64 56.96 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.369 -0.919 . . . . 0.0 111.505 -178.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.435 ' HB3' ' HB3' ' A' ' 26' ' ' CYS . 93.3 m -87.82 123.23 32.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.415 0.626 . . . . 0.0 110.561 179.573 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.25 141.49 28.49 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.675 179.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 45.8 t -73.65 120.9 19.89 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 121.104 0.478 . . . . 0.0 111.241 -179.487 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.1 t -129.03 64.85 1.46 Allowed 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.1 t90 -29.38 128.63 0.24 Allowed Pre-proline 0 N--CA 1.465 0.325 0 CA-C-N 114.26 -1.336 . . . . 0.0 112.978 -176.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.2 Cg_endo -96.64 33.53 9.75 Favored 'Cis proline' 0 CA--C 1.536 0.621 0 C-N-CA 123.542 -1.441 . . . . 0.0 114.149 0.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 15.3 m -140.93 141.77 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 112.96 0.726 . . . . 0.0 112.96 -179.328 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 77.3 m -82.35 136.34 35.01 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.771 178.344 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.4 t -150.84 167.02 28.75 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.852 0.358 . . . . 0.0 110.587 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 21.9 mmt85 -82.06 74.69 9.03 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.346 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 . . . . . 0 C--N 1.324 -0.524 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.476 -179.643 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 36.2 tp -160.74 127.77 2.6 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -67.29 135.72 37.81 Favored 'Trans proline' 0 N--CA 1.462 -0.341 0 C-N-CA 122.586 2.191 . . . . 0.0 111.835 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.527 HG13 ' SG ' ' A' ' 5' ' ' CYS . 7.7 p -65.92 -44.13 92.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.425 0.631 . . . . 0.0 110.635 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.562 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 4.6 m -94.75 157.02 16.13 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.844 178.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -172.98 24.82 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.099 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.462 ' HG3' ' H ' ' A' ' 15' ' ' ASN . 23.9 pm0 -83.15 144.86 29.55 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.191 0.52 . . . . 0.0 110.293 179.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.768 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.4 p -75.46 126.43 31.0 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.496 0.665 . . . . 0.0 111.429 -179.674 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.479 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 34.7 t -93.58 37.23 1.06 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.603 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.768 HG23 ' HB ' ' A' ' 8' ' ' THR . 48.0 t -60.91 -41.06 87.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.693 -179.16 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.37 23.22 22.93 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.753 179.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.94 45.16 95.54 Favored Glycine 0 CA--C 1.52 0.357 0 C-N-CA 121.394 -0.431 . . . . 0.0 113.288 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.9 t -150.85 151.98 33.04 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.046 0.45 . . . . 0.0 111.149 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 95.2 m -118.12 144.53 45.59 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.354 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.462 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 31.0 t30 -94.29 -48.53 6.13 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.366 -179.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.562 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 1.6 m -81.03 114.71 50.87 Favored Pre-proline 0 C--O 1.242 0.684 0 CA-C-O 121.334 0.588 . . . . 0.0 112.158 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 14.9 Cg_endo -56.95 137.92 83.89 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.686 2.257 . . . . 0.0 111.998 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 96.76 -23.28 36.1 Favored Glycine 0 N--CA 1.439 -1.147 0 C-N-CA 120.572 -0.823 . . . . 0.0 111.642 -178.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 7.3 m -90.64 131.89 36.08 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 120.404 -0.518 . . . . 0.0 110.913 179.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.9 t -89.87 158.28 17.52 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.823 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.2 t -79.29 129.17 34.2 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.216 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 29.6 m -134.79 67.24 1.51 Allowed 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 178.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 1.3 t90 -28.32 128.95 0.22 Allowed Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 114.11 -1.405 . . . . 0.0 113.091 -177.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 89.2 Cg_endo -95.64 31.69 12.1 Favored 'Cis proline' 0 N--CA 1.457 -0.642 0 C-N-CA 123.475 -1.469 . . . . 0.0 114.371 0.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.2 m -144.26 141.3 24.46 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 98.0 m -82.99 142.8 31.09 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.112 178.3 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.5 t -150.12 171.4 16.95 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.092 0.472 . . . . 0.0 110.925 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 19.9 tpp85 -95.53 117.22 30.02 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.881 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 35.5 t30 . . . . . 0 C--N 1.321 -0.635 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.711 -179.993 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.61 0 N-CA-C 112.136 -0.386 . . . . 0.0 112.136 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.586 ' HG ' ' HD3' ' A' ' 3' ' ' PRO . 3.6 pp -68.42 -34.3 5.59 Favored Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 114.443 1.275 . . . . 0.0 114.443 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.601 ' O ' ' HD3' ' A' ' 28' ' ' ARG . 59.2 Cg_endo -75.35 61.4 5.93 Favored 'Trans proline' 0 C--N 1.354 0.846 0 C-N-CA 122.101 1.868 . . . . 0.0 112.78 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 41.5 t -68.07 -47.47 78.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.208 0.528 . . . . 0.0 109.755 179.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.787 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 96.2 m 62.2 -168.82 0.19 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 114.561 -1.199 . . . . 0.0 112.527 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 146.16 -10.23 1.55 Allowed Glycine 0 N--CA 1.449 -0.492 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.541 -179.154 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.438 ' H ' ' CD ' ' A' ' 7' ' ' GLU . 0.8 OUTLIER -62.92 145.25 55.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.262 0.553 . . . . 0.0 111.009 179.933 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.655 ' HB ' HG23 ' A' ' 10' ' ' VAL . 7.9 p -69.12 126.66 30.48 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.202 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 35.9 t -86.66 47.21 1.45 Allowed 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.542 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.655 HG23 ' HB ' ' A' ' 8' ' ' THR . 17.8 t -76.15 69.63 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.505 0.669 . . . . 0.0 110.005 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 163.81 -20.58 0.15 Allowed Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.582 -0.736 . . . . 0.0 111.845 -179.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.87 42.89 4.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.873 -0.68 . . . . 0.0 111.593 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.9 t -152.11 154.42 35.87 Favored 'General case' 0 N--CA 1.446 -0.642 0 CA-C-O 120.67 0.271 . . . . 0.0 110.383 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 96.9 m -131.32 137.07 48.62 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.202 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 35.4 t30 -66.65 -56.54 10.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.082 -178.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.787 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 4.8 m -80.74 116.27 61.07 Favored Pre-proline 0 C--O 1.245 0.867 0 CA-C-O 121.622 0.725 . . . . 0.0 112.062 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_exo -60.45 125.91 18.63 Favored 'Trans proline' 0 N--CA 1.46 -0.449 0 C-N-CA 122.543 2.162 . . . . 0.0 110.834 179.329 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.51 -22.31 8.87 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -178.216 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.2 m -88.6 133.86 34.05 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.932 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.1 m -88.87 146.28 25.05 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.451 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 t -80.07 103.4 9.93 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.472 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 61.3 m -103.82 60.88 0.74 Allowed 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.459 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 11.5 t90 -28.51 130.21 0.21 Allowed Pre-proline 0 N--CA 1.465 0.298 0 CA-C-N 113.492 -1.686 . . . . 0.0 112.703 -177.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.4 Cg_endo -93.96 33.07 10.04 Favored 'Cis proline' 0 N--CA 1.456 -0.7 0 C-N-CA 123.16 -1.6 . . . . 0.0 114.492 1.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.5 m -138.9 138.59 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 N-CA-C 112.724 0.638 . . . . 0.0 112.724 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 67.6 m -81.96 135.84 35.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.326 178.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.546 ' HB ' ' OD1' ' A' ' 29' ' ' ASN . 10.7 m -150.74 149.82 30.26 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.601 ' HD3' ' O ' ' A' ' 3' ' ' PRO . 32.9 ptt180 -80.85 45.27 0.8 Allowed 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.206 0.526 . . . . 0.0 110.92 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.546 ' OD1' ' HB ' ' A' ' 27' ' ' THR . 15.3 p-10 . . . . . 0 C--N 1.322 -0.622 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.577 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.101 -0.4 . . . . 0.0 112.101 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 2' ' ' LEU . 3.0 mm? -68.34 146.04 97.69 Favored Pre-proline 0 C--N 1.325 -0.5 0 CA-C-O 120.862 0.363 . . . . 0.0 111.075 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.77 53.71 3.76 Favored 'Trans proline' 0 CA--C 1.529 0.237 0 C-N-CA 123.285 2.657 . . . . 0.0 112.726 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 47.2 t -68.08 -47.37 78.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.268 0.556 . . . . 0.0 110.342 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.3 m -85.26 155.25 21.46 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.195 179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -177.89 26.38 0.06 OUTLIER Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.968 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -88.38 144.51 26.34 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-O 121.182 0.515 . . . . 0.0 110.28 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 p -78.86 125.77 29.81 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.65 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 22.4 t -87.67 42.21 1.03 Allowed 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.423 0.63 . . . . 0.0 109.869 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.25 -34.84 71.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.865 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.93 22.56 40.37 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.552 179.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.99 45.9 94.5 Favored Glycine 0 C--N 1.332 0.328 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.12 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.3 t -151.36 155.56 38.92 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 120.933 0.397 . . . . 0.0 111.093 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 92.0 m -131.89 139.95 48.92 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.851 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -90.02 -47.29 7.94 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.629 -179.035 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 m -74.26 112.04 15.31 Favored Pre-proline 0 C--O 1.243 0.728 0 CA-C-O 121.328 0.585 . . . . 0.0 112.33 -178.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -60.76 131.56 38.19 Favored 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 122.625 2.217 . . . . 0.0 111.398 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.25 -28.72 11.25 Favored Glycine 0 N--CA 1.44 -1.083 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -178.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 6.5 m -91.52 128.44 37.35 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.165 0.507 . . . . 0.0 110.566 179.028 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 t -91.63 163.74 14.0 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.726 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.5 t -80.22 127.84 32.82 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.278 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 45.1 m -136.89 68.52 1.42 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 178.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.0 t90 -29.32 130.16 0.23 Allowed Pre-proline 0 N--CA 1.463 0.225 0 CA-C-N 114.133 -1.394 . . . . 0.0 113.064 -177.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.9 Cg_endo -95.76 31.28 12.66 Favored 'Cis proline' 0 N--CA 1.458 -0.604 0 C-N-CA 123.252 -1.562 . . . . 0.0 114.247 0.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.4 m -144.46 146.49 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -179.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 71.5 m -82.57 138.52 34.22 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.77 178.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.4 t -151.06 -171.45 3.94 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.724 0.297 . . . . 0.0 110.843 -179.664 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.9 ptp85 -89.76 136.68 32.89 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 . . . . . 0 C--N 1.317 -0.806 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.553 -179.488 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.422 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.364 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.422 ' HB2' ' O ' ' A' ' 1' ' ' GLY . 9.8 mp 71.12 141.48 0.08 OUTLIER Pre-proline 0 N--CA 1.468 0.425 0 C-N-CA 123.228 0.611 . . . . 0.0 111.473 -179.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 18.2 Cg_exo -66.03 121.57 8.93 Favored 'Trans proline' 0 N--CA 1.461 -0.411 0 C-N-CA 122.33 2.02 . . . . 0.0 111.477 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.1 m -64.44 -31.62 54.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.808 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 67.5 m -136.64 -52.95 0.71 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.954 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.4 -41.79 3.04 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.393 -0.821 . . . . 0.0 112.883 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 89.3 mt-10 -55.72 138.1 48.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.234 0.54 . . . . 0.0 111.333 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.698 HG22 HG12 ' A' ' 25' ' ' VAL . 5.9 p -95.69 127.58 41.84 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.711 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.434 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 16.1 t -89.48 39.05 0.93 Allowed 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.169 0.509 . . . . 0.0 109.908 179.618 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.3 p -63.01 -35.17 70.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.938 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.82 23.27 36.22 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.434 179.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.99 41.14 99.31 Favored Glycine 0 C--N 1.333 0.366 0 C-N-CA 121.284 -0.484 . . . . 0.0 113.167 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.0 t -151.38 153.17 34.21 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 121.025 0.44 . . . . 0.0 111.467 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 76.9 m -138.26 137.11 37.17 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -92.9 -47.17 7.16 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.559 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.43 ' HA ' ' HD3' ' A' ' 17' ' ' PRO . 86.8 m -65.53 115.46 22.32 Favored Pre-proline 0 C--O 1.24 0.589 0 CA-C-O 121.437 0.637 . . . . 0.0 111.805 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 25.5 Cg_exo -61.83 127.13 20.61 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.674 2.25 . . . . 0.0 111.097 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.74 -18.43 31.97 Favored Glycine 0 N--CA 1.441 -1.014 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 93.5 m -87.75 124.27 33.42 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.255 0.55 . . . . 0.0 110.361 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.6 m -91.88 146.16 23.98 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.795 179.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.9 t -74.22 129.63 38.18 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.28 0.562 . . . . 0.0 111.805 -179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 51.0 m -141.09 68.57 1.34 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 178.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.533 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.8 t90 -31.21 128.73 0.28 Allowed Pre-proline 0 N--CA 1.463 0.202 0 CA-C-N 114.306 -1.315 . . . . 0.0 112.892 -177.039 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.533 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.7 Cg_endo -97.82 34.18 8.94 Favored 'Cis proline' 0 CA--C 1.538 0.69 0 C-N-CA 123.527 -1.447 . . . . 0.0 113.906 0.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.698 HG12 HG22 ' A' ' 8' ' ' THR . 17.0 m -141.0 145.95 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 -179.225 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.429 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 79.9 m -83.66 128.56 34.62 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 178.042 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.8 t -112.05 173.73 6.22 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 110.129 -0.322 . . . . 0.0 110.129 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 31.8 ptt85 -89.64 137.43 32.34 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 . . . . . 0 C--N 1.317 -0.832 0 C-N-CA 120.336 -0.546 . . . . 0.0 110.816 -179.726 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 111.89 -0.484 . . . . 0.0 111.89 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 7.2 mp -74.1 136.86 75.85 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.728 -0.236 . . . . 0.0 110.428 179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.68 135.94 43.87 Favored 'Trans proline' 0 N--CA 1.464 -0.264 0 C-N-CA 122.618 2.212 . . . . 0.0 112.019 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.505 HG22 HG21 ' A' ' 16' ' ' THR . 7.5 p -67.98 -47.14 80.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.145 0.497 . . . . 0.0 110.911 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.8 m -86.54 164.69 16.76 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.394 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -167.92 -29.13 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.205 -0.998 . . . . 0.0 112.918 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.787 ' HG3' ' HA ' ' A' ' 14' ' ' CYS . 1.1 pm0 -62.79 142.55 58.14 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.56 0.695 . . . . 0.0 111.2 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.803 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.7 p -85.66 129.71 34.75 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.98 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.508 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 41.0 t -80.77 20.83 0.72 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.284 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.803 HG23 ' HB ' ' A' ' 8' ' ' THR . 53.4 t -58.68 -39.74 77.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 121.059 0.457 . . . . 0.0 110.583 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.12 23.78 33.37 Favored Glycine 0 N--CA 1.446 -0.665 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.055 179.025 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.13 53.48 44.32 Favored Glycine 0 C--N 1.334 0.449 0 C-N-CA 121.369 -0.443 . . . . 0.0 112.95 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 t -151.86 151.32 31.14 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.004 0.43 . . . . 0.0 111.739 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.787 ' HA ' ' HG3' ' A' ' 7' ' ' GLU . 84.4 m -142.34 134.66 27.74 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.189 179.165 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.457 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 71.5 m-80 -95.17 -46.24 6.86 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.933 0.397 . . . . 0.0 111.123 -179.239 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.56 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 7.7 m -64.41 121.2 71.15 Favored Pre-proline 0 C--O 1.238 0.469 0 CA-C-O 121.43 0.633 . . . . 0.0 111.77 -178.808 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -59.07 132.86 49.64 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.81 2.34 . . . . 0.0 112.191 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.68 -10.78 73.84 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.175 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.56 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 71.2 m -88.1 123.15 32.48 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.384 0.611 . . . . 0.0 110.163 179.61 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.6 m -88.97 143.3 26.95 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.184 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -72.85 119.05 16.55 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 30.2 m -135.15 70.67 1.43 Allowed 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.183 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 8.9 t90 -27.41 128.54 0.2 Allowed Pre-proline 0 N--CA 1.466 0.362 0 CA-C-N 114.036 -1.438 . . . . 0.0 112.916 -178.203 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 92.3 Cg_endo -96.37 29.53 15.24 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 C-N-CA 123.396 -1.501 . . . . 0.0 114.105 0.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.508 ' HA ' ' H ' ' A' ' 9' ' ' CYS . 9.3 m -145.89 148.06 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 -179.211 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.554 ' SG ' ' HG2' ' A' ' 7' ' ' GLU . 72.7 m -83.58 141.25 31.71 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.836 178.041 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.2 t -146.46 -168.87 3.13 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.404 ' HD3' ' CG1' ' A' ' 4' ' ' VAL . 21.0 mmm180 -96.62 45.13 1.06 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.896 0.379 . . . . 0.0 110.187 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.331 -0.212 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.792 -179.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 N-CA-C 112.062 -0.415 . . . . 0.0 112.062 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.451 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 7.1 mp -74.2 133.77 77.84 Favored Pre-proline 0 C--N 1.326 -0.428 0 N-CA-C 110.405 -0.22 . . . . 0.0 110.405 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 23.8 Cg_exo -63.93 118.71 5.64 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.492 2.128 . . . . 0.0 111.796 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 45.6 t -65.27 -37.4 80.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.118 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.811 ' HA ' HG21 ' A' ' 16' ' ' THR . 75.8 m -104.4 -55.22 2.39 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.579 -179.629 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 63.1 47.4 88.72 Favored Glycine 0 C--O 1.228 -0.228 0 CA-C-N 115.769 -0.651 . . . . 0.0 112.09 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.473 ' HG2' ' H ' ' A' ' 15' ' ' ASN . 6.6 tp10 -149.69 150.34 31.96 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.184 0.516 . . . . 0.0 110.229 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 12.6 p -109.92 127.94 55.05 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.041 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.49 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 20.5 t -90.7 38.46 0.95 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.278 0.561 . . . . 0.0 109.873 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -62.9 -36.8 77.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.239 -179.155 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.47 28.05 16.68 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.662 179.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.07 40.97 97.8 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 121.271 -0.49 . . . . 0.0 112.933 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -151.75 160.06 43.72 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.578 0.228 . . . . 0.0 110.528 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.7 m -143.81 120.57 11.21 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.147 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.473 ' H ' ' HG2' ' A' ' 7' ' ' GLU . 48.8 m-80 -79.32 -35.61 40.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.672 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.811 HG21 ' HA ' ' A' ' 5' ' ' CYS . 0.2 OUTLIER -67.91 114.27 19.45 Favored Pre-proline 0 C--O 1.242 0.709 0 CA-C-O 121.252 0.549 . . . . 0.0 111.639 -179.112 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -59.37 135.8 67.64 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.765 2.31 . . . . 0.0 112.322 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.65 -6.39 73.87 Favored Glycine 0 N--CA 1.444 -0.821 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.698 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.496 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 84.2 m -89.76 132.5 35.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 117.461 0.63 . . . . 0.0 111.335 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 m -88.93 148.4 23.83 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.297 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.6 t -79.31 127.54 32.2 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.012 0.434 . . . . 0.0 111.285 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.6 m -137.93 67.84 1.41 Allowed 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.703 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 9.3 t90 -31.39 128.83 0.29 Allowed Pre-proline 0 N--CA 1.465 0.294 0 CA-C-N 114.356 -1.293 . . . . 0.0 112.793 -177.211 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 98.2 Cg_endo -97.18 31.9 11.64 Favored 'Cis proline' 0 N--CA 1.456 -0.709 0 C-N-CA 123.554 -1.436 . . . . 0.0 113.772 0.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 8' ' ' THR . 16.1 m -136.64 141.79 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -178.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 80.7 m -85.0 135.02 34.2 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.608 178.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.2 t -149.05 142.37 25.14 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.557 0.694 . . . . 0.0 110.959 178.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -82.63 72.44 9.7 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.008 -0.997 . . . . 0.0 110.694 -179.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 31.5 t30 . . . . . 0 C--N 1.325 -0.467 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.026 -179.831 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.544 0 N-CA-C 112.076 -0.41 . . . . 0.0 112.076 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 14.1 mt -147.75 131.22 8.23 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-O 121.167 0.508 . . . . 0.0 110.945 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.99 52.56 3.08 Favored 'Trans proline' 0 CA--C 1.531 0.329 0 C-N-CA 123.575 2.85 . . . . 0.0 112.845 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 61.7 t -71.13 -45.19 72.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.286 0.565 . . . . 0.0 110.394 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.431 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 55.8 m -105.06 169.89 8.18 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.866 179.317 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -159.18 28.1 0.39 Allowed Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.26 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.431 ' OE2' ' HB3' ' A' ' 5' ' ' CYS . 4.0 mp0 -77.5 140.0 39.71 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.685 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.2 p -74.89 123.55 25.27 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-O 121.443 0.64 . . . . 0.0 110.52 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.503 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 21.8 t -93.77 35.14 1.15 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.91 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.685 HG23 ' HB ' ' A' ' 8' ' ' THR . 44.5 t -62.31 -40.76 89.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.286 -179.635 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.05 24.68 23.61 Favored Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.629 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.91 47.55 90.07 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 121.34 -0.457 . . . . 0.0 113.287 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 11.8 t -150.89 155.9 40.11 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.854 0.359 . . . . 0.0 110.954 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 94.8 m -133.26 -44.02 0.85 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.756 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 73.76 -46.51 0.63 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.778 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.411 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 2.6 m -63.04 110.68 3.75 Favored Pre-proline 0 C--O 1.243 0.749 0 CA-C-O 121.511 0.672 . . . . 0.0 111.863 -179.227 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 25.2 Cg_endo -61.62 131.77 37.24 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.573 2.182 . . . . 0.0 111.989 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.62 -22.85 37.07 Favored Glycine 0 N--CA 1.437 -1.272 0 C-N-CA 120.398 -0.906 . . . . 0.0 111.583 -179.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 15.3 m -98.43 134.7 41.05 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.342 0.591 . . . . 0.0 111.623 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.3 m -99.05 149.47 22.98 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.802 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 23.3 t -76.44 125.04 28.49 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.079 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 32.0 t -126.17 64.44 1.23 Allowed 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 178.365 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.1 t90 -26.74 128.48 0.19 Allowed Pre-proline 0 N--CA 1.467 0.417 0 CA-C-N 114.066 -1.425 . . . . 0.0 113.236 -177.083 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 84.1 Cg_endo -95.34 30.03 14.64 Favored 'Cis proline' 0 CA--C 1.536 0.584 0 C-N-CA 123.451 -1.479 . . . . 0.0 113.964 0.658 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.7 m -139.15 137.17 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 121.558 0.694 . . . . 0.0 112.633 -179.498 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 79.2 m -81.99 140.05 34.19 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.475 178.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.3 t -151.03 172.88 15.03 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.802 0.334 . . . . 0.0 110.636 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 12.7 tpt180 -96.89 128.7 44.1 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 22.9 p30 . . . . . 0 C--N 1.321 -0.664 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.872 -179.95 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.035 -0.426 . . . . 0.0 112.035 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.669 HD12 ' HD2' ' A' ' 3' ' ' PRO . 46.5 tp -74.39 123.0 88.81 Favored Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 110.385 -0.228 . . . . 0.0 110.385 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.669 ' HD2' HD12 ' A' ' 2' ' ' LEU . 65.6 Cg_endo -73.78 49.99 1.98 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 123.019 2.48 . . . . 0.0 112.751 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.8 p -79.45 -35.65 17.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.367 0.603 . . . . 0.0 109.964 179.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.544 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 59.6 m 60.26 -133.71 0.79 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 114.417 -1.265 . . . . 0.0 111.038 179.218 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.32 20.1 55.55 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.728 -179.438 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.611 ' HG2' HD21 ' A' ' 15' ' ' ASN . 1.1 mp0 -76.34 139.72 41.14 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 179.175 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.486 ' HB ' HG13 ' A' ' 10' ' ' VAL . 2.4 p -70.25 121.79 18.28 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-O 121.528 0.68 . . . . 0.0 110.498 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 18.9 t -87.96 40.98 0.97 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.903 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.486 HG13 ' HB ' ' A' ' 8' ' ' THR . 15.1 m -62.36 -33.93 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.333 -179.377 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.84 22.45 39.55 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.177 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.47 45.69 94.12 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.837 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -151.87 155.74 38.73 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.012 0.434 . . . . 0.0 111.426 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 55.9 m -133.61 146.6 51.08 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 179.349 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.611 HD21 ' HG2' ' A' ' 7' ' ' GLU . 21.4 p30 -102.71 -35.07 8.81 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.303 -0.559 . . . . 0.0 112.247 -179.005 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.544 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 13.0 m -80.74 112.84 35.21 Favored Pre-proline 0 C--O 1.244 0.795 0 CA-C-O 121.542 0.687 . . . . 0.0 111.488 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.411 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 39.2 Cg_exo -59.52 129.06 29.42 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.677 2.251 . . . . 0.0 111.803 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.2 -23.21 19.19 Favored Glycine 0 N--CA 1.438 -1.194 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.431 ' SG ' ' HB3' ' A' ' 28' ' ' ARG . 42.2 m -95.16 127.08 40.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.306 0.574 . . . . 0.0 111.515 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.62 147.19 23.47 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.195 -179.52 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.2 t -71.3 123.94 23.42 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.201 0.524 . . . . 0.0 111.176 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 37.9 m -128.44 66.54 1.39 Allowed 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 178.361 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 3.9 t90 -27.79 129.07 0.21 Allowed Pre-proline 0 N--CA 1.467 0.396 0 CA-C-N 113.904 -1.498 . . . . 0.0 113.051 -177.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 90.0 Cg_endo -95.3 31.34 12.61 Favored 'Cis proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.347 -1.522 . . . . 0.0 114.338 0.637 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.6 m -141.49 137.59 32.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 83.0 m -82.26 134.55 35.29 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.595 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.2 t -151.72 151.14 31.02 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.296 0.57 . . . . 0.0 110.879 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.431 ' HB3' ' SG ' ' A' ' 19' ' ' CYS . 6.7 ptm180 -84.3 56.27 3.71 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.781 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 15.6 p-10 . . . . . 0 C--N 1.326 -0.413 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.922 -179.957 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.505 ' H3 ' ' HD2' ' A' ' 28' ' ' ARG . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.226 -0.349 . . . . 0.0 112.226 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.681 HD12 ' HD2' ' A' ' 3' ' ' PRO . 29.9 tp -150.06 131.0 7.19 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.681 ' HD2' HD12 ' A' ' 2' ' ' LEU . 51.8 Cg_endo -69.46 62.12 1.59 Allowed 'Trans proline' 0 CA--C 1.533 0.438 0 C-N-CA 123.146 2.564 . . . . 0.0 113.33 -179.227 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 46.9 t -68.92 -44.96 81.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.175 0.512 . . . . 0.0 110.408 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.447 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 20.7 m -79.09 163.52 25.04 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.169 179.546 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -168.48 36.34 0.2 Allowed Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.967 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.548 ' H ' ' CD ' ' A' ' 7' ' ' GLU . 1.1 pm0 -85.62 143.22 28.56 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 179.117 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.566 ' HB ' HG23 ' A' ' 10' ' ' VAL . 1.4 p -72.0 125.41 27.18 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-O 121.684 0.754 . . . . 0.0 111.625 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.568 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.8 t -104.25 42.22 1.22 Allowed 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.118 -0.946 . . . . 0.0 109.164 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.566 HG23 ' HB ' ' A' ' 8' ' ' THR . 45.9 t -59.11 -40.94 82.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.967 -178.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.11 16.79 54.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.523 179.252 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.72 41.2 97.39 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 121.504 -0.379 . . . . 0.0 113.106 179.487 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.8 t -152.84 140.64 20.05 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-O 121.42 0.629 . . . . 0.0 112.26 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 91.1 m -152.49 148.9 27.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.613 -1.176 . . . . 0.0 109.087 178.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.536 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 4.5 m120 -115.71 11.64 15.76 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.864 -0.334 . . . . 0.0 111.281 -179.549 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -81.12 107.58 8.08 Favored Pre-proline 0 C--O 1.24 0.601 0 CA-C-O 121.248 0.547 . . . . 0.0 110.995 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.536 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 29.4 Cg_exo -60.91 131.81 39.11 Favored 'Trans proline' 0 CA--C 1.515 -0.431 0 C-N-CA 122.64 2.227 . . . . 0.0 112.684 -179.225 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.11 -18.16 56.75 Favored Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.221 -179.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 36.3 m -105.36 130.75 53.4 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.6 0.714 . . . . 0.0 111.668 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.6 m -97.98 148.47 23.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.141 -178.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.604 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 37.6 t -72.0 128.73 36.63 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.954 179.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.5 m -132.26 67.41 1.53 Allowed 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 3.7 t90 -26.61 128.67 0.19 Allowed Pre-proline 0 N--CA 1.467 0.385 0 CA-C-N 114.054 -1.43 . . . . 0.0 113.095 -177.203 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.48 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 85.4 Cg_endo -94.76 29.23 15.98 Favored 'Cis proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.464 -1.473 . . . . 0.0 114.261 0.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 6.7 m -143.04 137.16 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 CA-C-O 121.484 0.659 . . . . 0.0 112.653 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.604 ' SG ' ' HA ' ' A' ' 21' ' ' CYS . 61.2 m -83.56 140.83 32.01 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.876 178.441 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.9 t -152.44 165.22 35.74 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 120.878 0.37 . . . . 0.0 110.311 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.505 ' HD2' ' H3 ' ' A' ' 1' ' ' GLY . 0.3 OUTLIER -81.74 74.22 8.74 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.702 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 . . . . . 0 C--O 1.238 0.483 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.787 -179.738 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.514 0 N-CA-C 112.037 -0.425 . . . . 0.0 112.037 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -63.24 145.62 96.78 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-O 120.9 0.381 . . . . 0.0 110.947 179.327 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -68.33 121.45 8.42 Favored 'Trans proline' 0 N--CA 1.463 -0.296 0 C-N-CA 122.57 2.18 . . . . 0.0 112.016 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 39.2 t -71.91 -39.41 67.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.632 0.729 . . . . 0.0 110.167 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.581 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 2.7 m -138.46 156.43 47.55 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.586 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -134.64 39.06 1.74 Allowed Glycine 0 N--CA 1.449 -0.44 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -107.96 143.59 36.4 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.162 -0.519 . . . . 0.0 111.007 -179.366 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.669 HG22 HG12 ' A' ' 25' ' ' VAL . 3.2 p -89.8 126.84 35.83 Favored 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.563 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.417 ' H ' ' HA ' ' A' ' 25' ' ' VAL . 17.3 t -83.99 45.21 1.07 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.05 0.452 . . . . 0.0 110.424 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.604 HG23 ' HB ' ' A' ' 8' ' ' THR . 48.5 t -63.54 -39.89 87.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 120.993 0.425 . . . . 0.0 110.74 -179.143 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.73 22.38 25.07 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.738 -0.664 . . . . 0.0 112.948 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.98 39.81 94.67 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.335 -0.459 . . . . 0.0 113.269 179.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.7 t -152.25 158.31 42.64 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-O 120.773 0.32 . . . . 0.0 110.944 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -139.91 131.33 26.9 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -83.0 -46.42 12.89 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -178.35 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.581 ' HB ' ' SG ' ' A' ' 5' ' ' CYS . 4.5 m -70.38 113.61 19.49 Favored Pre-proline 0 C--O 1.246 0.915 0 CA-C-O 121.572 0.701 . . . . 0.0 112.343 -178.412 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_exo -61.22 127.56 22.46 Favored 'Trans proline' 0 N--CA 1.459 -0.555 0 C-N-CA 122.673 2.249 . . . . 0.0 111.291 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 116.52 -26.3 8.63 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -178.157 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 4.7 m -89.69 130.12 36.02 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 121.338 0.59 . . . . 0.0 110.947 179.178 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 m -96.6 146.95 24.37 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.063 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.7 t -72.26 127.49 32.74 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.203 0.525 . . . . 0.0 111.465 -179.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 28.3 t -136.94 64.66 1.53 Allowed 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 178.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.432 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 4.1 t90 -29.21 128.61 0.23 Allowed Pre-proline 0 N--CA 1.466 0.353 0 CA-C-N 114.381 -1.281 . . . . 0.0 113.04 -177.144 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.432 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 96.4 Cg_endo -97.31 34.26 8.96 Favored 'Cis proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.671 -1.387 . . . . 0.0 114.011 0.67 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.669 HG12 HG22 ' A' ' 8' ' ' THR . 17.6 m -140.82 146.96 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 O-C-N 121.898 -0.501 . . . . 0.0 112.33 -179.331 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 72.6 m -81.93 123.73 29.12 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 178.583 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.8 t -101.11 178.34 4.69 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 18.0 ptp180 -96.49 135.45 38.36 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 179.211 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 33.1 t30 . . . . . 0 C--N 1.319 -0.74 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.768 -179.603 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.405 ' HA3' ' HA3' ' A' ' 18' ' ' GLY . . . . . . . . 0 N--CA 1.449 -0.445 0 N-CA-C 112.254 -0.338 . . . . 0.0 112.254 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 15.8 tp -82.53 135.55 46.45 Favored Pre-proline 0 C--N 1.323 -0.555 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.705 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 15.1 Cg_exo -69.95 53.42 1.15 Allowed 'Trans proline' 0 CA--C 1.535 0.571 0 C-N-CA 123.348 2.699 . . . . 0.0 113.88 -178.824 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 3.2 t -91.17 21.31 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.968 0.89 . . . . 0.0 109.419 178.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 27.1 m -61.85 160.97 11.08 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.906 -1.043 . . . . 0.0 112.157 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 159.9 -27.27 0.34 Allowed Glycine 0 C--N 1.315 -0.584 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.117 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -57.69 149.47 21.82 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 113.737 -1.232 . . . . 0.0 110.698 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.489 HG22 HG12 ' A' ' 25' ' ' VAL . 2.0 p -98.07 126.68 43.61 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.564 -179.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 35.1 t -87.81 44.63 1.2 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.755 179.13 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.2 p -62.38 -38.35 81.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.517 -178.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.42 26.49 17.46 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.856 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 59.15 38.16 92.73 Favored Glycine 0 C--N 1.333 0.391 0 C-N-CA 121.31 -0.471 . . . . 0.0 112.949 179.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.9 t -152.51 163.11 40.22 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.6 m -145.02 120.12 10.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.027 179.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 33.5 t30 -78.94 -36.44 41.72 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.616 179.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 5.9 m -63.04 109.63 2.66 Favored Pre-proline 0 C--O 1.242 0.667 0 CA-C-O 121.414 0.626 . . . . 0.0 111.646 -179.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_exo -61.61 130.23 30.82 Favored 'Trans proline' 0 CA--C 1.515 -0.463 0 C-N-CA 122.844 2.362 . . . . 0.0 112.535 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.405 ' HA3' ' HA3' ' A' ' 1' ' ' GLY . . . 97.9 -20.02 52.27 Favored Glycine 0 N--CA 1.44 -1.062 0 CA-C-N 115.327 -0.852 . . . . 0.0 111.617 -179.39 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 72.0 m -89.81 123.93 34.22 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.321 0.581 . . . . 0.0 110.981 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.4 p -88.99 143.46 26.84 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.359 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.4 t -69.92 128.23 35.64 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.26 0.552 . . . . 0.0 112.005 -179.044 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 35.0 t -136.98 66.42 1.47 Allowed 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.435 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 6.8 t90 -29.46 128.62 0.24 Allowed Pre-proline 0 N--CA 1.464 0.269 0 CA-C-N 114.284 -1.325 . . . . 0.0 113.008 -176.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 97.0 Cg_endo -97.0 32.47 10.96 Favored 'Cis proline' 0 N--CA 1.458 -0.599 0 C-N-CA 123.49 -1.463 . . . . 0.0 114.031 0.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.489 HG12 HG22 ' A' ' 8' ' ' THR . 15.9 m -139.42 142.87 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 113.032 0.752 . . . . 0.0 113.032 -179.205 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 58.5 m -83.09 131.25 35.16 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.627 178.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 t -140.82 157.51 45.28 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.129 0.49 . . . . 0.0 111.062 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.71 81.48 8.19 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.02 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 32.1 t30 . . . . . 0 C--N 1.326 -0.449 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.645 179.799 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 N-CA-C 111.971 -0.451 . . . . 0.0 111.971 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.429 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 33.0 tp -75.65 122.12 86.48 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 17.7 Cg_exo -66.87 102.29 0.63 Allowed 'Trans proline' 0 C--O 1.233 0.244 0 C-N-CA 122.653 2.235 . . . . 0.0 112.177 -179.693 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 46.9 t -73.77 -43.74 53.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.17 0.51 . . . . 0.0 110.086 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 91.3 m 59.75 -113.0 0.6 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.905 -1.043 . . . . 0.0 111.649 179.299 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.83 14.52 80.8 Favored Glycine 0 N--CA 1.45 -0.395 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -178.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.615 ' OE1' ' HB3' ' A' ' 14' ' ' CYS . 64.6 mt-10 -71.87 139.49 48.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.056 -0.572 . . . . 0.0 110.075 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 17.3 p -75.34 123.75 25.9 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.131 0.491 . . . . 0.0 110.958 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.2 t -103.74 39.81 1.54 Allowed 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.434 179.7 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -59.16 -36.96 65.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.343 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.33 27.89 18.49 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.317 179.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.47 35.67 89.43 Favored Glycine 0 C--N 1.331 0.286 0 C-N-CA 121.365 -0.445 . . . . 0.0 112.993 179.748 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.8 t -153.06 156.4 38.66 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 120.646 0.26 . . . . 0.0 110.838 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.615 ' HB3' ' OE1' ' A' ' 7' ' ' GLU . 61.0 m -150.05 -153.09 0.47 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.787 179.237 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.417 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 72.4 m-80 -133.12 -52.94 0.9 Allowed 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -178.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 51.3 m -66.34 108.47 2.33 Favored Pre-proline 0 C--O 1.249 1.047 0 N-CA-C 113.523 0.934 . . . . 0.0 113.523 -177.375 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.417 ' HD3' ' O ' ' A' ' 15' ' ' ASN . 37.4 Cg_endo -65.6 125.48 14.44 Favored 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 122.461 2.107 . . . . 0.0 110.485 178.353 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.55 -27.38 6.03 Favored Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -177.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 14.2 m -89.86 129.41 36.23 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 120.15 -0.62 . . . . 0.0 110.067 178.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.518 ' HB ' ' OD1' ' A' ' 29' ' ' ASN . 3.7 m -88.14 144.86 26.23 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.533 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.2 t -72.98 122.68 22.11 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.12 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.0 m -127.73 67.28 1.33 Allowed 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 178.583 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.516 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 5.3 t90 -26.5 127.95 0.19 Allowed Pre-proline 0 N--CA 1.467 0.395 0 CA-C-N 113.921 -1.491 . . . . 0.0 113.058 -177.18 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.516 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 80.5 Cg_endo -95.56 31.55 12.3 Favored 'Cis proline' 0 N--CA 1.456 -0.707 0 C-N-CA 123.482 -1.466 . . . . 0.0 114.38 0.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 6.0 m -145.03 138.06 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 N-CA-C 112.873 0.694 . . . . 0.0 112.873 -179.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.482 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 94.6 m -82.19 140.29 33.81 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.571 178.254 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 8.8 t -148.11 158.84 44.29 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.041 0.448 . . . . 0.0 110.196 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 7.4 ptm180 -81.54 52.02 1.79 Allowed 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.196 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.518 ' OD1' ' HB ' ' A' ' 20' ' ' THR . 15.2 p-10 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.683 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.541 0 N-CA-C 111.975 -0.45 . . . . 0.0 111.975 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.439 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 48.9 tp -83.45 122.65 77.08 Favored Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 6.8 Cg_exo -73.41 48.25 1.51 Allowed 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 123.229 2.62 . . . . 0.0 112.802 -179.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.8 p -78.65 -42.25 25.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.641 0.734 . . . . 0.0 109.833 179.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.692 ' HB3' ' OE2' ' A' ' 7' ' ' GLU . 63.6 m -102.97 172.1 7.01 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.535 -1.211 . . . . 0.0 109.827 179.104 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 179.38 28.55 0.05 OUTLIER Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.535 -0.84 . . . . 0.0 112.519 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.692 ' OE2' ' HB3' ' A' ' 5' ' ' CYS . 1.3 pm0 -89.57 142.51 27.61 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.724 ' HB ' HG23 ' A' ' 10' ' ' VAL . 2.7 p -77.98 123.9 27.36 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-O 121.414 0.625 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.438 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 28.2 t -90.52 39.97 1.0 Allowed 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.052 179.775 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.724 HG23 ' HB ' ' A' ' 8' ' ' THR . 47.3 t -61.99 -40.31 86.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.653 -179.245 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.47 22.83 30.81 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.881 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.19 47.6 88.4 Favored Glycine 0 CA--C 1.52 0.362 0 C-N-CA 121.289 -0.482 . . . . 0.0 113.206 179.306 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.4 t -151.18 155.98 39.99 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 122.565 -0.373 . . . . 0.0 111.095 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 82.9 m -140.1 127.73 21.67 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.656 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -81.44 -41.18 22.22 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -179.202 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.433 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 15.5 m -75.82 109.46 8.15 Favored Pre-proline 0 C--O 1.246 0.885 0 CA-C-O 121.545 0.688 . . . . 0.0 112.223 -178.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 27.6 Cg_endo -61.96 131.19 33.83 Favored 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 122.564 2.176 . . . . 0.0 111.386 179.524 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 110.61 -29.32 9.13 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 -178.305 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.734 ' HA ' ' HB2' ' A' ' 28' ' ' ARG . 7.4 m -89.59 133.37 34.65 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.526 179.221 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.3 m -95.23 148.79 22.02 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.959 -178.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.3 t -70.07 126.6 30.15 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.875 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.7 m -134.22 67.96 1.5 Allowed 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 1.5 t90 -28.35 128.16 0.22 Allowed Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 113.976 -1.465 . . . . 0.0 112.989 -176.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 93.8 Cg_endo -96.71 32.52 10.92 Favored 'Cis proline' 0 CA--C 1.537 0.64 0 C-N-CA 123.595 -1.419 . . . . 0.0 114.151 0.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.2 m -143.71 141.78 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -179.572 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.438 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 65.8 m -82.68 132.54 35.18 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.234 178.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.2 t -152.46 164.72 37.0 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.014 0.435 . . . . 0.0 111.557 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.734 ' HB2' ' HA ' ' A' ' 19' ' ' CYS . 9.0 tpt180 177.36 -149.21 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.785 179.375 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 . . . . . 0 C--N 1.318 -0.794 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.665 179.735 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.587 ' HA2' ' HB ' ' A' ' 25' ' ' VAL . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.054 -0.418 . . . . 0.0 112.054 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.652 HD12 ' HD2' ' A' ' 3' ' ' PRO . 23.8 tp 69.01 131.68 0.04 OUTLIER Pre-proline 0 N--CA 1.466 0.348 0 C-N-CA 123.063 0.545 . . . . 0.0 110.941 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.652 ' HD2' HD12 ' A' ' 2' ' ' LEU . 57.8 Cg_endo -71.14 44.73 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 122.814 2.343 . . . . 0.0 112.715 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 85.2 t -146.82 -47.61 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.398 -0.819 . . . . 0.0 108.89 179.491 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.485 ' HA ' HG21 ' A' ' 16' ' ' THR . 71.1 m -91.42 -50.08 5.99 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.992 -1.003 . . . . 0.0 110.657 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.82 -46.99 3.64 Favored Glycine 0 N--CA 1.451 -0.355 0 CA-C-N 115.244 -0.889 . . . . 0.0 112.573 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.669 ' HG3' ' HB3' ' A' ' 15' ' ' ASN . 47.3 mm-40 -62.81 145.05 55.88 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 122.028 0.918 . . . . 0.0 112.61 -179.458 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.697 HG22 HG12 ' A' ' 25' ' ' VAL . 5.9 p -110.22 127.85 55.18 Favored 'General case' 0 N--CA 1.439 -1.019 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.825 178.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 12.7 t -83.65 41.35 0.78 Allowed 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.919 0.39 . . . . 0.0 110.841 -179.403 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.621 HG23 ' HB ' ' A' ' 8' ' ' THR . 47.6 t -64.73 -42.01 93.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.174 0.511 . . . . 0.0 110.314 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.24 28.62 12.3 Favored Glycine 0 N--CA 1.45 -0.397 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.638 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.08 42.55 98.52 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 121.27 -0.49 . . . . 0.0 113.237 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.8 t -151.61 160.17 43.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.648 0.261 . . . . 0.0 110.756 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 97.7 m -146.03 124.75 12.57 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.191 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.669 ' HB3' ' HG3' ' A' ' 7' ' ' GLU . 28.2 t-20 -81.04 -46.73 14.58 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.657 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.485 HG21 ' HA ' ' A' ' 5' ' ' CYS . 0.2 OUTLIER -58.33 111.77 4.01 Favored Pre-proline 0 C--O 1.238 0.481 0 CA-C-O 121.221 0.534 . . . . 0.0 112.146 -178.857 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 16' ' ' THR . 24.7 Cg_exo -62.24 130.59 31.0 Favored 'Trans proline' 0 N--CA 1.46 -0.448 0 C-N-CA 122.631 2.221 . . . . 0.0 111.63 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.38 -14.72 63.14 Favored Glycine 0 N--CA 1.442 -0.945 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.763 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.465 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 95.9 m -88.98 126.82 35.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.243 0.544 . . . . 0.0 110.816 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.87 148.76 23.69 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.412 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 t -75.48 128.6 35.67 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.127 0.489 . . . . 0.0 112.187 -178.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 57.6 m -139.99 69.13 1.35 Allowed 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 178.193 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.528 ' HA ' ' HA ' ' A' ' 24' ' ' PRO . 11.4 t90 -31.62 129.04 0.3 Allowed Pre-proline 0 N--CA 1.465 0.292 0 CA-C-N 114.227 -1.351 . . . . 0.0 112.886 -177.173 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 23' ' ' TRP . 97.6 Cg_endo -98.06 33.16 9.83 Favored 'Cis proline' 0 N--CA 1.457 -0.633 0 C-N-CA 123.71 -1.371 . . . . 0.0 113.75 0.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.697 HG12 HG22 ' A' ' 8' ' ' THR . 24.6 m -139.43 145.85 26.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -178.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 61.3 m -84.63 138.26 32.8 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.7 t -133.15 151.39 51.98 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.057 0.456 . . . . 0.0 110.449 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 50.7 ttp180 -84.19 51.48 2.09 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.675 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 . . . . . 0 C--N 1.325 -0.497 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.267 179.892 . . . . . . . . 0 0 . 1 stop_ save_